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SUMMARY 
The focus of this thesis was set on the modulation of the arachidonic acid (AA) cascade. In the 
first part, the influence of sex on the prostanoid formation in human whole blood and isolated 
cells was of interest, whereas the second part was dedicated to the search for suitable  
5-lipoxygenase (5-LO) inhibitors. The prostanoids are generated by the cyclooxygenase 
(COX)-1/2 enzymes, which convert AA in a two-step reaction to prostaglandin (PG)H2. PGH2 
is then further metabolized to distinct prostanoids by terminal synthases [1]. The role of COX 
and prostanoids in inflammation is well characterized and so is the existence of a sexual 
dimorphism in immunity and inflammatory diseases [2, 3]. However, little is known about the 
role prostanoids are playing in the observed sex differences. Recent findings suggest a 
differential regulation of the prostanoid expression in animal models of inflammation and also 
of the leukotriene (LT) biosynthesis by 5-LO in human male and female leukocytes, another 
class of lipid mediators [4, 5]. Hence, the regulation of the prostanoid expression in human 
whole blood and freshly isolated cells was evaluated in the first part of this thesis. Analysis of 
human blood cells showed generally higher cell numbers of lymphocytes and neutrophils in 
female blood, whereas monocyte numbers were higher in male blood. Long term incubations 
(24 h) of whole blood with various stimuli like lipopolysaccharide (LPS), the Ca2+ ionophore 
A23187 or N-formyl-methionyl-leucyl-phenylalanine (fMLP) resulted in significant enhanced 
levels of PGs, mainly PGE2, in males compared to females. The observed elevated prostanoid 
formation in males was not influenced by pre-incubation of the blood with sex hormones prior 
to LPS stimulation. It was also independent of COX-2 protein as well as COX-2 mRNA 
expression analyzed in freshly isolated monocytes and peripheral blood mononuclear cells 
(PBMC). Furthermore, a contributing role of COX-1 and of the ionophore A23187-induced 
release of AA in polymorphonuclear leukocytes (PMNL) could be excluded. It is noteworthy 
that the observed sex difference in prostanoid formation was not detectable in human whole 
blood or in isolated PMNL in short term incubations (up to 30 min). The influence of the time-
dependent prostanoid degradation was evaluated using SW033291, a specific inhibitor of the 
metabolizing enzyme 15-hydroxy prostaglandin dehydrogenase (15-PGDH). The results 
obtained in early time points (6h) suggested an involvement of 15-PGDH in the regulation of 
prostanoid levels. In female blood treated with the inhibitor the amount of PGE2 was increased 
to the same levels detected in male blood without previous inhibitor treatment. Additionally, 
PMNL and PBMC were isolated from human whole blood and stimulated separately or together 
after co-incubation to analyze the effect of cell-cell interactions on prostanoid formation. In co-
incubations, a more pronounced biosynthesis in males compared to females was observed. In 
conclusion, the underlying mechanisms leading to the sex difference of prostanoid formation 
in human whole blood upon stimulation with LPS, A23187 or fMLP for 24 h could not be 
elucidated completely. Nevertheless, the results suggest differences in the time-dependent 
prostanoid degradation and in cell-cell interactions within the whole blood as contributing 
mechanisms. 
Besides COX and the prostanoids, the 5-LO enzyme and leukotrienes play an important role 
in inflammation. 5-LO converts AA to 5(S)-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic 
acid (5-HpETE), which is further metabolized by 5-LO to LTA4 [6]. Upon cell stimulation, 5-LO 
and the cytosolic phospholipase (cPL)A2 translocate to the nuclear envelope, where together 
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with the 5-LO activating protein (FLAP) they are responsible for LT formation [7]. Recent 
investigations revealed the plant-derived compound embelin as potent 5-LO inhibitor [8]. Using 
embelin as lead structure, its 1,4-benzoquinone core was systematically modified resulting in 
three distinct series of potential 5-LO inhibitors: series (I) comprised sixteen 1,4- and  
1,2-benzoquinones substituted in 3-position with n-alkyl chains of 8 to 15 carbon atoms, series 
(II) containing five 1,2-benzohydroquinones with n-alkyl chains of 11 to 13 carbon atoms in  
3-position, and series (III) comprised fifteen 1,2-benzohydroquinones with rather bulky 
aromatic residues in 4-position. The first series was categorized according to their methylation 
pattern of the hydroxy groups on the benzoquinone core into the series A, B, C, and D. 
Evaluations of the inhibitory capacity in cell-based and cell-free settings revealed EA-110C of 
series C as most potent with IC50 values in the nanomolar range (IC50 = 50 - 120 nM). In series 
(II), the most promising 1,2-benzoquinones of series (I) were reduced to 1,2-benzyo-
hydroquinones and their inhibitory potential on 5-LO was analyzed in cell-free and cell-based 
settings. The reduced form of EA-110C (EA-110C RED) showed IC50 values in the nanomolar 
range as well (IC50 cell-free = 30 – 60 nM) confirming a 1,2-quinone/ hydroquinone core 
combined with a C13-n-alkyl residue as optimal structure to interfere with 5-LO product 
formation. Animal models of acute inflammation confirmed efficacy in vivo and additional 
analysis revealed a non-competitive inhibitory mechanism, supported by docking simulations 
proposing a binding site for EA-110C opposite of the substrate channel. In series (III) the two 
most potent hydroquinones F-XII and F-XVI were analyzed in detail. Both compounds showed 
highly potent inhibition of 5-LO with IC50 values in the nanomolar range in cell-based (IC50  
F-XII = 70 nM; F-XVI = 60 nM) as well as in cell-free preparations (IC50: F-XII und F-XVI =  
20 nM). 5-LO inhibition was reversible, independent of exogenously added AA and not 
primarily mediated due to radical scavenging and antioxidant properties. Docking simulations 
proposed binding of the 1,2-benzohydroquinone moiety to the amino acid Asp-166, which is 
involved in the salt bridge connecting the C-terminal catalytic domain with the N-terminal C2-
like domain. Furthermore, inhibition of 5-LO was independent of interference with cellular 
activation signals required for the 5-LO activation. The obtained results in the second part of 
the thesis revealed the benzohydroquinones F-XII and F-XVI as highly potent, direct, rather 
non-redox-type or novel type inhibitors of 5-LO with high selectivity in nanomolar 
concentrations, confirmed by investigations in human whole blood and in zymosan-induced 
peritonitis in mice as possible new drug candidates.
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ZUSAMMENFASSUNG 
In der vorgelegten Arbeit lag der Fokus auf der Modulation der Arachidonsäure (AA)-Kaskade. 
Im ersten Teil wurde der Einfluss von Sexualhormonen auf die Prostanoidbiosynthese in 
humanem Vollblut und daraus isolierten Zellen untersucht, wohingegen der zweite Teil der 
Suche nach geeigneten Inhibitoren der 5-Lipoxygenase (5-LO) gewidmet wurde. Die 
Prostanoide werden durch die Cyclooxygenasen(COX)-1/2 gebildet, welche die AA in zwei 
Schritten zu Prostaglandin (PG)H2 umwandeln. PGH2 wird danach durch terminale Synthasen 
weiter zu den einzelnen Prostanoiden umgesetzt [1]. Die Rolle der COX Enzyme und der 
Prostanoide in Entzündungen ist weitreichend untersucht und das Vorliegen eines 
Geschlechtsdimorphismus des Immunsystems und in entzündlichen Erkrankungen ist 
ebenfalls bekannt [2, 3]. Wenig untersucht ist dagegen die Rolle, welche die Prostanoide 
innerhalb der beobachteten geschlechtsspezifischen Unterschiede spielen. Neue 
Veröffentlichungen zeigen eine unterschiedliche Regulation der Prostanoidbiosynthese in 
Tiermodellen von Entzündungsreaktionen und ebenfalls in der Leukotrienbiosynthese in 
menschlichen weiblichen und männlichen Leukozyten, einer weiteren Klasse von 
Lipidmediatoren [4, 5]. Aufgrund dieser Ergebnisse wurde im ersten Teil der Arbeit die Bildung 
der Prostanoide sowohl in menschlichem Vollblut als auch in frisch daraus isolierten Zellen 
untersucht. Die Analyse der Bestandteile des Vollblutes ergab zunächst eine grundsätzlich 
erhöhte Zellzahl an Lymphozyten und neutrophilen Granulozyten in weiblichem Blut, 
wohingegen Monozyten in höherer Anzahl in männlichem Vollblut zu finden waren. 
Langzeitinkubationen (24 Stunden) mit verschiedenen stimulierenden Agenzien wie 
Lipopolysaccharid (LPS), dem Ca2+ Ionophor A23187 oder N-Formyl-Methionyl-Leucyl-
Phenylalanin (fMLP) resultierten in signifikant erhöhten Prostanoidspiegeln, vorwiegend PGE2, 
in männlichen Proben im Vergleich zu weiblichen. Die beobachtete Erhöhung der Prostanoide 
in den männlichen Blutproben wurde nicht durch die Vorinkubation mit Sexualhormonen vor 
der eigentlichen Stimulation mit LPS beeinflusst und war unabhängig von der COX-2 Protein- 
und mRNA-Expression, die in isolierten Monozyten und mononukleären Zellen des peripheren 
Blutes (PBMC) untersucht wurde. Des Weiteren konnte eine Beteiligung von COX-1 und von 
der Ionophor A23187-induzierten AA Freisetzung in polymorphkernigen Leukozyten (PMNL) 
ausgeschlossen werden. In Kurzzeitinkubationen (bis 30 min) von humanem Vollblut und 
PMNL wurde ebenfalls kein geschlechtsabhängiger Unterschied der Prostanoidbiosynthese 
beobachtet. Mit SW033291, einem spezifischen Inhibitor der 15-Prostaglandindehydrogenase 
(15-PGDH) wurde der Einfluss auf den Prostanoidabbau untersucht. Die Ergebnisse aus 
Kurzzeit-untersuchungen (6 Stunden) stützen die Vermutung einer Beteiligung von 15-PGDH 
an der Regulation der Prostanoidspiegel. Nach Vorbehandlung weiblichen Blutes mit dem 
Inhibitor wurde die PGE2-Menge auf das gleiche Niveau angehoben, das in männlichem Blut 
ohne Inhibitorvorbehandlung festzustellen war. Zusätzlich wurden PBMC und PMNL aus 
humanem Vollblut isoliert und entweder getrennt oder nach Koinkubation stimuliert, um 
Einflüsse von Zell-Zell-Interaktionen auf die Prostanoidbiosynthese zu untersuchen. In 
Koinkubationen von männlichen Zellen konnte im Vergleich zu weiblichen eine verstärkte 
Bildung der Prostanoide beobachtet werden. Zusammenfassend kann gesagt werden, dass 
die zugrundeliegenden Mechanismen, die nach 24 stündiger Stimulation mit LPS, A23187 
oder fMLP zu dem geschlechtsspezifischen Unterschied der Prostanoidbiosynthese in 
humanem Vollblut führen, nicht vollständig aufgeklärt werden konnten. Dennoch zeigen die 
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Ergebnisse eine Beteiligung des zeitabhängigen Prostanoidabbaus und einer unterschiedlich 
ausgeprägten Biosynthese durch Zell-Zell Interaktionen nach Stimulation als mögliche 
Ursachen.  
Neben COX und den Prostanoiden, spielen die 5-LO und die LTs eine wichtige Rolle im 
Entzündungsgeschehen. Die 5-LO wandelt AA zu dem Produkt 5(S)-hydroperoxy-6-tans-
8,11,14-cis-eicosatetraensäure (5-HpETE) um, welches von der 5-LO weiter zu LTA4 
metabolisiert wird [6]. Nach Zellaktivierung translozieren 5-LO und die zytosolische 
Phospholipase (PL)A2 zur Kernmembran, wo sie zusammen mit dem 5-LO aktivierenden 
Protein (FLAP) für die Biosynthese der LTs verantwortlich sind [7]. Kürzlich veröffentlichte 
Ergebnisse identifizierten den pflanzlichen Inhaltsstoff Embelin als potenten 5-LO Inhibitor [8]. 
Embelin wurde in dieser Studie als Leitsubstanz verwendet und dessen 1,4-Benzochinon-
struktur systematisch modifiziert, so dass drei unterschiedliche Substanzserien synthetisiert 
werden konnten: Serie (I) enthielt 16 1,4- und 1,2-Benzochinone, die in 3-Position mit einer n-
Alkylkette mit 8 bis 15 Kohlenstoffatomen substituiert wurden, Serie (II) enthielt fünf 1,2-
Benzohydrochinone mit n-Alkylketten von 11 bis 13 Kohlenstoffen in 3-Position und Serie (III), 
bestehend aus 15 1,2-Benzohydrochinonen mit eher sperrigen aromatischen Resten in 4-
Position. Serie (I) wurde je nach Hydroxylierungsmuster des Benzochinonkerns nochmals in 
A, B, C und D unterteilt. Die Untersuchung des Potentials der Substanzen die 5-LO in 
zellulären und zellfreien Experimenten zu hemmen, identifizierte EA-110C aus der C-Serie als 
potenteste Substanz mit IC50-Werten im nanomolaren Bereich (IC50= 50 - 120 nM). In Serie (II) 
wurde bei den vielversprechendsten Substanzen aus Serie (I) das 1,4-Benzochinongerüst zu 
einem 1,2-Benzohydrochinongerüst reduziert und deren Fähigkeit die 5-LO zu hemmen in 
zellfreien und zellbasierten Experimenten analysiert. Die reduzierte Form der Substanz  
EA-110C (EA-110C RED) zeigte erneut IC50-Werte im nanomolaren Bereich (IC50 = 30 -  
60 nM) was ein 1,2-Benzochinon/-Benzohydrochinongrundgerüst kombiniert mit einer  
n-Alkylkette mit 13 Kohlenstoffatomen in 3-Position also optimale Struktur auszeichnete um 
mit der 5-LO Produktbildung zu interagieren. Die Untersuchung in Entzündungsmodellen am 
Tier bestätigte die Effektivität in vivo. Weitere Untersuchungen deckten eine nicht-kompetitive 
Hemmung auf, die zusätzlich durch Docking Simulationen gestützt wurde. Diese zeigten eine 
sehr wahrscheinliche Bindung von EA-110C RED auf der gegenüberliegenden Seite des AA-
Substratkanals. In Serie (III) wurden die zwei potentesten Substanzen F-XII und F-XVI im 
Detail untersucht. Beide Substanzen wiesen eine überaus potente Hemmung von 5-LO mit 
IC50-Werten im nanomolaren Bereich in zellbasierten (IC50 F-XII = 70 nM; F-XVI = 60 nM) und 
in zellfreien Experimenten (IC50: F-XII und F-XVI = 20 nM) auf. Die Hemmung der 5-LO war 
reversibel, unabhängig von der zugesetzten Substratmenge (AA) und nicht hauptsächlich 
durch Radikalfänger- oder antioxidative Eigenschaften vermittelt. Docking Simulationen 
deuteten auf eine Bindung des 1,2-Benzohydrochinonkerns an die Aminosäure Asp-166, die 
Teil einer verbindenden Salzbrücke zwischen der C-terminale katalytische Domäne und der 
N-terminale C2-ähnliche Domäne ist. Die Hemmung der 5-LO war darüber hinaus unabhängig 
von zellulären Signalen, die für die 5-LO Aktivierung notwendig sind. Die erhaltenen 
Ergebnisse aus dem zweiten Teil der vorgelegten Arbeit identifizierten die Benzohydrochinone 
F-XII und F-XVI als außerordentlich potente, direkte Inhibitoren der 5-LO vom sogenannten 
„non-redox-type“ oder „novel type“ mit hoher Selektivität in nanomolaren Konzentrationen, was 
in Experimenten mit Vollblut und in einem Zymosan-induzierten Peritonitis Tiermodell bestätigt 
werden konnte. 
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1.1 Acute inflammation and resolution 
Inflammation is defined as a complex biological process involving microbial invasion, trauma 
or irritation by toxins or non-degradable particles (e.g. asbestos) that causes tissue damage 
accompanied by the five typical pathological phenomena: tumour (swelling), calor (elevated 
temperature), rubor (redness), dolor (pain) and functio laesa (loss of function). Under normal 
conditions, acute inflammation is understood as a beneficial reaction of the host innate immune 
system to erase invading pathogens and restore tissue homeostasis. If dysregulated or 
unresolved, inflammation can become detrimental and progress to a chronic status, driving a 
wide range of diseases like atherosclerosis, intestinal bowl diseases, diabetes and asthma [9, 
10]. Invading pathogens and their secreted products are recognized by soluble receptors (e.g. 
nucleotide binding oligomerisation domain(NOD)-like receptors) or cell-surface receptors (e.g. 
toll-like receptors (TLR)) leading to the release of mediators like histamine, eicosanoids, 
cytokines and chemokines by mast cells and macrophages. The secretion of histamine and 
leukotrienes lead to an increase of vascular permeability, whereas formation of prostaglandins 
and nitric oxide (NO) leads to vasodilation [11-13]. Secretion of pro-inflammatory cytokines like 
tumor necrosis factor (TNF) and interleukins promotes the recruitment of neutrophils from the 
circulating blood to the site of infection or inflammation [14]. Following chemotactic factors (e.g. 
LTB4, fMLP) neutrophils eventually interact with endothelial cells, initiating their extravasation 
into the inflamed tissue to kill pathogens directly by engulfment or by degranulation releasing 
toxic granule contents like reactive oxygen species (ROS), proteinases and antibiotic proteins 
[12, 13]. Migration of classical monocytes to the inflamed tissue typically occurs after neutrophil 
recruitment with a maximum after 72 to 96 h.  
 
Figure 1.1: The inflammatory reaction and the resolution phase. Modified from Soenhlein et al. [14]. 
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At sites of inflammation, monocytes can differentiate to macrophages or dendritic cells, 
producing mediators like TNFα and NO to enhance microbial clearance [15, 16]. After 
successful elimination of the pathogens, neutrophils undergo apoptosis thereby signaling their 
own clearance by macrophage-driven phagocytosis and additionally prompt macrophage 
differentiation to an anti-inflammatory phenotype promoting wound healing [17, 18]. However, 
these processes not only eradicate pathogens but can also cause collateral damage of host 
tissue [19, 20]. Therefore, resolution of inflammation is a complex and actively regulated 
process, which also involves soluble mediators like specialized pro-resolving mediators (SPM), 
namely lipoxins, resolvins, maresins and protectins derived from AA and the omega-3-fatty 
acids eicosapentaenoic acid (EPA) and docosapentaenoic acid (DHA) [21]. Already in the early 
stages of inflammation activated neutrophils start producing lipoxins together with endothelial 
cells or platelets by transcellular biosynthesis, switching from a pro- to an anti-inflammatory 
response  [22, 23]. SPMs, reduce neutrophil infiltration, enhance the phagocytic capability of 
macrophages, cause recruitment of anti-inflammatory monocytes and have wound healing 
properties [21, 24-26]. Furthermore, COX-2 produces 15deoxy-PGJ2 (15d-PGJ2) via PGD2 
exerting similar effects as the lipoxins, e.g. promotion of neutrophil apoptosis and dampening 
of monocyte migration [18]. In contrast, to other classical nonsteroidal anti-inflammatory drugs 
(NSAID) acetylsalicylic acid (ASA) initiates the formation of so called aspirin-triggered epimeric 
forms of SPMs by COX-2 or the P450 pathway exhibiting pro-resolving activities. Thereby, 
ASA dampens the inflammatory reaction and supports the resolution as well [24]. In sum, acute 
inflammation and resolution are highly complex processes, where mediators and cells have to 
function together in a fine tuned clockwork to eliminate invading pathogens, prevent potential 
necrotic damage and restore tissue integrity and homeostasis. 
1.1.1 Chronic inflammation and related diseases 
When resolution fails, inflammation persists and escalates to chronic conditions leading to 
tissue degeneration and can finally peak in chronic diseases like atherosclerosis, asthma, 
inflammatory bowel diseases, rheumatoid arthritis and cancer [10]. Although the involvement 
of inflammatory pathways in the initiation of chronic inflammatory diseases is well-established, 
              
Figure 1.2: (A) Time course of inflammation and resolution, (B) Overview of selected lipid mediators and 
their actions regarding inflammation and resolution. Modified from Serhan et al. [21]. 
(A) (B) 
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the specific role by which inflammation contributes to their pathogenesis is not fully understood. 
The persistence of inflammatory stimuli of an exogenous origin often entails non-resolving 
inflammation. In fact, in many chronic infections not the toxins produced by the foreign 
organisms are responsible for the inflammatory tissue damage but the host response itself [10, 
27]. Impaired recruitment of neutrophils or the disability to undergo apoptosis can accelerate 
inflammatory conditions. Moreover, not fully cleared apoptotic neutrophils undergo secondary 
necrosis generating pro-inflammatory signals due to the release of intracellular products. 
These defects in resolution and the deficiency to clear phagocytic macrophages into lymphatic 
drainages are linked to systemic lupus erythematosus [10, 17, 18]. Additionally, resolution fails 
when the production and release of soluble mediators like SPMs is deficient or inhibited [21]. 
Another important player in inflammatory conditions is the transcription factor NF-κB, 
regulating the formation of pro- vs. anti-inflammatory interleukins. An enhanced NF-κB 
activation can lead to chronic and serious inflammatory diseases, since an overactivation of 
NF-κB is linked to atherosclerosis, asthma and ulcerative colitis [28, 29]. Especially in 
rheumatoid arthritis an excessive secretion of interleukins (mainly IL-17) is obvious that causes 
degradation of the synovial joint tissue by the release of oxidants and proteases [30]. 
Furthermore, prostaglandins which exert important roles in the onset of acute and chronic 
inflammation, and partially also in the resolution phase, can additionally prolong inflammation 
by acting as “cytokine amplifier”. PGE2 can enhance the expression of pro-inflammatory 
cytokines in macrophages and stimulate the production of leukocyte attracting chemokines 
[31]. Additionally, failure in tissue regeneration and in reconstitution of the vasculature can 
result in atrophy and fibrosis leading to loss of function of the affected organ [32].  
1.1.2 Chronic inflammation and the development of cancer 
Epidemiological data indicate that over 25% of all cancer are related to chronic infections or 
other types of unresolved inflammation [33]. Both, persistent infection and sterile chronic 
inflammation are triggers for the development of cancer, seen in infections with Helicobacter 
pylori linked to gastric cancer or inflammatory bowel diseases linked to colon cancer [34, 35]. 
Even though in many cases tumor cells use inflammatory responses to promote their own 
growth and survival, not all chronic inflammatory diseases lead to the susceptibility to develop 
cancer (e.g. rheumatoid arthritis or psoriasis) [34, 36]. Inflammation plays an important role in 
the initiation of tumor growth due to the release of ROS and therefore the promotion of DNA 
alterations [37, 38]. The tumor develops due to an enhanced expression of cytokines and 
chemokines in cancer cells, attracting inflammatory leukocytes to the site of malignancy where 
they release cytokines themselves, fostering the establishment of an inflammatory 
microenvironment [36, 37, 39]. During the progression stage, COX-2 is found among other 
enzymes highly expressed producing PGE2, which represents an angiogenetic factor and 
sustains proliferation [31]. Moreover, a high number of tumor associated macrophages (TAM) 
together with regulatory T (Treg) cells suppress the antitumor response of the adaptive immune 
system promoting cell survival, angiogenesis, tumor growth and metastasis [36, 37, 39, 40].  
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1.1.3 Toll-like receptor mediated signaling 
Upon pathogen invasion toll-like receptors (TLR) recognize distinct microbial components 
(pathogen-associated molecular patterns; PAMPs) and activate an intracellular signaling 
cascade leading to the formation of pro-inflammatory cytokines and chemokines. TLRs are 
pattern-recognition receptors (PRR) that are expressed constitutively, mainly on immune cells, 
including macrophages, monocytes and dendritic cells. To date, 13 TLRs have been identified 
in mammals, 10 in humans and 13 in mice whereas TLR4 is the most intensely studied [41]. 
The TLRs can be divided in two subfamilies, depending on their localization and the PAMPs 
they recognize. TLR1, TLR2, TLR4, TLR5, TLR6 and TLR11 are expressed on the cell surface 
and recognize bacterial membrane components such as lipids and lipoproteins, whereas 
TLR3, TLR7, TLR8 and TLR9 are localized in intracellular components (e.g. endosomes, 
endoplasmic reticulum) recognizing microbial nucleic acids. TLR4 is able to recognize a variety 
of different ligands including lipopolysaccharide (LPS) from the outer membrane of gram-
negative bacteria [42]. TLRs are type I integral membrane glycoproteins, characterized by an 
extracellular domain containing leucine-rich-repeat (LRR) motifs and an intracellular 
Toll/Interleukin 1 receptor (TIR) domain. Following PAMP binding, the TLRs form active homo- 
or heterodimers (TLR2/TLR1, TLR2/TLR6) to induce signal transduction. TLR4 activation 
requires further association with the soluble protein myeloid differentiation factor 2 (MD-2) with 
the extracellular LRR domain. For LPS activation, LPS has to bind to the plasma protein LPS 
binding protein (LPB) and is then provided via the cluster of differentiation 14 protein (CD14) 
to the MD-2/TLR4 complex [43, 44]. Formation of cytokines and chemokines follows two 
distinct signaling pathways: The myeloid differentiation primary response gene 88 (MyD88)-
dependent pathway used by all TLRs except TLR3 which is considered to mediate signaling 
in the early phase or the MyD88-independent/ TIR domain-containing adaptor inducing IFN-β 
(TRIF)-dependent pathway used by TLR3 and TLR4 observed with delayed kinetics. Both 
signaling cascades result in the activation of NF-κB and the formation of pro-inflammatory 
cytokines (TNFα, IL-6, IL-8, IL-1β) and the expression of COX-2 or in the activation of TBK1 
directly activating the interferon response factor 3 (IRF-3) and thereby inducing the 
transcription of type I interferons (INF-α/β) (Figure 1.3) [42, 44]. Upon LPS stimulation, the 
delay in NF-κB and IRF-3 activation in the MyD88-independen/ TRIF-dependent pathway is 
considered to be due to the internalization of the LPS/CD-14/MD-2/TLR4 assembly. 
Endocytosis creates an early endosome, where the association with the TIRAP/MyD88 
complex is disrupted and paves the way for interactions with TRAM/TRIF complex [45, 46]. 
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1.2 The arachidonic acid cascade 
Eicosanoids and docosanoids are formed by conversion of ω3 and ω6 20- and 22-carbon fatty 
acids, whereas arachidonic acid (AA) and docosahexaenoic acid (DHA) play crucial roles. AA 
is stored esterified in phospholipids in cellular membranes and is released by phospholipases 
(PLAs) allowing the conversion to the diverse eicosanoids. Eicosanoids represent a family of 
hormonally active mediators, which exert autocrine and paracrine functions. They can be 
divided into prostanoids produced by cyclooxygenases, leukotrienes and lipoxins produced by 
lipoxygenases and epoxy and dihydroxy fatty acids formed by the cytochrome P450 system 
[47]. 
 
 
Figure 1.3: TLR-signaling. A) MyD88-dependent, B) TRIF-dependent signaling. TIRAP, TIR-associated protein; 
IRAK, Interleukin 1 receptor (IL-1R)-associated kinase; TRAF, tumor necrosis factor receptor-associated factor; 
TAK1, TGF-β-activated kinase; MEKK, mitogen-activated protein kinase (MAPK) kinase kinase; ERK1/2, 
extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase; AP-1, activator protein 1; CREB, cAMP 
response element-binding protein; IKK, inhibitor of κB (IκB) kinases; TRIF, TIR domain-containing adaptor 
inducing IFN-β; TRAM, TRIF-related adaptor molecule; RIP1, receptor-interacting protein 1; TBK1, TRAF family 
member-associated NF-κB activator (TANK)-binding kinase 1; IRF3, interferon response factor 3. 
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1.2.1 Cyclooxygense-1/2 expression and protein function 
In the 1970s and 1980s, cyclooxygenase (COX) enzymes were purified and cyclooxygenase 
and hydroperoxidase activities were identified. COXs are present in nearly every cell type of 
the human organism and are the key enzymes in the formation of prostaglandins, prostacyclins 
(PIs) and thromboxanes (Txs), together referred to as prostanoids. Formation of prostanoids 
occurs after the release of AA from cell membrane phospholipids via PLAs in two steps: AA is 
first converted to prostaglandin G2 (PGG2) and in a second step to the intermediary 
 
Figure 1.4: The arachidonic acid cascade. The biosynthetic pathway of eicosanoids, modified after Nakamura, 
M. et al. [141]. PGES, PGE2 synthase; PGDS, PGD2 synthase; PGFS, PGF2α synthase; PGIS, PGI2 synthase; 
TxAS, TxA2 synthase; LTA4H, LTA4 hydrolase; LTC4S, LTC4 synthase; γ-GT, γ-glutamyl-transpeptidase; DP, 
dipeptidase. 
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prostaglandin endoperoxide H2 (PGH2) followed by formation of the single prostanoids via 
terminal synthases. Prostanoids are involved in a wide range of physiological and pathological 
processes including regulation of inflammation, fever and pain, platelet aggregation, ovulation 
and maintenance of renal function [48]. Two distinct COX isoforms have been described, the 
constitutively and ubiquitously expressed COX-1 exerting housekeeping functions like platelet 
aggregation, renal water balance and gastric cytoprotection and COX-2, induced as a 
response to pro-inflammatory stimuli like cytokines, endotoxins and mitogens involved in 
inflammatory diseases and cancer [49, 50]. However, constitutive COX-2 expression could be 
shown as well, for example in the brain, the kidney and the female reproductive systems and 
COX-2 could also be found contributing to gastric mucosal defense [51, 52]. The two isoforms 
arise from different genes but share 60% sequence homology. The gene for COX-1 is located 
on chromosome 9, is approximately 22 kb in length and contains 11 exons, whereas the gene 
for COX-2 is located on chromosome 1, is about 8.6 kb in length and contains 10 exons. In 
contrast to COX-1 mRNA, COX-2 mRNA is relatively unstable [48]. The translated enzymes 
contain three domains, including the epidermal growth factor-like (EGF-like), membrane 
binding, and catalytic domain [53], also see figure 1.5 after Smith et al [54]. 
Both are located in the endoplasmic reticulum (ER) and the nuclear envelope, whereas  
COX-2 is reported to be localized to a greater extend at the nuclear envelope than in the ER 
[55, 56]. The constitutive expression of COX-1 in most tissues makes transcriptional studies 
difficult, but investigations revealed a preferential expression in specific cells like vascular 
endothelial cells, monocytes or platelets and cells undergoing development or mimicking 
developmental processes [47]. Nevertheless, the expression of COX-1 can be induced as well, 
for example via shear stress or growth factors in vascular endothelial cells or via phorbol esters 
(PMA) in monocytes [48, 57]. In contrast to COX-1, several potential transcriptional regulatory 
elements have been identified in the promotor region of COX-2, e.g. two NF-κB sites. After 
LPS stimulation COX-2 expression is regulated in monocytes and macrophages via TLR4 
involving ERK1/2, JNK, and p38 MAPK together with NF-κB. Upon stimulation with 
inflammatory cytokines (e.g. IL-1β) JNK and p38 mediate the expression of COX-2, whereas 
the active proto-oncogene Ras requires ERK1/2 activation to mediate COX-2 expression [48]. 
           
Figure 1.5: Ribbon diagram of ovine COX-1 with flurbiprofene bound to the active site. Epidermal growth 
factor-like (EGF) domain is shown in green, membrane binding (MBD) domain in cyan, heme group at the 
peroxidase active site in red, catalytic domains in dark and light blue, flurbiprofene in yellow. Saccharide unit of 
glycosylation is shown in the ball-and-stick form in black. Modified after Smith et al. [54]. 
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1.2.1.1 Prostanoid formation 
Formation of the precursor PGH2  
AA, bound at the sn2 position of glycerophospholipds 
in cellular membranes, is released via activated 
phospholipases, mainly the cytosolic (c) or secretory 
(s) PLA2, converted by COX to PGH2 and further 
processed to distinct prostanoids by specific 
synthases. The COX enzymes are active as 
homodimers and are bifunctional catalysing both a 
cyclisation and a subsequent reduction. The 
peroxidase reaction occurs at a heme-containing 
active site, whereas the cyclooxygenase reaction 
occurs in a hydrophobic channel [54]. First, released 
AA is bisoxygenized with two molecules O2 to PGG2. 
Second, the 15-hydroperoxyl group of PGG2 is 
subsequently reduced to PGH2 in a peroxidase 
reaction, where other peroxidases like glutathione 
peroxidase may contribute. The COX enzymes 
require oxidation from the resting state to the 
catalytically active form. This oxidation is achieved by 
alkyl hydroperoxides or peroxynitrite formed by 
inflammatory cells [58]. During activation, an electron 
is transferred from the peroxidase heme iron to  
Tyr-385 generating a tyrosyl radical, which is able to 
remove the 13-pro-S hydrogen from AA bound in the 
oxygenase active site. Thereby, a free radical is 
created, which allows the regioselective addition of 
oxygen at the C11 atom. The caused hydroperoxid 
radical forms a cyclic peroxide with C9 leaving an 
adjacent carbon radical leading to a cyclopentane 
ring, in which a bond is formed between C8 and C12. 
After addition of the second O2 molecule in C15, 
another peroxyl radical is created, which is reduced 
by a hydrogen atom provided by Tyr-385 to from PGG2. Subsequently, the peroxidase activity 
reduces the 15-hydroperoxyl by two electrons to PGH2 containing a hydroxyl group [54, 59]. In 
contrast to COX-2, COX-1 requires a higher concentration of peroxides to become activated 
and to sustain the formation of PGG2 and furthermore, needs higher concentrations of AA  
(> 10 µM AA) than COX-2 to initiate the formation of PGH2 [50]. Originating from PGH2 the 
prostanoids are formed by specific synthases: PGD2 by the hematopoietic and the lipocaline-
type PGD synthase (H-/L-PGDS), PGE2 by microsomal (m) PGE synthase-1/2 (mPGES-1/2) 
and the cytosolic (c) PGES, PGF2α by the PGF synthase (PGFS), PGI2 by PGI synthase (PGIS) 
and TxA2 by the TxA synthase (TxAS) [54]. 
 
 
 
 
Figure 1.6: Proposed reaction mechanism 
of PGH2 formation, modified after Smith, W. 
L. [54], Kim, S. F. [58] and Seo, M. J. et al. 
[60]. 
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PGD2  
PGD2 is formed via the isomerization of the endoperoxide of PGH2 to a 9-hydroxy and 11-keto 
group by H- or L-PGDS. H-PGDS is predominantly found in mast cells, dendritic cells, and Th2 
cells, whereas L-PGDS is mostly found in tissue of the heart, testis or kidney, and monocytes 
after LPS treatment [54, 60]. PGD2 is an important mediator in allergic rhinitis and asthma, 
which exerts its biological activity via two GPCRs, DP1 and DP2 [61]. Eventually, dehydration 
of PGD2 leads to the formation of 15d-PGJ2 in various inflammatory tissues, which modulates 
the synthesis of pro-inflammatory cytokines [62]. 
PGE2 
The conversation of PGH2 to PGE2 is mediated by three different synthases, mPGES-1/-2 and 
cPGES. mPGES-2 and cPGES are constitutively expressed with unclear importance, whereas 
mPGES-1 is an inducible key enzyme simultaneously expressed with COX-2 upon 
inflammatory stimuli [63-65]. mPGES-1 is a member of the membrane-associated proteins in 
eicosanoid and glutathione metabolism (MAPEG) family, requires GSH as cofactor and is 
active as a homotrimer [66, 67]. Isomerization of the 9,11-endoperoxide of PGH2 to a 11-
hydroxy and 9-keto group via GSH forms PGE2. PGE2 is the most abundant product of COX 
challenged with AA and plays a pivotal role in inflammatory reactions, inflammatory diseases, 
cancer and in resolution of inflammation via its four distinct receptor subtypes EP1-4 [61, 68]. 
PGF2α 
Formation of PGF2α can be achieved by two electron reduction of the PGH2 peroxide or 
additionally, by the reduction of the 9-keto group of PGE2 or the 11-keto group of PGD2. PGFS 
enzymes are classified as aldo-keto reductases, containing a NADPH-dependent oxido-
reductase activity [54]. PGF2α is a widely distributed prostaglandin in various organs and 
mediates contraction of smooth muscle in the vasculature, the bronchial tubes and most 
important in the human uterus via the PGF2α receptor (FP).  
PGI2 
The PGIS is a member of the cytochrome P450 family (CYP8A1) where heme is bound via the 
thiolate anion of Cys-441 to the iron. The initial step of the PGI2 synthesis seems to be a radical 
reaction involving the heme iron with subsequent cyclisation and double bond formation [54, 
60]. PGIS is preferentially co-localized with COX-2 in the nuclear envelope and plays a 
protective role in cancer development [69, 70]. PGI2 is primarily produced by endothelial cells 
and mediates vasodilatory, anti-thrombotic and atheroprotective effects via the PGI2 receptor 
(IP), maintaining cardiovascular homeostasis.  
TxA2 
Like the PGIS, the TXAS is a member of the P450 family with a heme bound iron. TxA2 is 
synthesized by creation of a radical and subsequent formation of the characteristic oxirane 
ring. Besides synthesis of TxA2, TXAS catalyzes the formation of 12-hydroxy-heptadeca-
trienoic acid (12-HHT) from PGH2 possessing wound healing properties [60, 61, 71]. Platelets 
release TxA2 formed by COX-1 and TXAS, whereas in macrophages and monocytes COX-2 
can be involved. The pro-thrombotic vasoconstrictor TxA2 plays a crucial role in regulation of 
cardiovascular homeostasis and platelet aggregation via the TP receptor expressed in thymus, 
spleen, kidney, platelets, endothelium and smooth muscle of vasculature [72]. 
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1.2.1.2 COX in inflammatory diseases and cancer 
Since prostanoids play a pivotal role in inflammatory reactions, persistent activation of COX-2 
is linked to the development of numerous inflammatory diseases, e.g. rheumatoid arthritis, 
colitis, asthma and allergic conditions [31, 54]. As mentioned above, COX-2 and mPGES-1 
overexpression is also found in many types of cancer, including colorectal, gastric and breast 
cancer [48]. Overexpression of both enzymes mediates elevated levels of PGE2, which can 
exert immunosuppressive and angiogenetic effects. An increase in PGE2 levels entails a 
decrease in PGD2 simultaneously decreasing the formation of anti-inflammatory 15d-PGJ2 [62]. 
The treatment with NSAIDs has been shown to reduce cancer risk and cancer related death 
via inducing apoptosis or cell cycle rest, thereby decreasing cellular proliferation [73, 74]. 
Although, cyclooxygenases are not only involved in the onset of inflammation but also in 
resolution and wound healing, treatment with anti-inflammatory drugs like NSAIDs can prolong 
the inflammation and delay the resolution. 
1.2.2 Sex differences in immunity and inflammation 
Already in the 1960s a differential immune response between male and female children to 
bacterial infection has been observed [75]. Up to now it is known that female individuals are 
more resistant to certain bacterial infections but suffer from a higher incidence of autoimmune 
diseases, for example rheumatoid arthritis, asthma or systemic lupus erythematosus (SLE), 
whereas males are more susceptible to infections, sepsis/septic shock and atherosclerosis. 
This circumstance is based on different mechanisms of the innate and adaptive immunity of 
males and females, also called the sexual dimorphism in immunity [76, 77]. In infections, the 
higher immune response of females results in the accelerated clearance of the pathogens but 
also increases the risk of developing an autoimmune or inflammatory disease. The number 
and activity of immune cells differ between the sexes and so the production of cytokines. 
Whereas the number of T lymphocytes is lower in males compared to females, the number of 
monocytes is higher producing elevated levels of pro-inflammatory cytokines (IL-1β, IL-6,  
IL-12 and TNFα) in males. In contrast, granulocytes are found in higher numbers in females 
and they exert an increased phagocytic effectivity as compared to males [2, 78]. Moreover, 
antigen presenting cells (APCs) are more efficient in females resulting in an increased 
activation of naïve T cell differentiation to T helper 1 cells [79]. The sex-specific difference in 
immune responses involves effects of the sex hormones. Both, the estrogen receptor and the 
androgen receptor are found in numerous cell types, including T and B cells, dendritic cells, 
macrophages, and endothelial cells [79]. Besides the capability to modulate neutrophil activity 
and the T cell expression, estrogen decreases the formation of TNFα, IL-6 and IL-12 and is 
able to increase the nitric oxide (NO) synthase. Additionally, estrogen enhances the production 
of antibodies by B cells (IgG and IgM) and has been reported to promote the expression of 
mediators responsible for B cell survival. Thus, strengthening the adaptive immune response, 
these mechanisms eventually lead to the induction of autoantibody formation and elevate the 
susceptibility to autoimmune diseases [2]. Also, the involvement of estrogen in the regulation 
of ROS mediated damages and expression of antioxidant enzymes together with the ability to 
decrease low-density lipoprotein (LDL) serum levels are discussed effects of atherosclerotic 
protection [80, 81]. However, recent findings suggest a cardioprotective role of androgens in 
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men but not in woman [82, 83] and show that testosterone improves vasodilation [84]. 
Regarding the difference in the immune responses to pathogens of males and females, the 
expression of TLRs and associated proteins, as well as the COX-2 pathway was evaluated 
intensively in animal models and in human diseases with inconsistent results, however 
indicating a rather higher expression level of TLR4 and COX-2 in male individuals [85-87]. 
Besides, differential expression of lipid mediators between sexes could be determined. The 
predominant expression of leukotrienes in female monocytes and neutrophils compared to 
males seems to be regulated by androgens via activation of ERK1/2 and a different subcellular 
distribution of the 5-LO [4, 88]. Taken together, sex plays a crucial role in the immune response 
and the severity of certain diseases. However, little is known about the mechanisms underlying 
these differences. The dimorphism has to be elucidated in further studies to enlighten the 
understanding of the underlying mechanisms, and to be able to treat male and female 
individuals with optimal customized pharmacotherapy. 
1.2.3 Human lipoxygenases 
Besides COX enzymes the lipoxygenases (LOs) play a prominent role in inflammatory 
conditions, diseases and cancer. The LO superfamily consists of lipid-peroxidizing enzymes 
that catalyze the dioxygenation of polyunsaturated fatty acids containing a series of cis double 
bonds. Six human LOs are known, 5-LO, 12-LO, 12/15-LO, 15-LO type 2, 12(R)-LO and 
epidermal LO, named after the position of oxygen insertion. Except for the 12(R)-LO the 
stereochemistry of the oxygenated carbon is S [89]. 
1.2.3.1 5-lipoxygenase expression and regulation of activity 
In 1976, an enzyme converting AA to 5(S)-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic 
acid (5-HpETE) in rabbit polymorphonuclear leukocytes (PMNL) has been discovered and 
soon its significance in human became evident [90, 91]. The 5-lipoxygenase is one of the six 
human lipoxygenases mainly found in leukocytes, responsible for leukotriene and lipoxin 
formation [92]. Upon leukocyte activation, AA is released by cPLA2 from cellular membranes 
and delivered to 5-LO by the 5-LO activating protein (FLAP). Subsequently, the leukotrienes 
are biosynthesized via 5-H(p)ETE forming the unstable epoxide LTA4, which is further 
converted to LTB4 by enzymatic hydrolysis or to the cysteinyl LTs (cys-LTs) LTC4, LTD4 and 
LTE4 by addition of GSH [93]. LTs promote chemotaxis of leukocytes and increase vascular 
permeability, driving hypersensitivity reactions and allergic responses, like allergic rhinitis and 
asthma through distinct GPCRs [94, 95]. Furthermore, they are involved in the development 
of atherosclerosis and cancer [96, 97]. 5-LO expression is primarily restricted to leukocytes 
and the promoter region shows typical properties of a housekeeping gene, which is 
constitutively expressed. The expression of 5-LO can be regulated via DNA-methylation and 
can be up-regulated by TGF-β and 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) in differentiating 
Mono Mac 6 cells due to posttranscriptional events and by GM-CSF in mature neutrophils [98, 
99]. 5-LO is a soluble 78 kDa protein containing 672 or 673 amino acids consisting of two 
domains, the regulatory N-terminal C2-like domain (residues 1-112) and the catalytic  
C-terminal domain (residues 126-673). The C2-like domain contains the binding site for Ca2+, 
for membrane phosphatidylcholines (PC) and coactosin-like proteins (CLP), whereas the 
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catalytic domain contains the non-heme iron active site [100]. The two domains are connected 
via a salt bridge between Arg-101 on the C2-like domain and Asp-166 on the catalytic domain 
[101]. Recently, a mutated form of the 5-LO protein could be crystallized, the “stable-5-LO” 
with some sequence modifications [102]. The crystallized structure revealed a unique property 
of the small helix α2 in the catalytic domain, of which the side chains of Phe-177 and Tyr-181 
appear to be able to block the entrance to the active site (“FY cork”), controlling access to the 
catalytic iron [89, 102]. The iron is coordinated by three conserved histidines (His-367, 372, 
550), Asn-554 as well as the carboxylate of the C-terminal Ile-673. In the inactive state, the 
iron is present in the ferrous from (Fe2+) while activation with lipid hydroxyperoxides (LOOH) 
like 5-HpETE or 12-HpETE transfer it to the active ferric form (Fe3+) [103]. The cavity of the 
active site is formed by the hydrophobic chains of the amino acids Leu-368, 373, 414, 607 and 
Ile-406, positioning the pentadien structure of AA in the required position [102]. The 
mechanism how AA enters the cavity, is not exactly known, but there exist two hypotheses. 
AA could either enter the cavity with its ω-end or the “FY-cork” is somehow unplugged and AA 
enters with its carboxyl head first [6]. 
Calcium and ATP 
Activation of 5-LO is induced by Ca2+-mediated binding to PCs or CLP and further increased 
by ATP-binding. The stimulatory effect of ATP appears to increase with the number of 
phosphates (AMP < ADP < ATP) even though without the need to be hydrolyzed [104]. The 
C2-like domain has been shown to bind Ca2+ in a stoichiometry of about 2:1 per 5-LO protein 
with a Kd of about 6 µM. The half-maximal activation is obtained in presence of 1-2 µM calcium, 
whereas fully in vitro activation is reached at a concentration of 4-10 µM. Ca2+-binding 
mediates the translocation to the nuclear envelope and increases the hydrophobicity of the 
enzyme by neutralizing negatively charged amino acids, allowing to associate close to the 
membrane [105, 106]. Mutagenesis studies revealed the amino acids Asn-43, Asp-44 and  
Glu-46 situated in the loop 2 of the regulatory C2-like domain important for Ca2 binding [107]. 
 
Figure: 1.7: Structure of human 5-LO. A) Model of 5-LO based on the crystal structure of rabbit reticulocyte  
15-LO. C2-like domain: green; catalytic domain: purple; active site: dark blue; phosphorylated serine residues: light 
blue; Ca2+ binding site: red; PC/CLP binding site: yellow. According to Rådmark et al. [100]. B) The 5-LO active 
site. Amino acids coordinating the iron (orange sphere): His-367, His-372, His-550, Ile-673, Asn-554 in white sticks. 
Amino acids creating the elongated cavity: Leu-368, Leu-373, Leu-414, Leu-607, Ile-406 in green sticks, according 
to Gilbert et al. [102]. 
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Membranes and phosphatidylcholines 
The binding of 5-LO to membranes activates the enzyme and could be mimicked using PC 
containing vesicles, which act as scaffold factors. Like Ca2+, PCs increase the hydrophobicity 
and are required for basal and Ca2+-activated 5-LO activity. The PC selectivity is suggested to 
direct 5-LO to the nuclear envelope and stabilizes the structure of the enzyme as well as of the 
membrane. Responsible for membrane binding are the three tryptophans in the C2-like 
domain, i.e. Trp-13, 75 and 102 [100]. 
Coactosin-like protein 
The CLP is a member of actin-binding protein family able to bind F-actin. The binding sites for 
F-actin and 5-LO are similar and overlap, resulting in a competition for CLP binding [108]. CLP 
functions as a scaffold for 5-LO and can additionally support Ca2+-mediated activity in the 
absence of PCs leading to 5-HETE formation but nearly no LTs. When CLP was present 
together with PCs activity was enhanced leading to a 3-fold higher LTA4 formation [109]. 
Phosphorylation 
Activation of 5-LO can be mediated by phosphorylation of different serine residues. Upon cell 
stress (e.g. phorbol esters, osmotic stress, heat shock), activated p38 MAPK phosphorylates 
the MAPK activated kinases-2/3 (MK-2/3), which in turn phosphorylates 5-LO at Ser-271 [110] 
whereas the MAPK ERK1/2 phosphorylate 5-LO at Ser-663 [111]. Both phosphorylations 
induce translocation and increase the 5-LO enzyme activity, in particular when both residues 
are phosphorylated at the same time. The activation by both kinases is promoted by fatty acids 
including AA [112]. In contrast, exogenous adenosine and increased cAMP are able to activate 
proteinkinase A (PKA) which phosphorylates 5-LO at Ser-523 thereby inhibiting 5-LO 
translocation [113]. 
Agents capable of activating 5-LO in the cell 
Compounds leading to an elevation of the intracellular Ca2+ level are crucial for LT formation, 
for example ionophores, thapsigargin, platelet-activating factor (PAF), LTB4, fMLP and 
complement component 5a (C5a). Among these compounds, Ca2+ ionophores mediate the 
strongest 5-LO product formation, whereas natural compounds are less efficient [114]. LT 
generation can be enhanced by “priming” with compounds, which do not increase 5-LO activity 
themselves. For example, priming with LPS followed by stimulation with fMLP strongly 
increases 5-LO product formation and elevates kinase activity phosphorylating cPLA2 [115]. 
1.2.3.2 Subcellular translocation and the role of FLAP 
In which cell compartment 5-LO is found in resting cells, is dependent on the cell type. In 
primary neutrophils, 5-LO is rather found in the cytoplasm, whereas in primary monocytes  
5-LO is distributed between the nucleus and the cytosol [100, 116]. Independent of the cellular 
localization, upon cell stimulation 5-LO translocates in a Ca2+-mediated manner to the outer or 
inner leaflet of the nucleus where membrane bound FLAP transfers AA to 5-LO to initiate 
leukotriene formation [117]. 
FLAP 
FLAP is an 18-kDa integral nuclear membrane protein, a member of to the MAPEG family and 
was discovered as a target of MK886 [118]. FLAP forms active trimers anchored in the inner 
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as well as in the outer nuclear membrane partly associated with LTC4-synthase (LTC4S) and 
is necessary for the LT formation, although it lacks enzymatic activity. It is thought to act as a 
transfer protein, which enables conversion of AA to LTs, although the exact mechanism of AA 
transfer is currently unknown [7]. FLAP is required for the conversion of endogenous AA, but 
can enhance the transformation of exogenous AA as well [119, 120]. The expression coexists 
with 5-LO expression and upregulation is often observed coincidently as well [114]. 
1.2.3.3 Leukotriene formation 
The 5-LO enzyme contains two distinct activities, 
dioxygenase activity and epoxide formation by the LTA4S 
activity. 5-LO catalyzes the stereospecific insertion of 
molecular O2 at C5 of AA forming 5(S)-hydroperoxy-6-
trans-8,11,14-cis-eicosatetraenoic acid (5-HpETE) 
followed by immediate dehydration forming the unstable 
5(S)-trans-5,6-oxido-7,9-trans-11,14-cis-eicosa-
tetraenoic acid (LTA4) [121]. For 5-LO catalytic activity the 
active site iron hast to be oxidized from the inactive 
ferrous to the active ferric state. Ferrous 5-LO reacts with 
hydroperoxides (e.g. 5-HpETE, 12-HpETE) creating an 
oxygen-substituted lipid radical and a hydroxide ion. The 
ferric form later reacts with a reducing agent to regenerate 
the ferrous form [104]. Lipid peroxides can also be 
generated for example via ROS formation. The first step 
in the generation of 5-HpETE is the abstraction of the pro-
S hydrogen at C7. Radical rearrangement leads to the 
formation of a radical at C5, where molecular oxygen is 
inserted generating a peroxy radical. The iron is 
subsequently oxidized by electron transfer to the peroxy 
radical giving a peroxy anion, followed by protonation 
resulting in the hydroperoxide and the active ferric (Fe3+) 
state [6]. The LTA4S activity mediates abstraction of the 
pro-R hydrogen at C10 with radical migration to C6 and 
double bond rearrangement to form the unstable epoxide 
(LTA4) with a conjugated triene system. 5-HpETE can 
alternatively be reduced by glutathione peroxidases to the 
corresponding alcohol 5(S)-hydroxy-6-trans-8,11,14-cis-
eicosatetraenoic (5-HETE) [122]. 5-LO is additionally 
involved in the formation of 5-oxo-eicosatetraenoic acid (5-oxo-ETE) from 5-HETE [123] and 
together with 12-LO and 15-LO in the formation of anti-inflammatory lipoxins by transcellular 
mechanisms [124]. Subsequent hydrolysis by the soluble LTA4-hydrolase (LTA4H) yields the 
bioactive 5(S),12(R)-dihydroxy-6,14-cis-8,10-trans-eicosatetraenoid acid (LTB4). In 
preparations of purified 5-LO enzyme, LTA4 non-enzymatically degrades into two isomers  
(6-trans-LTB4 and 6-trans-12-epi-LTB4) [125]. In contrast, LTC4S mediates conjugation of GSH 
to the epoxide moiety generating 5(S)-hydroxy-6(R)-S-glutathionyl-7,9-trans-11,14-cis-
 
 
Figure 1.8: 5-LO catalytic formation 
of 5-HpETE and LTA4, modified after 
Rådmark [104] and Haegstrom et al. 
[6]. 
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eicosatetraenoic acid (LTC4). LTC4 is released from the cell and extracellular enzymes 
consecutively cleave the GSH tripeptide forming 5(S)-hydroxy-6(R)-S-cysteinylglycyl-7,9-
trans-11,14-cis-eicosatetraenoic acid (LTD4) and 5(S)-hydroxy-6(R)-cysteinyl-7,9-trans-11,14-
cis-eicosatetraenoic acid (LTE4). The γ-glutamyl transferase eliminates γ-glutamyl yielding 
LTD4, whereas dipeptidases cleave glycine generating LTE4 [126]. LTB4 and LTC4 can also be 
generated through transcellular mechanisms between two different cell types, like epithelial 
cells and platelets [127].  
1.2.3.4 Other enzymes involved in the leukotriene biosynthesis 
Cytosolic phospholipase A2 
The phospholipase family contains more than 30 different enzymes possessing PLA2 or related 
activity, characterized by their structure, localization and requirement of Ca2+ [128]. The 
cytosolic PLA2 group IV (cPLA2)α is constitutively expressed in most cells and tissue and is 
responsible for the release of sn-2 bound AA from cellular membranes in the leukotriene 
pathway. cPLA2 is an 85 kDa protein consisting of an N-terminal C2 domain and a C-terminal 
catalytic α/β hydrolase domain. Ca2+ binding at the C2 domain neutralizes negative charges, 
activates the enzyme and initiates translocation to the perinuclear membrane. The C2 domain 
anchors cPLA2 in the membrane allowing hydrophobic interaction of the catalytic domain with 
membrane phospholipids preferentially with phosphocholine head groups [128-130]. 
LTA4 hydrolase 
LTA4 hydrolase (LTA4H) catalyzes the conversion from LTA4 to LTB4. LTA4H is found in most 
cells and tissues, preferentially in neutrophils, however, with low levels in eosinophils and 
completely absent in basophils and platelets. The 68 kDa enzyme gets inactivated by its own 
substrate LTA4, called a suicide inactivation [6]. LTA4H is a zinc-dependent epoxide hydrolase 
and aminopeptidase containing an N-terminal, a catalytic and a C-terminal domain [131]. The 
opening of the epoxide of LTA4 (C5 to C6) generates a carbocation delocalized over the 
conjugated triene system creating the essential cis double bond between C6 and C7 followed 
by insertion of the 12(R)-hydroxyl group [132]. 
LTC4 synthase 
Like FLAP, the LTC4 synthase (LTC4S) is an 18 kDa protein and a GSH-dependent member 
of the MAPEG family, expressed in leukocytes including eosinophils, mast cells and 
monocytes. LTC4S is responsible for the conversion of LTA4 to LTC4, the parental compound 
of the cys-LTs [131]. LTC4S is active as a heterotrimer, containing three transmembrane 
domains, situated at the nuclear membrane, partially colocalized with FLAP. LTA4 binds in a 
hydrophobic gap, where it is in the optimal position for conjugation with GSH [133, 134]. Attack 
of the GSH anion leads to inversion and formation of the R-configuration followed by the 
formation of the 5(S)-hydroxyl group [135]. 
1.2.3.5 Biological and pathological effects of leukotrienes 
Leukotrienes exert their biological activity via cognate GPCRs on target cells. They are 
predominantly produced by pro-inflammatory cells, like polymorphonuclear leukocytes, mast 
cells and macrophages and are involved in allergic reactions and inflammatory diseases. 
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LTB4 
LTB4 is the most potent chemoattractant released by neutrophils mediating recruitment of 
inflammatory cells like eosinophils, monocytes, macrophages as well as T cells, linking the 
innate and the adaptive immune system. At the site of inflammation, LTB4 promotes neutrophil 
activation and degranulation, is involved in enhancing phagocytic mechanisms and increases 
the production of inflammatory cytokines (IL-1, IL-2, IL-6) and chemokines [136], associating 
LTB4 with atherosclerosis [137], rheumatoid arthritis and also with cancer [97, 138]. 
Furthermore, LTB4 is released by alveolar macrophages, bronchial epithelial cells and 
fibroblasts, indicating a role in asthma and chronic obstructive pulmonary diseases (COPD) 
[139]. The effects of LTB4 are mediated by 2 distinct GPCRs, BLT1 exclusively expressed in 
inflammatory cells and BLT2 ubiquitously expressed in various tissue. BLT2 functions as a 
low-affinity receptor for LTB4, additionally binding 12-HETE, 15-HETE and with high affinity  
12-HHT [6]. 
Cys-LTs 
Cys-LTs are a group of lipid mediators composed of LTC4, LTD4 and LTE4, known as the “slow 
reacting substance involved in anaphylaxis” (SRS-A). They are mainly produced by 
eosinophils, basophils, mast cells and macrophages and can additionally be generated by 
transcellular mechanisms together with platelets or endothelial cells [127]. The classical effects 
mediated by the cys-LTs are contraction of smooth muscle, increased vascular permeability 
and plasma leakage leading to oedema formation, mucus secretion and damage to the mucus 
layer in the lung [140]. Furthermore, cys-LTs enhance the production of chemokines (MCP-1) 
and mediate increased adhesion of neutrophils and eosinophils [141]. These effects associate 
the cys-LTs preferentially with asthma [142], but also with atopic dermatitis and cardiovascular 
diseases [141]. Cys-LTs mediate their effects via the two GPCRs CysLT1 and CysLT2 which 
preferably bind LTD4 and LTC4 and are widely expressed, e.g. in spleen, smooth muscle, lung 
and inflammatory cells [143, 144]. Since both CysLT receptors bind LTE4 with low affinity it 
could be shown that LTE4 mediates its pro-inflammatory activity via P2Y12, a receptor for 
adenosine diphosphate [145]. 
1.2.3.6 12- and 15-lipoxygenases 
The lipoxygenases are classified according to the position where they mediate the 
regioselective dioxygenation of AA, i.e. at C12 or C15 resulting primarily in 12-H(p)ETE and 
15-H(p)ETE. 12-LO is preferentially expressed in platelets (platelet-type 12-LO), whereas  
15-LO is expressed in leukocytes like eosinophils and epithelial cells [92]. Both 12-H(p)ETE 
and 15-H(p)ETE mediate inflammatory reactions: Together with LTB4 12-H(p)ETE regulates 
platelet aggregation and is associated with cancer risk (colorectal cancer, breast cancer),  
15-H(p)ETE plays a role in cardiovascular diseases like atherosclerosis and modulates cellular 
oxidative stress [96]. In contrast, cooperation of 5- and 12-LO, and 5- and 15-LO, respectively, 
leads to the generation of anti-inflammatory class of lipoxins [124]. 
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1.2.3.7 5-LO inhibitors 
In order to develop selective and potent drugs to interfere with the inflammatory effects of LTs, 
different approaches were made. Besides the use of LT receptor antagonists like montelukast, 
direct targeting of 5-LO is a promising therapeutic strategy to suppress leukotriene formation. 
Furthermore, the development of specific FLAP, LTA4H or LTC4S inhibitors are currently 
pursued. 5-LO inhibitors can be classified into four main groups based on their molecular mode 
of action: redox-type inhibitors, iron-ligand inhibitors, non-redox-type inhibitors and novel-type 
inhibitors acting at the C2-domain [121]. 
Redox-type inhibitors of 5-LO 
Redox-type inhibitors are lipophilic substances, which interfere with intracellular peroxides 
(LOOH) [146], the intracellular oxidative tone or directly reduce the active site iron to the 
inactive ferrous (Fe2+) state [147, 148]. Many of these compounds are plant-derived products 
like flavonoids, caffeic acid, coumarins, quinones and polyphenols [149]. Examples for 
synthetic compounds are BW-755C and L-656,224. However, due to low selectivity for 5-LO 
they lack efficacy in vivo and exert severe adverse effects like methemoglobin formation by 
interacting with other redox catalyzed enzymes or production of reactive superoxide anions 
[150]. Additionally, many of these natural compounds are insoluble and thus poorly 
bioavailable [151]. Regarding these negative properties. it is not surprising that no redox-type 
5-LO inhibitor could be introduced into the market so far. 
Iron ligand inhibitors 
Studies to improve the efficacy in vivo and to reduce the adverse effects revealed compounds 
with hydroxamic acids or related N-hydroxy urea structures as potent inhibitors. They chelate 
the active site iron thereby inhibiting the enzyme and stimulate peroxidase activity [152, 153]. 
BWA4C, a N-acylhydroxylamine compound showed selectivity for 5-LO and potent inhibitory 
potential (IC50 = 40 nM in intact cells), however, the essential hydroxamate group is rapidly 
metabolized to an inactive carboxylate form generating toxic nitride radicals [154, 155]. Further 
development yielded the more hydrolytically stable zileuton containing a N-hydroxy urea 
 
Figure 1.9: Synthetic redox-type inhibitors of human 5-LO. 
 
 
 
Figure 1.10: Iron ligand inhibitors. 
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structure (IC50 = 0.5 - 1 µM in intact cells). So far, zileuton is the only direct 5-LO inhibitor 
introduced to the market [156], of which the extended-release formulation is approved in the 
USA for the treatment of asthma (Zyflo®), whereas the immediate-release formulation was 
withdrawn in 2008. Based on zileuton, the thiophene analogue ABT-761 (atreleuton) was 
designed with promising efficacy blocking bronchoconstriction in asthma [157] but phase III 
clinical trials have been discontinued. For the treatment of acute coronary syndrome it is 
currently investigated in phase II trials [158]. 
Non-redox-type inhibitors 
Promising structures like methoxytetrahydropyrans were identified to compete with AA or 
LOOH for the binding to 5-LO, probably in an allosteric mode of action [159, 160] and 
compounds like ZM-230487 and ZD-2138 showed promising selective oral activity (IC50 = 20 - 
50 nM in human whole blood) [114, 161]. Their activity was impaired by increased peroxide 
levels, but could be potentiated by the addition of GSH or dithiothreitol (DTT) indicating the 
involvement of glutathione peroxidases [162]. Moreover, it could be shown that the inhibitory 
potency of these non-redox-type inhibitors is impaired by the activation of kinases 
phosphorylating the enzyme [163].  
To date, numerous novel series with different basic structures were developed, for example 
urea derivatives with dodecyl chains (RBx 7796; IC50 = 5 µM in intact cells) [164], substituted 
coumarin structures and derivatives (L-739,010) [165], imidazoles and tetrahydropyran-
carboxamides (CJ-13,610, IC50 = 70 nM in intact cells) [166] of which all exert promising anti-
inflammatory effects in vitro and in vivo [121]. Recent findings show that compounds bearing 
a Michael acceptor structure potently inhibit 5-LO by binding to four cysteines (Cys-159, -300, 
-416 and -418) situated close to the catalytic center, e.g. AA-861 (IC50 = 0.2 µM in intact cells) 
[167]. Another promising approach to improve 5-LO inhibitors was pursued based on the potent 
inhibition of the plant-derived 1,4-benzoquinone embelin (IC50 = 60 nM in intact cells) [8]. 
Structural optimization yielded the compounds RF-Id [168, 169] and RF-22c (IC50 = 22 nM in 
intact cells) [170], both remarkably effective in cell-based assays as well as in inflammatory 
animal models of bronchoconstriction. 
 
 
Figure 1.11: Non-redox-type inhibitors of 5-LO. 
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Novel type inhibitors 
Additionally, there are inhibitors which cannot be classified by the three groups mentioned 
before. A possible mode of action is interference with the C2-like domain as described for  
3-O-acetyl-11-keto-boswelic acid (AKBA) derived from Boswellia species and hyperforin from 
Hypericum perforatum. It is indicated that AKBA interacts with the PC binding site of the C2-
like domain or with a second regulatory selective binding site different from the AA-binding site 
in a Ca2+-dependent manner. Unfortunately, AKBA failed to inhibit LT generation in whole 
blood [171], whereas a Boswellia serrata extract has reached Phase II trial for osteoarthritis 
[172]. The compound hyperforin interferes with the 5-LO C2-like domain preventing the 
interaction of 5-LO with CLP and the translocation to the nuclear membrane and displays 
efficacy in vivo models like carrageenan-induced pleurisy [153]. 
Dual 5-LO/COX inhibitors 
In order to provide a more efficient inhibition of eicosanoid formation, dual inhibitors of COX 
and 5-LO were designed. The prototype licofelone (ML3000) was found to interact with FLAP, 
COX-1 and mPGES-1 [163, 173] and is currently tested in Phase III clinical trials for 
osteoarthritis, though there is no development report for this study. Recently, new structures 
based on the COX-2 selective coxibes were designed, since celecoxib was shown to impair  
5-LO activity as well [174]. Numerous novel structures like diaryl-dithiolane and isothiazole and 
series of phenylsulfonyl urenyl chalcone (e.g. Me-UCH 1) derivatives were identified as 
promising dual inhibitors [175] exerting anti-inflammatory effects in vitro as well as in vivo [176].  
Dual 5-LO/mPGES-1 inhibitors 
Based on the dual 5-LO/COX inhibitors, more specialized compounds were designed to lower 
adverse effects. Thus, compounds like pirinixic acid derivatives interfering with 5-LO and 
mPGES-1 were introduced. They potently suppressed the formation of 5-LO products and the 
   
 
Figure 1.12: Novel type inhibitors. 
    
Figure 1.13: dual inhibitors of 5-LO/COX and 5-LO/mPGES-1. 
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generation of PGE2 in vitro (IC50 = around 1 µM, for both enzymes) and in vivo [177, 178]. 
Another class of dual 5-LO/mPGES-1 inhibitors comprise the benzo[g]-indole-3-carboxylate 
structures. The lead compound of this series potently hampers 5-LO (IC50 = 0.23 µM in intact 
cells, 0.83 - 1.6 µM in human whole blood) and mPGES-1 activity (IC50 = 0.6 µM, isolated 
enzyme) and additionally showed efficacy in animal models of inflammation [179, 180]. 
1.2.3.8 Inhibition of other enzymes involved in LT formation 
FLAP inhibitors 
A novel strategy to circumvent direct inhibition of 5-LO activity but still block LT formation is 
interference with FLAP [181]. The first determined FLAP inhibitor was the indole MK886, with 
potent inhibitory properties (IC50 = 2.5 nM in intact cells) but was unfortunately about 50-fold 
less active in human whole blood (IC50 = 1.1 µM) [182]. Intensive research revealed novel 
compounds highly active also in human whole blood with additional confirmed efficacy in 
asthma patients as determined for GSK2190915 [183, 184]. Promising results were also 
obtained with the nonacidic benzimidazole BRP-7 and its structurally optimized derivatives 
regarding inhibition of 5-LO product synthesis in cell-based assays as well as zymosan-
induced peritonitis in mice [185, 186]. Other indole derivatives like AM103 (IC50 = 4.2 nM, 
FLAP-binding assay) [187] and AM803 (IC50 = 76 – 506 nM, FLAP-binding assay) [188] 
displayed potent inhibition of 5-LO and both compounds were investigated in clinical trials. 
However, the current status for AM103 is not publicly known and for AM803 testicular toxicity 
in rats was reported. 
LTA4 hydrolase and LTC4 synthase inhibitors 
In contrast of classical 5-LO and FLAP inhibitors, the inhibition of LTA4H and LTC4S still allows 
the generation of LTA4 necessary for the formation of anti-inflammatory lipoxins. Thus, 
intensive studies are made in this field and revealed azabenzthiazole [189] and substituted 
benzofurans [190] as potent LTA4H inhibitors. With ARM1 the first inhibitor that selectively 
blocks the hydrolase activity and spares the aminopeptidase activity was reported [191]. The 
search for LTC4S inhibitors yielded tandem benzophenone amine pyridines (TK04, TK04A, 
TK05), which apparently interact with the amino acids Arg-104 and Arg-36 in the active site 
and potently suppress LTC4 formation in vitro and in vivo promoting the generation of lipoxins 
[192, 193]. 
    
Figure 1.14: Inhibitors of FLAP, LTA4 hydrolase and LTC4 synthase. 
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2 AIM OF THE THESIS 
In general, acute inflammation is an immune response exerted by the host organism to restore 
the healthy state [20]. However, acute inflammation can shade off into chronic inflammation 
escalating in diseases like atherosclerosis, rheumatoid arthritis, asthma and even cancer [28, 
34]. It is known that female individuals undergo a stronger immune response, leading to a 
faster recovering but also to a higher susceptibility for autoimmune diseases like SLE or 
rheumatoid arthritis. In contrast, male individuals are more susceptible to infections and 
atherosclerosis [2]. In order to provide optimal pharmacological therapy, much effort has gone 
into the investigation of the sexual dimorphism in the past years, revealing several factors 
contributing to the gender disparity. Recently, the differential regulation of the 5-LO product 
formation in human neutrophils as well as in vivo could be detected [4, 194]. Like leukotrienes, 
prostaglandins are factors able to promote and sustain inflammation and evidence confirming 
a diverse production in male and female human neutrophils and in animal models of 
inflammation could be shown [5]. However, little is known about the role of prostaglandins and 
the COX pathway in the sexual dimorphism in healthy individuals and investigations of different 
research groups reported inconsistent results [85, 86]. The aim of the first part of the thesis 
was to reveal if there is a sex difference in prostanoid formation in human leukocytes and if so, 
to elucidate the underlying mechanisms. The prostanoid formation in each sex was analyzed 
upon stimulation with different agents in human whole blood and isolated leukocytes in short 
and long term incubations. To determine the observed difference in prostanoid formation in 
detail, processes influencing the amount of prostanoids like TLR4 protein expression,  
COX-1/2 protein and mRNA expression and the activity of the metabolizing enzyme 15-PGDH 
were evaluated. Furthermore, the effect of sex hormones in human whole blood and on freshly 
isolated PBMC was investigated regarding a modulation of the prostanoid biosynthesis. 
The second part of this thesis was dedicated to small molecules that modulate 5-LO activity 
and LT formation. LTs play a pivotal role in inflammatory conditions and diseases, especially 
the cys-LTs in asthma [195]. Over the past years, numerous inhibitors were designed to 
interfere directly or indirectly with 5-LO aiming to suppress LT formation. However, only one 
direct 5-LO inhibitors, namely zileuton [196] and few indirect inhibitors like montelukast could 
be introduced to the market to date for the treatment of asthma [197]. A plethora of different 
structures were proposed as 5-LO inhibitors exerting different modes of action, involving redox 
activity, direct chelation of the catalytic iron or allosteric inhibition. Previous findings support 
the inhibitory potential of 1,4-benzoquinones [169] and consequent structurally modifications 
lead to a series of 1,2-benzoquinones and 1,2-benzohydroquinones highly effective in 
suppression of LT synthesis [198]. To evaluate the mechanism underlying the inhibition of the 
5-LO product formation by small molecules, the efficacy in cell-free assays as well as in human 
leukocytes upon challenge with different stimuli and the detailed impact of the test compounds 
on the 5-LO activity was investigated. Biological data was verified by docking simulations and 
confirmed in animal models of inflammation. Furthermore, a special focus was placed on the 
selectivity for 5-LO as target. 
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3 MATERIALS AND METHODS 
3.1 Materials 
[3H]-arachidonic acid    BIOTREND Chemikalien GmbH, Köln, Germany 
11β-PGE2     Cayman Chemical, Ann Arbor, MI, USA 
17β-Estradiol     Sigma-Aldrich, Deisenhofen, Germany  
5-LO primary antibody  Prof. Steinhilber, Goethe University of 
Frankfurt/Main, Germany 
5α-DHT     Sigma-Aldrich, Deisenhofen, Germany 
Acetic acid     Carl Roth GmbH Co. KG, Karlsruhe, Germany 
Acetonitril     Thermo Fisher Scientific Inc., MA, USA 
Acrylamide     Applichem GmbH, Darmstadt, Germany 
Adenosine deaminase   Sigma-Aldrich, Deisenhofen, Germany 
Ampicillin     Applichem GmbH, Darmstadt, Germany 
Arachidonic acid    Cayman Chemical, Ann Arbor, MI, USA 
AUDA      Cayman Chemical, Ann Arbor, MI, USA 
B2M primer (forward and reverse)  TIB MOLBIOL Syntheselabor, Berlin, Germany 
Biotase     Biochrom GmbH, Berlin, Germany 
Bromophenol blue    Merck, KGaA, Darmstadt, Germany 
BSA      Applichem GmbH, Darmstadt, Germany 
BSA, fatty acid free    Sigma-Aldrich, Deisenhofen, Germany 
BWA4C     Sigma-Aldrich, Deisenhofen, Germany 
Ca2+ ionophore A23187   Cayman Chemical, Ann Arbor, MI, USA 
CaCl2      Applichem GmbH, Darmstadt, Germany 
CD14 primer antibody, Cat#MHCD1427 Thermo Fisher Scientific Inc., MA, USA 
CD19 primer antibody, Cat#302205  BioLegend, San Diego, CA, USA 
CD3 primer antibody, Cat#317307  BioLegend, San Diego, CA, USA 
Celecoxib     Sigma-Aldrich, Deisenhofen, Germany 
Charcoal, dextran-coated   Sigma-Aldrich, Deisenhofen, Germany 
Citric acid, monohydrate   Applichem GmbH, Darmstadt, Germany 
COX-1, ovine     Cayman Chemical, Ann Arbor, MI, USA 
COX-1 primary antibody, Cat#9896  Cell Signaling Technology Inc., MA, USA 
COX-2 primer (forward and reverse) TIB MOLBIOL Syntheselabor, Berlin, Germany 
COX-2, human    Cayman Chemical, Ann Arbor, MI, USA 
COX-2 primary antibody, Cat#4842  Cell Signaling Technology Inc., MA, USA 
D’PBS SERVA Electrophoreses GmbH, Heidelberg, 
Germany 
d4-LTB4     Cayman Chemical, Ann Arbor, MI, USA 
d4-TxB2     Cayman Chemical, Ann Arbor, MI, USA 
d5-LXA4     Cayman Chemical, Ann Arbor, MI, USA 
d8-5S-HETE     Cayman Chemical, Ann Arbor, MI, USA 
d9-PGE2     Cayman Chemical, Ann Arbor, MI, USA 
DAPI      Sigma-Aldrich, Deisenhofen, Germany 
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DCFH-DA     Sigma-Aldrich, Deisenhofen, Germany 
Dexamethasone    Sigma-Aldrich, Deisenhofen, Germany 
Dextran     Sigma-Aldrich, Deisenhofen, Germany 
DMEM (high glucose)   Biochrom GmbH, Berlin Germany 
DMSO      Merck, KGaA, Darmstadt, Germany 
DPI      Sigma-Aldrich, Deisenhofen, Germany 
DPPH      Cayman Chemical, Ann Arbor, MI, USA 
EDTA      Applichem GmbH, Darmstadt, Germany 
FCS  PAA/GE Healthcare Europe GmbH, Freiburg 
Germany 
FeCl2      Applichem GmbH, Darmstadt, Germany 
FeSO4 7×H2O     Applichem GmbH, Darmstadt, Germany 
FLAP primary antibody, Cat#ab85227 Abcam plc, Cambridge, UK 
fMLP      Sigma-Aldrich, Deisenhofen, Germany 
Formic acid     Sigma-Aldrich, Deisenhofen, Germany 
Fura-2-AM     Sigma-Aldrich, Deisenhofen, Germany 
G-418 sulfate, Geneticin   Carl Roth GmbH Co. KG, Karlsruhe, Germany 
Glucose     Applichem GmbH, Darmstadt, Germany 
Glutathione, reduced    Applichem GmbH, Darmstadt, Germany 
Glycerole     Caesar & Loretz GmbH, Hilden, Germany 
Glycine     Carl Roth GmbH Co. KG, Karlsruhe, Germany 
HCl      Grüssing GmbH, Filsum Germany 
Hemoglobin     Sigma-Aldrich, Deisenhofen, Germany 
Histopaque     Sigma-Aldrich 
Human serum AB    Lonza Group Ltd, Basel, Switzerland 
Hygromycin  Thermo Fisher Scientific Inc., MA, USA 
IgG Alexa Fluor 488, Cat#A11034 Thermo Fisher Scientific Inc., MA, USA 
IgG Alexa Fluor 555, Cat#A21424 Thermo Fisher Scientific Inc., MA, USA 
IgG APC-Alexa Fluor 750, Cat#A-21006 Thermo Fisher Scientific Inc., MA, USA 
IL-1β      ReproTech, Hamburg, Germany 
Indomethacin     Sigma-Aldrich, Deisenhofen, Germany 
IRDye 680LT secondary antibody  LI-COR Bioscience Inc., Bad-Homburg, Germany 
   Cat#925-68020 and -68021 
IRDye 800CW secondary antibody  LI-COR Bioscience Inc., Bad-Homburg, Germany 
   Cat#925-3221 and -32211 
KH2PO4     Sigma-Aldrich, Deisenhofen, Germany 
Leupeptin hemisulfate salt   Sigma-Aldrich, Deisenhofen, Germany 
L-glutamine     Biochrom GmbH, Berlin Germany 
LPS      Sigma-Aldrich, Deisenhofen, Germany 
LSC fluid Rotiszint eco plus   Carl Roth GmbH Co. KG, Karlsruhe, Germany 
LTA4-methyl ester    Cayman Chemical, Ann Arbor, MI, USA 
LTC4-d5-methyl ester   Cayman Chemical, Ann Arbor, MI, USA 
MgCl2      Merck, KGaA, Darmstadt, Germany 
MgSO4     Applichem GmbH, Darmstadt, Germany 
MK886     Cayman Chemical, Ann Arbor, MI, USA 
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MTT      Sigma-Aldrich, Deisenhofen, Germany 
Na3VO4     Applichem GmbH, Darmstadt, Germany 
Na4P2O7     Sigma-Aldrich, Deisenhofen, Germany 
NaCl      Carl Roth GmbH Co. KG, Karlsruhe, Germany 
NADH      Applichem GmbH, Darmstadt, Germany 
NaF      Applichem GmbH, Darmstadt, Germany 
Nonidet P-40     Applichem GmbH, Darmstadt, Germany 
p-38 MAPK primary antibody, Cat#8690 Cell Signaling Technology Inc., MA, USA 
p-44/42 MAPK primary antib., Cat#4695 Cell Signaling Technology Inc., MA, USA 
Pam3CSK4     InvivoGen, San Diego, CA, USA 
Paraformaldehyde    Carl Roth GmbH Co. KG, Karlsruhe, Germany 
Penicillin/streptomycin solution  Biochrom GmbH, Berlin Germany 
Peptone     Carl Roth GmbH Co. KG, Karlsruhe, Germany 
PGB1      Cayman Chemical, Ann Arbor, MI, USA 
PGH2      Larodan, Malmö, Sweden 
PHOME     Cayman Chemical, Ann Arbor, MI, USA 
Phospho-p-38 MAPK, primary antibody Cell Signaling Technology Inc., MA, USA 
   Cat#4631  
Phospho-p44/42 MAPK, primary antibody Cell Signaling Technology Inc., MA, USA 
   Cat#5726 
PMA      Applichem GmbH, Darmstadt, Germany 
PMSF      Sigma-Aldrich, Deisenhofen, Germany 
Ponceau     Sigma-Aldrich, Deisenhofen, Germany 
Powdered milk, low fat   Carl Roth GmbH Co. KG, Karlsruhe, Germany 
Progesterone     Sigma-Aldrich, Deisenhofen, Germany 
Pyruvate  PAA/GE Healthcare Europe GmbH, Freiburg 
Germany 
RPMI 1640     Sigma-Aldrich, Deisenhofen, Germany 
RSC-3388     Cayman Chemical, Ann Arbor, MI, USA 
SDS      Carl Roth GmbH Co. KG, Karlsruhe, Germany 
Staurosporine     Merck, KGaA, Darmstadt, Germany 
STI      Sigma-Aldrich, Deisenhofen, Germany 
Sucrose     Applichem GmbH, Darmstadt, Germany 
SW033291     Sigma-Aldrich, Deisenhofen, Germany 
Testosterone     Sigma-Aldrich, Deisenhofen, Germany 
TLR4 fluorescent antibody, Cat#564215 BD Bioscience, San Jose, CA, USA 
Trifluoroacetic acid    Applichem GmbH, Darmstadt, Germany 
Tris/HCl     Carl Roth GmbH Co. KG, Karlsruhe, Germany 
Triton X-100     Carl Roth GmbH Co. KG, Karlsruhe, Germany 
Trypan blue     Sigma-Aldrich, Deisenhofen, Germany 
Trypsin-EDTA     Thermo Fisher Scientific Inc., MA, USA 
Tween 20     Carl Roth GmbH Co. KG, Karlsruhe, Germany 
U0126      Enzo Life Science Inc., NY, USA 
Yeast extract     Carl Roth GmbH Co. KG, Karlsruhe, Germany 
Zileuton     Sequoia Research Products, Oxford, UK 
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β-actin primer (forward and reverse)  TIB MOLBIOL Syntheselabor, Berlin, Germany 
β-actin primary antibody,   Cell Signaling Technology Inc., MA, USA 
   Cat#58169 and 4970 
β-glycerophosphate    Sigma-Aldrich, Deisenhofen, Germany 
β-mercaptoethanol    Carl Roth GmbH Co. KG, Karlsruhe, Germany 
 
Compounds 
Embelin, benzoquinones and hydroquinones were synthesized by the group of Dr. Rosanna 
Filosa, University of Salerno, Italy. 
Buffer solutions 
D’PBS: phosphate buffer containing 10 mM PO43-, 137 mM NaCl, 2.7 mM KCl, pH 7.4 
PG: D’PBS containing 0.1% glucose 
PGC: PG containing 1 mM Ca2+ 
D’PBS-C: D’PBS containing 1 mM Ca2+ 
CCM-5% FCS: RPMI 1640 cell culture medium containing 5% (v/v) heat-inactivated fetal calf 
serum (FCS), L-glutamine (2 mM), penicillin (100 U/ml) and streptomycin (100 µg/ml) 
CCM-10% FCS: RPMI 1640 cell culture medium containing 10% (v/v) heat-inactivated FCS, 
L-glutamine (2 mM), penicillin (100 U/ml) and streptomycin (100 µg/ml) 
CCM-0.5% CSS: RPMI 1640 cell culture medium containing 0.5% (v/v) charcoal-stripped 
human serum (CSS), L-glutamine (2 mM), penicillin (100 U/ml) and streptomycin  
(100 µg/ml) 
DMEM-10% FCS: Dulbecco’s modified eagle medium (DMEM) containing 10% (v/v) heat-
inactivated FCS, 100 U/ml penicillin, 100 µg/ml, 400 µg/ml Geneticin and 200 µg/ml 
hygromycin B 
FACS buffer I: D’PBS containing 1% (m/v) bovine serum albumin (BSA), 0.1% (m/v) NaN3,  
2 mM EDTA 
FACS buffer II: D’PBS containing 1% (m/v) BSA, 2 mM EDTA 
 
3.2 Methods 
3.2.1 Human whole blood 
3.2.1.1 Complete blood count of human blood donations 
Peripheral venous blood (30 - 50 ml) was taken from voluntary healthy donors by venipuncture 
at the Institute of Transfusion Medicine, Jena University Hospital. The blood was collected in 
heparinized monovettes (16 I.E. heparin/ml blood, Sarstedt, Nümbrecht, Germany). Subjects 
have not taken any anti-inflammatory drugs for at least ten days prior to blood donation. Freshly 
drawn blood was processed not later than within two hours. Counting of blood cells was done 
in the laboratories of the Jena University Hospital by flow cytometry (Sysmex, Norderstedt, 
Germany). 
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3.2.1.2 Isolation of plasma from human blood and sex hormone 
depletion 
To obtain human plasma, heparinized peripheral venous blood was centrifuged at 600 × g,  
10 min at 20 °C. The supernatant was additionally centrifuged again (800 × g, 15 min at 20 °C) 
and afterwards checked for cellular remnants. In order to eliminate sex hormones human 
plasma, fetal calf serum (FCS) or human serum was striped by continuous agitation (4 °C, 
overnight) with dextrane-coated charcoal (20 µg/ml) and centrifuged twice at 2000 × g, 15 min 
at 4 °C. The stripped plasma or serum was filtered, once through 45 µm pore-sized filter, with 
subsequent sterile filtration with 22 µm pore size (Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany). Plasma was stored at -80 °C until use.  
3.2.1.3 Determination of lipoxygenase and cyclooxygenase activity in 
human blood 
For human whole blood assays, fresh peripheral venous blood was collected at the Jena 
University Hospital as described in 3.2.1.1. To determine lipoxygenase product formation, 
aliquots of 2 ml were preincubated with inhibitors or vehicle (0.1% DMSO) for 15 min at 37 °C, 
followed by stimulation with the A23187 or AA as indicated in the distinct experiments for 10 
min at 37 °C. Alternatively, blood was primed with 1 µg/ml lipopolysaccharide from  
E. coli 0127:BS (LPS) for 30 min and 0.3 U/ml adenosine deaminase (ADA) for 20 min at  
37 °C, followed by stimulation with 1 µM fMLP for 15 min at 37 °C. Test compounds, vehicle 
(1% DMSO) and control inhibitors were added 15 min prior fMLP stimulation. The reactions 
were stopped on ice and samples were centrifuged at 400 × g, 10 min at 4 °C. Collected 
plasma was mixed with 4 volumes of methanol, 200 ng prostaglandin B1 (PGB1) were added 
as internal standard and samples were frozen for 2 h at -20 °C. Denatured samples were 
centrifuged at 800 × g, 15 min at 4 °C and obtained supernatants were diluted with the equal 
amount of D’PBS and 25 µl/ml 1 N HCl. Lipoxygenase products were extracted by solid phase 
extraction (SPE) (3.2.6) and determined by liquid chromatography tandem mass spectrometry 
(LC-MS/MS) (3.2.7). To determine cyclooxygenase products, aliquots of 1 ml whole blood or 
whole blood homogenates (sonication: 3 × 10 s, 4 °C, cell disruption confirmed by light 
microscopy) were stimulated as indicated in the respective experiments. The reaction was 
stopped on ice and samples were centrifuged at 400 × g, 10 min at 4 °C. Prostanoids were 
determined by enzyme-linked immunosorbent assay (EIA, PGE2 EIA Kit, Biotrend, Köln, 
Germany) following manufacturer’s instructions or extracted by SPE (3.2.6) and determined 
by LC-MS/MS (3.2.7). For that, aliquots of 200 - 400 µl were mixed with 100 ng/ml PGB1, 50 
ng/ml deuterated prostaglandin E2 (PGE2-d9) and 50 ng/ml deuterated thromboxane B2 (TxB2-
d4) as internal standards and 30 µl/ml 1 N HCl. Samples were frozen at -20 °C for at least 2 h 
and subsequently the denatured samples were centrifuged at 800 × g, 5 min at 4 °C.  
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3.2.2 Cells 
3.2.2.1 Isolation of human primary cells from leukocyte concentrates 
Human primary cells (PMNL, monocytes, platelets) were isolated from leukocyte concentrates 
generated at the Institute of Transfusion Medicine, Jena University Hospital. Blood was 
collected from adult healthy donors, which have not been taken any anti-inflammatory 
medication for at least ten days prior to blood donation. Cells for the gender study were isolated 
directly from heparinized whole blood whereby human plasma was separated prior to cell 
isolation for several experiments. Cells from the leucocyte concentrations were isolated by 
dextran sedimentation (5% (w/v) dextran from Leuconostoc spp. (Mr = 500,000 g/ml) in D’PBS) 
at room temperature (RT) with subsequent density gradient centrifugation on leucocyte 
separation medium (Histopaque-1077, Sigma Aldrich, Deisenhofen, Germany) at 800 × g,  
10 min at 20 °C without brakes (Heraeus Multifuge X3R Centrifuge, Thermo Scientific, MA, 
USA). Density centrifugation results in different layers: platelet rich plasma (PRP) on top, 
followed by a layer of monocytes, T and B cells (PBMC) at the plasma/Histopaque®-1077 
interface, and a pellet containing PMNL and remaining erythrocytes. To obtain platelets, PRP 
was diluted with cold D’PBS pH 5.9 (2:3) and centrifuged at 2100 × g, 15 min, at RT followed 
by washing with a mixture of 0.9% NaCl and D’PBS pH 5.9 (1:1; 1900 × g / 10 min / RT). 
Platelets were resuspended in cold D’PBS and immediately used for experiments. To purify 
PMNL, remaining erythrocytes in the obtained pellet were removed by hypotonic lysis with  
10 ml cold H2O for 45 s and subsequent dilution with D’PBS. After two additional washing steps 
(400 × g / 10 min / 4 °C) with D’PBS, PMNL were resuspended in PG buffer. PBMC were 
obtained by two washing steps (400 × g / 10 min / 4 °C) with D’PBS after density gradient 
centrifugation and resuspended in CCM-5% FCS or CCM-0.5% CSS. Monocytes were isolated 
from PBMC by adherence to cell culture flasks with a cell density of 2 × 107/ml in CCM-10% 
FCS for 1-1.5 h, 37 °C, 5% CO2 (Heracell incubator, Heraeus, Hanau, Germany), as described 
in [4]. For gender studies, human serum or FCS was stripped as described in chapter 3.2.1.2. 
Before performing experiments, cells were counted by mixing with trypan blue solution (1:1, 
0.2%) with a Vi-cell counter (Beckmann Coulter GmbH, Krefeld, Germany) or manually with a 
buerker haemocytometer under a light microscope. 
3.2.2.2 HEK293 cells 
HEK293 cells (human embryonic kidney cell line) were cultured in DMEM-10% FCS at 37 °C, 
5% CO2. HEK293 cells stably expressing FLAP and 5-LO_wt, or 5-LO_3W mutant or 5-LO_4C 
mutant, respectively, were selected using 400 µg/ml geneticin (for 5-LO) and 200 µg/ml 
hygromycin B (for FLAP). Cells were detached by trypsin-EDTA for 5 min at 37 °C, 5% CO2  
2-3 times per week, resuspended in DMEM-10% FCS and seeded in density of 0.25 × 106/ml 
at 37 °C, 5% CO2. For determination of 5-LO products, cells (1 × 106/ml) were resuspended in 
PGC buffer, preincubated with compounds or vehicle (0.1% DMSO) for 15 min at 37 °C 
followed by stimulation with 2.5 µM A23187 with 3 µM AA. The reaction was stopped with 1 ml 
methanol, 500 µl D’PBS, 30 µl 1 N HCl and 200 ng PGB1 as internal standard on ice. 
Lipoxygenase products were separated using solid phase extraction (SPE; 3.2.6) and 
determined using RP-HPLC (3.2.8). 
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3.2.3 Cellular assays 
3.2.3.1 Determination of COX products in cellular test systems  
To determine COX products, PBMC or monocytes (0.6 - 3 × 106/ml) were seeded in 12-well 
plates in CCM-0.5% CSS and stimulated with 10 µg/ml LPS for 24 h at 37 °C, 5% CO2. 
Alternatively, freshly isolated PMNL (5 × 106/ml) were resuspended in PGC buffer and 
stimulated with 5 µM AA for 10 min. For inhibitor studies, freshly isolated monocytes (106/ml) 
seeded in 12-well plates in CCM-5% FCS were stimulated with 1 µg/ml LPS for 24 h at 37 °C, 
5% CO2. After 24 h, medium was replaced by D’PBS-C, cells were preincubated with 
compounds or vehicle (0.1% DMSO) for 15 min at 37 °C and stimulated with 1 µM AA for  
30 min at 37 °C. The reactions were stopped on ice, supernatants were collected and 
centrifuged (400 × g / 10 min / 4 °C). Aliquots of 500 µl were mixed with 100 ng/ml PGB1,  
50 ng/ml PGE2-d9 and 50 ng/ml TxB2-d4 as internal standards and 30 µl/ml 1 N HCl. Samples 
were centrifuged (800 × g / 5 min / 4 °C) and COX products were extracted by SPE (3.2.6) and 
determined by LC-MS/MS (3.2.7). Alternatively, freshly isolated platelets (108/ml) resuspended 
in PGC buffer were preincubated with test compounds or vehicle (0.1% DMSO) for 15 min at 
RT followed by stimulation with 5 µM AA for 10 min at 37 °C. The reaction was stopped by 
addition of methanol and samples were treated as described for lipoxygenase product 
formation in cellular test systems (3.2.3.2). The formed COX-1 product 12-HHT was 
determined by RP-HPLC, according to [199]. 
3.2.3.2 Determination of lipoxygenase products in cellular test systems  
PMNL or monocytes (2 - 3 × 106/ml) were resuspended in PGC buffer and preincubated with 
compounds or vehicle (0.1% DMSO) for 15 min at 37 °C followed by stimulation with either  
2.5 µM A23187 alone or together with 20 µM AA for 10 min at 37 °C. Alternatively, cells were 
primed with 1 µg/ml LPS for 30 min and 0.3 U/ml ADA for 20 min at 37 °C, followed by 
stimulation with 1 µM fMLP for 5 min at 37 °C. Compounds or vehicle (1% DMSO) were added 
15 min prior fMLP stimulation. The reactions were stopped by addition of 1 ml methanol 
together with 500 µl D’PBS and 30 µl 1 N HCl on ice. 200 ng PGB1 were added as internal 
standard and samples were centrifuged (800 × g / 10 min / 4 °C). Eicosanoids were extracted 
by SPE (3.2.6) and determined by RP-HPLC (3.2.8). For lipid mediator profiling, 1.5 × 106 
monocytes/ml seeded in 6-well plates in D’PBS-C were preincubated with compounds or 
vehicle (0.1% DMSO) for 15 min at 37 °C, followed by stimulation with 0.5 µM A23187 for  
90 min at 37 °C. The reactions were stopped by addition of two volumes of methanol and 
addition of the internal standards (d4-PGE2, d4-LTB4, d5-LXA4, d8-5S-HETE) on ice. 
Subsequently, samples were stored at -20 °C for at least 30 min. Afterwards, samples were 
centrifuged (1200 × g / 10 min / 4 °C), pH was adjusted to 3.5 by dilution with acidified H2O 
and the content of methanol thereby was reduced to 25%. Samples were transferred to SPE 
(3.2.6) and lipid mediators were determined by LC-MS/MS (3.2.7). For cys-LT determination  
3 × 106 monocytes/ml resuspended in PGC buffer were preincubated with compounds or 
vehicle (0.1% DMSO) for 15 min at 37°, followed by stimulation with 2.5 µM A23187 for 10 min 
at 37 °C. The reaction was stopped on ice, samples were centrifuged (400 × g / 10 min / 4 °C) 
and cys-LTs in the supernatants were determined by ELISA (cysteinyl leukotrienes ELISA kit, 
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Enzo Life Science Inc., NY, USA) following manufacturer’s instructions. Leukotriene B4 (LTB4) 
was analyzed using RP-HPLC (3.2.8). 
3.2.3.3 Determination of extracellular cytokine level 
Freshly isolated monocytes (1.5 × 106/ml) were seeded in 96-well plates (200 µl cell 
suspension/well) in CCM-5% FCS. After 1 h at 37 °C, cells were preincubated with compounds 
or vehicle (0.5% DMSO) for 30 min at 37 °C, 5% CO2, followed by stimulation with LPS  
10 ng/ml for 4 h (determination of interleukin-8 (IL-8), tumor necrosis factor α (TNFα)), or 18 h 
(determination of IL-6, IL-1β) at 37 °C, 5% CO2. Reaction was stopped on ice and cytokines in 
the supernatants were determined by in-house made ELISA. 
3.2.3.4 Analysis of mRNA expression 
PBMC (3 × 106) freshly isolated from heparinized whole blood resuspended in CCM-0.5% CSS 
were seeded in 12-well plates. After 1 h at 37 °C, cells were stimulated with 10 µg/ml LPS for 
5 h or 18 h at 37 °C, 5% CO2 or left untreated. Total RNA amount of PBMC was isolated using 
the E.N.Z.A. Total RNA Kit I (Omega Bio-tek Inc., GA, USA), following manufacturer’s 
instructions. Total mRNA amount was detected by photometric measurement at 230 nm,  
260 nm, 280 nm and 320 nm with a Nanodrop (Thermo Fisher Scientific Inc., MA, USA). Quality 
of isolated mRNA was confirmed by the ratios of A260 nm/A280 nm and A260 nm/A230 nm. 
cDNA was obtained from mRNA by reverse transcription using SuperScript® III First-Strand 
Synthesis SuperMix (Life technologies, MA, USA) with random hexamers incubated as follows: 
5 - 10 min at 25 °C, followed by 50 min at 50 °C. The reaction was terminated at 85 °C for  
5 min. cDNA was amplified by PCR (Mx3005P qPCR system, Agilent Technologies, CA, USA) 
with primers for COX-2, β-actin and beta-2-micoglobulin (B2M) (Table 3.2). PCR was 
conducted with the following protocol: Initial denaturation at 95 °C for 10 min (1 cycle), followed 
by 15 s denaturation at 95 °C, 30 s annealing at 60 °C and 30 s extension at 72 °C (45 cycles). 
The procedure was terminated with 60 s at 95 °C, 30 s at 55 °C and 30 s at 95 °C (1 cycle). 
To calculate the relative amount of COX-2 mRNA (normalized to β-actin), Maxima SYBR 
Green/ROX qPCR Master Mix (Fermentas, Darmstadt, Germany) was used in combination 
with the 2(-∆∆C(T)) method, according to [200]. Data was analyzed with the MxPro Software 
(Mx3005P/version 4.10, Agilent Technologies, CA, USA). 
 
Table 3.1: Primer sequences. 
Primer name Strand nucleotide sequence 
COX-2 reverse 5’-AAAGGCGCAGTTTACGCTGTC-3‘ forward 5’-TGCATTCTTTGCCCAGCACT-3‘ 
Β-actin reverse 5’- GAGCTGGAAGCAGCCGTGG-3’ forward 5’-CTCACCGAGCGCGCTACGA-3’ 
B2M reverse 5’-TTTGGAGTACGCTGGATAGCCT-3’ forward 5’-CTCCGTGGCCTTAGCTGTG-3’ 
MATERIALS AND METHODS  
30 
3.2.3.5 Determination of COX-2 protein expression, ERK1/2 and p-38 
phosphorylation 
For COX-2 protein expression, freshly isolated PBMC from human blood or PBMC or 
monocytes from leukocyte concentrates (1-3 × 106) seeded in 12-well plates in CCM- 0.5% 
CSS were incubated with 10 µg/ml LPS for 24 h at 37 °C, 5% CO2. COX-2 expression was 
evaluated in whole cell lysates obtained according to 3.2.3.6 using SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE; 3.2.9) with gels containing 10% acrylamide. Phosphorylation of 
ERK1/2 and p-38 MAPK was evaluated in freshly isolated PMNL (50 × 106/ml), resuspended 
in PGC buffer. Aliquots of 100 µl were preincubated with compounds or vehicle (1% DMSO) 
for 15 min at 37 °C, followed by stimulation with fMLP for 1.5 min at 37 °C. The reactions were 
stopped by addition of equal amounts of 2 × SDS-loading buffer (1 mM Tris/HCl (pH 8), 0.2 M 
EDTA, 10% (v/v) SDS, freshly added 10% (v/v) β-mercaptoethanol) on ice. To generate cell 
lysates, samples were treated as described in 3.2.3.6 and ERK1/2 and p-38 MAPK 
phosphorylation was determined as described in 3.2.9. 
3.2.3.6 Generation of whole cell lysates 
Cell lysates of PBMC and isolated monocytes were generated using NP-40 lysis buffer 
containing of 1% (v/v) NP-40, 1 mM sodium vanadate, 10 mM sodium fluoride, 5 mM sodium 
pyrophosphate, 25 mM β-glycerophosphate and 5 mM EDTA, 10 µg/ml leupeptin hemisulfate, 
60 µg/ml soybean trypsin inhibitor (STI) and 1 mM phenylmethylsulfonyl fluoride (PMSF). Cells 
were lyzed for 30 min on ice with occasional agitation and cautious detachment of the cells 
from the culture plate. Lysates were centrifuged (10,000 × g / 5 min / 4 °C) and the protein 
amount in the supernatants was determined with a protein assay (Bio-Rad Laboratories, CA, 
USA). Subsequently, SDS-loading buffer I (50 mM Tris/HCl, pH 6.8, 2% (w/v) SDS, 10% (v/v) 
glycerol, 10% (v/v) β-mercaptoethanol, 12.5 mM EDTA, 0.02% (w/v) bromophenol blue) was 
added (loading buffer:supernatant = 1:4) and samples were boiled for 5 min at 96 °C. Protein 
expression was analyzed by SDS-PAGE (3.2.9).  
Cell lysates of PMNL were generated by addition of the equal amount of SDS-loading buffer II 
(20 mM Tris/HCl, pH 8,5% (w/v) SDS, 10% (v/v) glycerol, 10% (v/v) β-mercaptoethanol,  
20 mM EDTA) on ice followed by boiling for 5 min at 96 °C. Subsequently, samples were 
shattered by sonication (output 1, duty cycle 40%, 3 × 10 s on ice; SFX250, Branson, CT, US). 
After dilution with one fifth of bromophenol blue solution (33% (w/v) in glycerol), cell lysates 
were centrifuged (10,000 × g / 5 min / 4 °C) and analyzed by SDS-PAGE (3.2.9). 
3.2.3.7 Fluorescence-activated cell sorting (FACS) 
For evaluation of cell surface markers, freshly isolated monocytes (106/ml) seeded in 12-well 
plates in CCM-0.5% CSS were preincubated with 10 µg/ml LPS for 1 h at 37 °C, 5% CO2 or 
left untreated. Monocytes were detached with biotase for 30 min at 37 °C, 5% CO2 and 
centrifuged at 350 × g, for 6 min at 4 °C. The cells were resuspended in mouse serum (1:10) 
for 30 min at 4 °C followed by dilution with FACS buffer I (D’PBS containing 1% (m/v) BSA, 
0.1% (m/v) NaN3, 2 mM EDTA) and centrifugation (350 × g / 6 min / 4 °C). Subsequently, cells 
were mixed with the respective fluorescent antibodies (Table 3.5) for 15 min at 4 °C in the dark. 
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After centrifugation (350 × g / 6 min / 4 °C), cells were resuspended in FACS buffer I and cell 
surface markers were analyzed with the FACSCanto II (BD Bioscience, San Jose, CA, USA). 
Cell viability was monitored using 4’,6-damidino-2-phenylindole (DAPI), IgG (mouse) was used 
as isotype control. For cell sorting, freshly isolated PBMC (50 × 106) were resuspended in 
FACS buffer II (D’PBS containing 1% (m/v) BSA, 2 mM EDTA) and mixed with the respective 
fluorescent antibodies (Table 3.5) for 20 min at 4 °C in the dark. After one washing step (350 
× g / 6 min / 4 °C) cells were resuspended in FACS buffer II and sorted using the FACSAriaTM 
Fusion (BD Bioscience, San Jose, CA, USA) at 4 °C by double cell exclusion. Cell viability was 
monitored by addition of DAPI. Cells were immediately used. 
 
Table 3.2: Fluorescent antibodies used for FACS analysis. 
Marker Fluorochrome Source 
TLR4 PE mouse 
CD3 PE mouse 
CD19 FITC mouse 
CD14 APC-Alexa® Fluor 750 mouse 
IgG APC-Alexa® Fluor 750 mouse 
 
3.2.3.8 Determination of [3H]-AA-release and [3H]-AA derived products in 
PMNL  
To determine the release of AA and AA-derived products, freshly isolated PMNL (5 × 106) were 
resuspended in RPMI 1640 without additives and incubated with tritium-labelled AA  
(0.5 µCi/ml) for 2 h at 37 °C, 5% CO2. Cells were washed twice with freshly prepared PG buffer 
containing 2 mg/ml fatty acid free BSA (600 × g / 10 min / 4 °C) and cell number was adjusted 
to 20 × 106/ml. The cell preparation was divided into aliquots of 0.5 ml, 1 mM Ca2+ was added 
and samples were incubated with the control inhibitor or vehicle (0.5% DMSO) for 10 min at 
37 °C, followed by stimulation with A23187 for indicated times. The reaction was stopped on 
ice, samples were centrifuged (500 × g / 15 min / 4 °C) and 300 µl of obtained supernatants 
were mixed with 2 ml of liquid scintillation counting (LSC) fluid. Radioactivity was determined 
by scintillation counting (Micro Beta Trilux, Perkin Elmer, AM, USA). 
3.2.3.9 Cell viability assay 
MTT-assay 
To evaluated the influence of the compounds on cell viability, a 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay was performed according to [201]. Freshly 
isolated monocytes (2 × 105/100 µl) were seeded in sterile 96-well plates CCM-5% FCS and 
after 1 h, cells were incubated with compounds or vehicle (0.3% DMSO) for 24 h at 37 °C, 5% 
CO2. After addition of 20 µl MTT solution (5 mg/ml MTT in D’PBS, sterile filtered), samples 
were incubated for another 2-4 h at 37 °C, 5% CO2 until blue formazan crystals appeared in 
the vehicle control due to reduction of MTT. To lyze the crystals, 100 µl SDS lysis buffer (10% 
(m/v) SDS in 20 mM HCl, pH 4.5) were administrated and samples were shaken for 20 h in the 
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dark at RT. Absorption was measured at 570 nm with a microplate reader (Thermo Fisher 
Scientific Inc., MA, USA). 
LDH-assay 
In order to determine the influence of test compounds on cell integrity, the lactate 
dehydrogenase (LDH) assay was performed. For this, 0.3 × 106 monocytes/200 µl were 
seeded in sterile 96-well plates in CCM-5% FCS. Cells were incubated with compounds or 
vehicle (0.3% DMSO) for 24 h at 37 °C, 5% CO2, followed by collection of the supernatants by 
centrifugation at 600 × g, 5 min at 4 °C. To 100 µl of obtained supernatants 200 µl reaction mix 
(75 mM Tris, 1.5 mM pyruvate, 0.3 mM nicotinamide adenine dinucleotide (NADH) in H2O) 
were added and absorbance of converted NADH was immediately assessed at 490 nm using 
a NOVOstar microplate reader (BMG Labtechnologies GmbH, Offenburg, Germany). 
3.2.3.10 Immunofluorescence microscopy 
To investigate subcellular 5-LO distribution, immunofluorescence microscopy was applied. 
Freshly isolated PMNL (3 × 106/ml) were seeded on poly-D-lysine-covered cover slips 
(Neuvitro Corp., Vancouver, WA, USA) in 12-well plates in PGC buffer. Cells were 
preincubated with compounds or vehicle (0.1% DMSO) for 15 min at 37 °C, followed by 
stimulation with 2.5 µM A23187 for 5 min at 37 °C. Subsequently, supernatant was removed 
and cells were fixed with paraformaldehyde (PFA, 4% (w/v)) solution for 20 min at RT. 
Autofluorescence of free formaldehyde was quenched with ammonium chloride (50 mM) for 
20 min at RT. Cells were washed twice with D’PBS, permeabilized with ice cold acetone 
(100%) for 5 min at 4 °C and incubated with primary antibodies (5-LO, mouse, monoclonal, 
1:100; FLAP, rabbit, polyclonal, 1:150) overnight at 4 °C in a humidity chamber. Samples were 
brought to RT and extensively washed with D’PBS, followed by incubation with fluorescent-
labelled secondary antibodies Alexa Fluor 488 goat anti-rabbit IgG (1:1000) and Alexa Fluor 
555 goat anti-mouse IgG (1:1000) for 30 min at RT. Samples were placed on microscope slides 
using ProLong® Diamond Antifade Mountant with DAPI (Thermo Fisher Scientific Inc., 
Waltham, MA, USA). The slides were stored at 4 °C in the dark until evaluation. For 
microscopic analysis of fluorescence an Axio Observer.Z1 inverted microscope and a LCI 
Plan-Neofluar 63x1.3 Imm Corr DIC M27 objective was used. Images were taken with an 
AxioCam MR3 camera and processed with AxioVision 4.8 software (all components from Carl 
Zeiss, Jena, Germany). 
3.2.3.11 Determination of intracellular Ca2+ 
Freshly isolated PMNL (50 × 106) were stained with the Ca2+-sensitive dye Fura-2-
acetoxymethyl ester (Fura-2-AM; 2 µM) for 45 min at 37 °C, 5% CO2 in PG buffer in the dark, 
followed by a washing step (400 × g / 6min / 4 °C). Cells were resuspended in PG buffer 
containing 0.01% (m/v) BSA and the cell number was adjusted to 5 × 106/ml. Aliquots of  
100 µl cell suspension were transferred to a 96-well plate and samples were preincubated with 
compounds or vehicle (1% DMSO) for 10 min at 37 °C. 2 min prior to stimulation with 1 µM 
fMLP, 1 mM Ca2+ was added. Fluorescence was monitored by excitation at 340 nm (Ca2+ 
bound Fura-2) and 380 nm (free Fura-2) and emission at 510 nm at 37 °C with a NOVOstar 
microplate reader (BMG Labtechnologies GmbH, Offenburg, Germany). After addition of triton 
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X-100 the maximal Ca2+ signals were detected at 340 nm, after addition of 10 mM EDTA the 
minimal Ca2+ signals at 380 nm. The amount of Ca2+ was calculated from the ratio of the signals 
at 340 and 380 nm, according to [202]. 
3.2.3.12 Determination of cellular reactive oxygen species formation 
To determine cellular formation of reactive oxygen species (ROS) freshly isolated PMNL  
(0.5 × 106/100 µl, PG buffer) were pre-warmed in a 96-well plate for 3 min at 37 °C followed 
by pre-incubation with compounds or vehicle (0.3% DMSO) for 15 min at 37 °C. Oxidant-
sensing fluorescent probe 2’,7’-dichlorodihydrofluorescin diacetate (DCFH-DA) and 1 mM Ca2+ 
were added 2 min prior to stimulation with 1 µM fMLP or 0.1 µg/ml PMA. Fluorescence of the 
deacetylated dye (DCF) was monitored at an excitation of 485 nm and an emission of 535 nm 
using a NOVOstar microplate reader (BMG Labtechnologies GmbH, Offenburg, Germany). 
3.2.3.13 Generation of cell homogenates  
To generate cell homogenates, PMNL (50 × 106/ml) were resuspended in D’PBS containing  
1 mM EDTA and kept at 4 °C for 5 min followed by sonication (3 × 10 s, 4 °C). After verifying 
cell disruption by light microscopy using trypan blue staining, homogenates were diluted  
10-fold and inhibitor studies were performed as described for purified 5-LO enzyme (3.2.25). 
3.2.4 In vivo evaluation of anti-inflammatory properties 
The in vivo evaluation of the anti-inflammatory potential of the test compounds was performed 
at the laboratories of Dr. Lidia Sautebin at the Department of Pharmacy, University of Naples, 
Italy or the laboratories of Dr. Bruno D’Agostino, Department of Experimental Medicine, 
University of Naples. Male CD-1 mice (6-8 weeks, Charles River Laboratories, Calco, Italy) 
were housed in a controlled environment and provided with standard rodent chow and water. 
The experimental protocols were approved by the Animal Care Committee of the University of 
Naples, in compliance with Italian regulations on protection of animals used for experimental 
and other scientific purpose (Ministerial Decree 116/92) as well as with the European 
Economic Community regulations (Official Journal of E.C. L 358/1 12/18/1986). Compounds 
(10 mg/kg), zileuton (10 mg/kg) or vehicle (0.5 ml of 0.9% saline solution containing 2% DMSO) 
were given intraperitoneal (i.p.) 30 min before zymosan injection (0.5 ml of 2 mg/ml in 0.9% 
w/v saline). At specific time points after peritonitis induction (30 min and 4 h), mice were 
sacrificed by CO2 inhalation and peritoneal exudates were collected by a lavage with D’PBS 
of the peritoneal cavity. Cells were counted using a light microscope in a Burker’s chamber 
after vital trypan blue staining, exudates were centrifuged and stored at -80 °C for the 
determination of cys-LT formation. For carrageenan-induced paw oedema mice were lightly 
anaesthetized by inhalation of enflurane. Compounds (1 mg/kg) or vehicle (DMSO) were given 
i.p. 30 min before oedema was induced by subplantar injection of 50 µl carrageenan (1% (w/v)). 
Paw volume was measured with a hydroplethismometer (Ugo Basile, Milan, Italy) before and 
after indicated time points of carrageenan application.  
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3.2.5 Cell-free assays 
3.2.5.1 Expression and purification of recombinant 5-LO 
E. coli (BL21) was transformed with pT3-5-LO plasmid and recombinant 5-LO protein was 
expressed as described before with minor modifications [203]. Briefly, E. coli was cultured in 
LB-medium (5 g/l yeast extract, 10 g/l NaCl, 10 g/l peptone, pH 7.2) containing 100 µg/ml 
ampicillin, 5 µM iron(II) sulfate and 2 mM magnesium sulfate for 4 - 6 h at 30 °C. Once, an 
OD620 of 0.2-0.3 was reached, 190 µg/l isopropyl-β-D-thiogalactopyranoside was added to 
induce 5-LO expression at 30 °C, overnight. E.coli was collected by centrifugation at  
7,700 × g for 15 min at 4 °C, resuspended in lysis buffer (50 mM triethanolamine (TEA)/HCl 
pH 8.0, 5 mM EDTA, 60 µg/ml STI, 1 mM PMSF, 2 mM DTT, 1 mg/ml lysozyme from chicken 
egg white) and kept on ice for 45 min. Cell lysis was completed by sonication (3 × 15 s, on ice) 
and the lysate was centrifuged at 40,000 × g, 20 min at 4 °C. The 5-LO enzyme protein was 
purified by affinity chromatography using an ATP-agarose column (Sigma A2767, Sigma-
Aldrich, Taufkirchen, Germany), which was equilibrated with D’PBS containing 1 mM EDTA. 
After application of the supernatant the column was washed with 50 mM phosphate buffer 
containing 1 mM EDTA and 0.5 M NaCl, followed by phosphate buffer pH 7.4 with 1 mM EDTA. 
5-LO protein was eluted with ATP solution (20 mM ATP, 50 mM phosphate buffer, 1 mM EDTA) 
[204]. 
3.2.5.2 Determination of lipoxygenase formation in cell-free systems 
Semi-purified 5-LO was diluted with D’PBS/EDTA (1 mM). 3 µg aliquots were preincubated 
with compounds or vehicle (0.1% DMSO) for 15 min at 4 °C, followed by stimulation with 2 mM 
Ca2+ and 20 µM AA for 10 min at 37 °C. The reaction was stopped by addition of 1 ml methanol 
on ice. 500 µl D’PBS, 30 µl 1 N HCl, and 200 ng PGB1 as internal standard were added and 
5-LO products were subjected to SPE (3.2.6) and determined by RP-HPLC (3.2.8) as 
described before. For evaluations of reversible inhibition, partially purified 5-LO was 
preincubated with compounds at concentrations of 3 and 30 nM for 10 min at 4 °C. An aliquot 
of the 30 nM sample was diluted with the equal amount of assay buffer. After 10 min 
equilibration, both aliquots were stimulated with 2 mM Ca2+ and 20 µM AA for 10 min at 37 °C. 
Sample preparations and analysis was performed as described above. 
3.2.5.3 Activity of isolated COX-1/2 
To determine the influence of the compounds on isolated COX-1 and 2 [173], 50 U/ml ovine 
COX-1 and 20 U/ml human COX-2 were diluted in assay buffer (100 mM Tris, pH 8.0, 5 mM 
GSH, 5 µM hemoglobin, 100 µM EDTA) at 4 °C and aliquots of 1 ml were preincubated with 
compounds or vehicle (0.1% DMSO) for 5 min at RT. Samples were pre-warmed for 60 s at 
37 °C, followed by stimulation with 5 µM AA (COX-1) or 2 µM AA (COX-2) for 5 min at 37 °C. 
The reaction was stopped with 1 ml methanol, 500 µl D’PBS, 30 ml 1 N HCl and 200 ng PGB1 
as internal standard on ice. The COX product 12-HHT was purified by SPE (3.2.6) and 
determined by RP-HPLC (3.2.8) as described before [199]. 
MATERIALS AND METHODS  
35 
3.2.5.4 Induction of mPGES-1 expression in A549 cells, preparation of 
microsomes, and determination of mPGES-1 activity 
Preparations of A549 cell microsomes and determination of mPGES-1 activity were performed 
as described before [177]. In brief, A549 cells (1 × 105/ml) were seeded in DMEM high glucose 
(4.5 g/l) supplemented with 10% (v/v) FCS, 2 mM L-glutamine, 100 U/ml penicillin and 100 
µg/ml streptomycin for 20 h at 37 °C, 5% CO2. After exchange of DMEM containing 2% (v/v) 
FCS cells were stimulated with 2 ng/ml IL-1β for 72 h at 37 °C, 5% CO2. The cells were 
detached with trypsin/EDTA and washed with D’PBS (600 × g / 10 min / 20 °C). The obtained 
cell pellet was frozen in liquid nitrogen for 1 min, resuspended in homogenization buffer  
(0.1 M potassium phosphate buffer, pH 7.4, 1 mM PMSF, 60 µg/ml STI, 1 µg/ml leupeptin,  
2.5 mM GSH and 250 mM sucrose) and sonicated (3 × 20 s). The homogenate was centrifuged 
(10,000 × g / 10 min / 4 °C) and microsomal fraction was extracted from obtained supernatant 
(174,000 × g / 1 h / 4 °C). Microsomal membranes were resuspended in homogenization buffer 
and the total protein concentration was determined with protein assay (Bio-Rad Laboratories, 
CA, USA). For determination of mPGES-1 activity, microsomal membranes (300 µg protein/ml) 
were diluted in homogenization buffer, preincubated with compounds or vehicle (1% DMSO) 
for 15 min at 4 °C, followed by initiation of product formation with 20 µM PGH2 for 1 min at  
4 °C. The reaction was stopped with 100 µl stop solution (40 mM iron(II) chloride, 80 mM citric 
acid, 10 µM 11β-PGE2 as internal standard in H2O) and samples were transferred to C18 
columns (Clean-Up columns, UTC, Bristol, PA, USA) to extract PGE2. Columns were 
preconditioned with 1 ml acetonitrile and 1 ml H2O, samples were washed twice with 0.4 ml 
H2O, eluted with 200 µl acetonitrile and extracts were diluted with 0.4 ml H2O. PGE2 formation 
was quantified by RP-HPLC using a C18 column (Nova-Pak cartridge, 5 × 100 mm, 4 µM 
particle size; Waters, Eschborn, Germany) with a mobile phase of acetonitrile/H2O/TFA 
(30/70/0.007). PGE2 was detected at 195 nm. 
3.2.5.5 Preparation of microsomes from LTC4S expressing HEK293 cells 
and determination of LTC4S activity 
Preparation of microsomes and determination of LTC4S activity was performed as described 
before [193]. Briefly, 3 × 108 HEK293 cells expressing LTC4S were harvested by trypsination, 
washed with D’PBS and frozen in liquid nitrogen. Afterwards, the cell pellet was resuspended 
in homogenization buffer (0.1 M potassium phosphate pH 7.4, 1 mM PMSF, 60 µg/ml STI,  
1 µg/ml leupeptin, 2.5 mM glutathione, 250 mM sucrose). After incubation for 15 min, cell 
disruption was achieved by sonication (3 × 20 s, 4 °C) and the lysate was centrifuged twice 
(10,000 × g / 10 min / 4 C; 174,000 × g / 1 h / 4 °C). The microsomal fraction was resuspended 
in homogenization buffer and the protein amount was determined by a protein assay (Bio-Rad 
Laboratories, CA, USA). 2.5 µg/ml of protein was diluted in homogenization buffer containing 
5 mM GSH and preincubated with compounds or vehicle (1% DMSO) for 10 min at 4 °C, with 
subsequent initiation of the product formation with 1 µM LTA4-methyl ester. The reaction was 
stopped by addition of methanol, acidified D’PBS, and 5 ng LTC4-d5-methyl ester as internal 
standard. The LTC4S products were purified by SPE (3.2.6) and determined using LC-MS/MS 
(3.2.7). 
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3.2.5.6 Purification of soluble epoxide hydrolase and determination of 
activity 
Human recombinant sEH was expressed in Sf9 cells and purified with affinity chromatography 
as described before [205, 206]. In brief, Sf9 insect cells were grown in suspension at 27 °C. 
Cells were infected with the recombinant baculovirus (kindly provided by Dr. B. Hammock, 
University of California, Davis, CA, USA) for 72 h, harvested and sEH was purified by affinity 
chromatography, dialyzed and concentrated using Amicon-ultra-15 centrifugal units (Merck 
Millipore, Darmstadt, Germany). To determine enzyme activity, the non-fluorescent substance 
3-penyl-cyano(6-methox-2-naphthalenyl)-methyl ester-2-oxiraneaceic acid (PHOME) was 
used, based on conversion to the fluorescent 6-methoxy-naphtaldehyde by sEH. sEH was 
diluted in assay buffer (25 mM Tris/HCl, pH 7.0, 0.1 mg/ml BSA), preincubated with compounds 
or vehicle (1% DMSO) for 10 min at RT and to evaluate enzyme activity 50 µM PHOME were 
added for 60 min at RT in the dark. The reaction was stopped with zinc sulfate on ice and the 
fluorescence emission was monitored at 465 nm after excitation at 330 nm using a NOVOstar 
microplate reader (BMG Labtechnologies GmbH, Offenburg, Germany). 
3.2.5.7 Evaluation of radical scavenging capacity 
To evaluate the radical scavenging activity, reduction of the stable free radical 2,2-diphenyl-1-
picrylhydrazyl (DPPH) was analyzed as described [207]. In brief, compounds were diluted to 
indicated concentrations and 100 µl were added to 100 µl DPPH solution (50 µM in ethanol, 
acetate buffered, pH 5-6.5) in a 96 well plate. Preparations were shaken for 30 min at RT in 
the dark following detection of the absorbance of the neutralized DPPH at 520 nm with a 
microplate reader (Thermo Fisher Scientific Inc., MA, USA). 
3.2.6 Solid phase extraction 
For solid phase extraction, sample preparations were centrifuged (800 × g / 10 min / 4 °C) and 
transferred to C18 SPE columns (Clean-Up columns, UTC, Bristol, PA, USA), which were 
washed with 1 ml methanol (100%) and preconditioned with 1 ml H2O. To extract lipid 
mediators, columns were washed with 1 ml H2O and 1 ml methanol (25%) and eluted from the 
column with 300 µl methanol (100%). Extracts were diluted with 120 µl H2O, centrifuged 
(15,000 × g / 5 min / 4 °C) and lipid mediators were either determined with RP-HPLC (3.2.8) 
or LC-MS/MS (3.2.7). To extract prostanoids, columns were washed twice with 0.5 ml H2O and 
eluted with 250 µl methanol (100%). After centrifuging twice (15,000 × g / 5 min / 4 °C) 
prostanoids were determined using LC-MS/MS (3.2.7). To extract eicosanoids for lipid 
mediator profiling in monocytes, obtained sample preparations were transferred to C18 columns 
(SepPak Vac C18 6cc, Waters, Milford, MA, USA), which were washed with 6 ml methanol 
(100%) and preconditioned with 2 ml H2O. Columns were washed with 6 ml H2O and 6 ml 
hexane followed by elution with 6 ml methyl formate. Samples were evaporated until dryness 
using a TurboVap (TurboVap LV, Biotage, Uppsala, Sweden) with 5 - 10 PSI (N2). 
Subsequently, samples were reconstituted in 100 µl Methanol/H2O (1:1) and centrifuged twice 
(15,000 × g / 5 min / 4 °C). Lipid mediators were determined using LC-MS/MS (3.2.7). 
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3.2.7 UPLC-MS/MS analysis 
Liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis was conducted with 
an Aquity UPLC BEH C18 column (1.7 µm, 2.1 × 50 mm, Waters, Milford, MA, USA) for 
eicosanoid evaluation or an Aquity UPLC BEH C18 column (1.7 µM, 2.1 × 100 mm, Waters, 
Miford, MA, USA) for the lipid mediator profiling in monocytes using an AquityTM UPLC system 
(Waters, Milford, MA, USA). For Eicosanoid evaluation, chromatography was performed with 
a mobile phase composed of H2O/acetonitrile (90/10, A) and acetonitrile (B), both acidified with 
0.07% (v/v) formic acid, with a flow rate of 0.8 ml/min at 45 °C column temperature. Isocratic 
elution at A/B = 70/30 was performed for 2 min and followed by a linear gradient to A/B = 30/70 
within 5 min. For the lipid mediator profiling in monocytes, chromatography was performed with 
a mobile phase composed of H2O (A) and methanol (B), both acidified with 0.01% acetic acid, 
with a flow rate of 0.3 ml/min at 50 °C (column temperature). Elution by a linear gradient starting 
at A/B = 58/42 to 2/98 within 12.5 min, followed by isocratic elution performed for 3 min. The 
UPLC was coupled to a QTRAP 5500 mass spectrometer (AB Sciex, Darmstadt, Germany) 
equipped with a Turbo VTM source and electrospray ionisation (ESI) probe. All lipid mediators 
were detected by multiple reaction monitoring (MRM) using the negative ion mode, based on 
specific ion fragmentation (Table 3.1) with following parameters: The ions spray voltage was -
4000 to -4500 V, the declustering potential -30 to -120 eV, the entrance potential -5 to -10 eV 
and the collision cell exit potential -11 to -17 eV at a heater temperature of 500 °C. The curtain 
gas pressure was 35 psi, the nebulizer gas pressure 50 psi and the Turbo V gas pressure  
80 psi. Detected eicosanoids were quantified using Analyst 1.6 software (AB Sciex, Darmstadt, 
Germany) with automatic peak integration using IntelliQuan default settings. Data were 
normalized to the internal standards PGB1 given as relative intensities or d9-PGE2 or d4-TxB2, 
given as ng/ml. 
Table 3.3.1: specific fragment ions and conditions used in MRM. Q1, first quadrupole; Q3, third quadrupole; 
Part 1. 
 transitions 1 transition 2  
mediator Q1 
(m/z)2 
Q3 
(m/z)3 
collision 
energy (eV) 
Q1 
(m/z)2 
Q3 
(m/z)3 
collision 
energy (eV) 
retention time 
(min) 
Eicosanoid evaluation; column: 2.1 × 50 mm 
PGB1 335.2 113.2 -31 335.2 221.2 -28 1.7 
d9-PGE2 360.2 189.0 -22 360.2 280.0 -20 0.6 
d4-TxB2 373.2 199.0 -38 - - - 0.4 
PGE2 351.2 189.0 -22 351.2 271.0 -20 0.6 
TxB2 369.2 195.0 -18 369.2 169.1 -25 0.4 
PGF2α 353.2 193.0 -35 - - - 0.6 
12-HHT 279.0 163.0 -30 - - - 3.3 
Epi- trans LTB4 335.2 195.0 -22 - - - 2.6 
LTB4 353.2 129.1 -26 353.2 195.0 -22 2.7 
5-HETE 319.2 115.0 -20 319.2 203.0 -20 5.0 
12-HETE 319.2 179.0 -18 - - - 4.8 
15-HETE 319.2 219.0 -18 - - - 4.5 
d5-LTC4-ME 643.0 272.0 -30    3.1 
LTC4 624.0 272.0 -30    1.6 
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Table 3.3.2: specific fragment ions and conditions used in MRM. Q1, first quadrupole; Q3, third quadrupole; 
Part 2. 
 transitions 1 transition 2  
mediator Q1 
(m/z)2 
Q3 
(m/z)3 
collision 
energy (eV) 
Q1 
(m/z)2 
Q3 
(m/z)3 
collision 
energy (eV) 
retention time 
(min) 
Lipid mediator profiling; column: 2.1 × 100 mm 
d8-5S-HETE 327.3 116.1 -17 - - - 10.9 
d4-PGE2 355.3 193.2 -25 - - - 5.1 
d4-LTB4 339.3 197.2 -22 - - - 8.1 
d5-LXA4 356.3 115.2 -19 - - - 5.8 
PGE2 351.3 189.1 -25 351.2 271.0 -20 5.1 
PGD2 351.3 233.1 -16 - - - 5.2 
PGE1/PGD1 353.2 317.4 -18 335.2 273.4 -28 5.4 
PGF2α 353.3 193.1 -34 - - - 5.4 
TxB2 369.3 169.1 -22 - - - 4.7 
12-HHT 279.0 163.1 -30 - - - 8.7 
ep/t-LTB4 335.2 195.1 -22 - - - 7.6 
LTB4 335.2 195.1 -22 - - - 8.1 
20-OH-LTB4 351.3 195.1 -24 - - - 3.8 
5-HEPE 317.2 115.2 -18 - - - 10.1 
5-HETE 319.2 115.1 -21 - - - 11 
11-HEPE 317.2 167.1 -19 - - - 9.6 
11-HETE 319.2 167.1 -21 - - - 10.5 
12-HEPE 317.2 179.1 -19 - - - 9.7 
12-HETE 319.2 179.1 -21 - - - 10.6 
14-HDHA 343.2 205.1 -17 - - - 10.6 
15-HEPE 317.2 219.1 -18 - - - 9.6 
15-HETE 319.2 219.1 -19 - - - 10.3 
5,15-diHEPE 333.3 115.1 -22 333.3 235.1 -22 6.8 
5,15-diHETE 335.3 201.0 -22 335.3 235.1 -30 7.8 
RvD5 
 
359.2 199.1 -21 359.2 261.1 -20 7.8 
3.2.8 Reversed phase-HPLC 
To determine 5-, 12- and 15-LO products, samples were centrifuged twice (15,000 × g / 5 min 
/ 4 °C) after SPE to remove all solid particles. Chromatography was conducted with 50 µl of 
sample preparation on a C18 column (Nova-Pak cartridge, 5 × 100 mm, 4 µM particle size, 
Waters, Eschborn, Germany) using methanol/H2O/trifluoroacetic acid (TFA) (73/27/0.007) as 
mobile phase with a flow rate of 1.2 ml/min at RT and isocratic elution [208]. The 
chromatographic system was coupled to an UV detector and leukotrienes (e.g. LTB4 and its 
all-trans isomers) were detected at 280 nm, whereas metabolites with two conjugated double 
bonds (e.g. 5-H(p)ETE, 12-H(p)ETE, 12-HHT, 15-H(p)ETE) were detected as 235 nm. Based 
on PGB1 as internal standard, metabolites were quantified by peak area integration. 
3.2.9 SDS-PAGE and Western blot 
Proteins from cell lysate preparations were separated using SDS-PAGE. A Mini-Protean 
electrophoresis system (Mini-PROTEAN® Tetra Cell, Bio-Rad Laboratories Inc., Hercules, CA, 
USA) was used. Cell lysates were added on a 10% or 12% polyacrylamide gel and vertically 
segregated immersed in running buffer (192 mM glycine, 25 mM Tris, 3.5 mM SDS). Using a 
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pre-stained marker (Protein-Marker IV, VWR Peqlab, Erlangen, Germany) size analysis could 
be conducted in a range between 10 to 170 kDa. For Western Blot analysis, proteins were 
electroblotted on nitrocellulose membranes (Amersham Bioscience, Little Chalfont, UK) with a 
tank blotting method (Bio-Rad Mini Trans-Blot® cell, Bio-Rad PowerpacTM Basic, Bio-Rad 
Laboratories Inc., Hercules, CA, USA) at 90 V for 90 min performed in a transfer buffer (48 mM 
Tris, 40 mM glycine, 20% (v/v) methanol). In order to verify appropriate protein transfer, 
membranes were stained by Ponceau (5% (w/v) Ponceau S in 5% (v/v) acetic acid). After 
blotting, membranes were washed and blocked in 5% BSA or 5% low fat powdered milk in 
TBS for 1 h at RT, followed by incubation with the primary antibody in TBS-Tween (TBS-T, 
0,1% (v/v) Tween®20) containing 5% BSA overnight at 4 °C (antibodies see table 3.3). 
Afterwards, membranes were washed three times in TBS-T and incubated with fluorescent-
labelled secondary antibodies IRDye 800 CW (dilution 1:10,000) and IRDye  
680 LT (dilution 1:80,000) for 1 h at RT. Membranes were washed three times with TBS-T and 
once with TBS before drying at 37 °C in the dark. Proteins were detected using the Odyssey 
Infrared Imaging System (LI.COR Bioscience, Bad Homburg, Germany) and analyzed with 
Odyssey application software. 
Table 3.4: Primary antibodies. Antibodies were diluted as indicated in 5% BSA or 5% low fat powdered milk in 
TBS-T. 
antibody source dilution 
COX-1 mouse, polyclonal 1:200, 5% BSA 
COX-2 rabbit, polyclonal 1:1000, 5% milk 
β-actin mouse or rabbit, monoclonal 1:1000, 5% BSA or 5% milk 
ERK1/2 rabbit, polyclonal 1:1000, 5% BSA 
Phosphorylated-ERK1/2 mouse, monoclonal 1:1000, 5% BSA 
p-38 rabbit, monoclonal 1:1000, 5% BSA 
phosphorylated-p38 rabbit, monoclonal 1:1000, 5% BSA 
3.2.10 Docking simulations with 5-LO 
Docking simulations were performed in collaboration with Dr. Daniela Schuster (University of 
Innsbruck, Austria). The target protein was based on the 5-LO crystal structure 3o8y. To return 
the stable 5-LO [102] to wild type, four residues were exchanged in silico (Glu13Trp, His14Phe, 
Gly75Trp, Ser76Leu). Subsequently, the structure was energetically minimized in DS version 
4.0. The binding site was defined in a 10 Å radius around Ile167. All ligands were drawn in 
ChemDraw version 14.0, converted to sd files with pipeline pilot version 9.1 and energetically 
minimized with OMEGA version 2.2.1. Simulations were conducted in GOLD version 5.2. 
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3.2.11 Statistics 
Results are given as means ± standard error of the mean (SEM) of n observations, where n 
represents the number of different experiments at different days. Statistical evaluation was 
performed using GraphPad Prism 4 Software (San Diego, CA, USA). For paired observations, 
the Student’s t-test was used with Welch’s correction if variances were significantly different, 
for multiple comparison one-way ANOVA followed by a Bonferroni (≤ 5 groups) or Tukey-
Kramer (> 5 groups) post-hoc test was applied. To determine normal distribution, the 
D'Agostino-Pearson omnibus test was performed. Paired observations which were not 
distributed normally were evaluated with the Mann-Whitney U test. A p value of 0.05 was 
considered significant (*). IC50 values were calculated by nonlinear regression (sigmoidal dose 
response/four-parameter logistic) with GraphPad Prism 4 Software.  
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4 RESULTS 
4.1 The influence of sex on prostanoid formation  
4.1.1 Difference in cell numbers of male and female whole blood 
Recently published data by our group showed a sex-dependent difference in PGE2 formation 
in zymosan-induced peritonitis in mice and carrageenan induced pleurisy in rats [5]. To 
investigate whether this sex difference appears also in human, fresh human whole blood 
(HWB), randomly collected from healthy volunteers, was used for experiments.  
Evaluation of cell numbers of HWB samples, revealed sex differences in the amount of different 
cell types in male and female HWB, which is consistent with other studies [209, 210]. Except 
for platelets, all blood cell types (erythrocytes, all leukocytes) revealed significant sex 
differences in the cell number (Figure 4.1). There were higher amounts of white blood cells in 
female HWB, which arise from higher counts of lymphocytes and neutrophils. Only monocytes 
and red blood cells showed significant higher cell numbers in male HWB. Given that monocytes 
together with neutrophils are the main producers of prostanoids in HWB [48, 211], this study 
focused on these cell types in the subsequent investigations and related data of HWB was 
always normalized to the cell number of monocytes plus PMNL. 
4.1.2 Evaluation of prostanoid formation in male and female whole 
blood 
The first step was to investigate effects of different physiological and non-physiological stimuli 
on the prostanoid formation in male and female blood. After stimulation for 24 h with various 
agents (Figure 4.2 and 4.3), the amounts of biosynthesized prostanoids were detected via 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) or enzyme-linked 
immunosorbent assays (ELISA). In order to elucidate a COX-related group effect, three 
prostanoids were chosen for investigations: prostaglandin E2 (PGE2), thromboxane B2 (TxB2) 
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Figure 4.1: Blood cell population counts of human whole blood differ between sexes. F, female; M, male. 
Cell numbers of HWB were detected via flow cytometry at the laboratories of the blood donation centre of the Jena 
University Hospital. Data are shown as 25th, 50th, 75th percentiles and range; n = 174. Data for PLT, RBC, WBC 
and PMNL passed normality D'Agostino-Pearson omnibus test; **p < 0.01, ***p < 0.001, female vs. male, paired  
t-test. Data for lymphocytes and monocytes did not pass normality test; ***p < 0.001, female vs. male, Mann-
Whitney U test. 
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and prostaglandin F2α (PGF2α). For physiological cell stimulation, two distinct toll-like receptor 
(TLR) activating ligands were applied, first LPS a TLR4 agonist and second Pam3CSK4, a 
TLR2/TLR1 agonist. Stimulation of HWB for 24 h with LPS (Figure 4.2 A) led to a significant 
higher biosynthesis of PGE2 and PGF2α in male blood compared to female. For PGF2α, there 
was already a sex-related difference in unstimulated conditions evident. However, TxB2 
showed the same tendency, but was not significant. Stimulation with the TLR2/TLR1 agonist 
Pam3CSK4 revealed a similar pattern (Figure 4.2 B). There was a tendency for higher amounts 
of PGE2 and TxB2 in male HWB. Furthermore, it seemed Pam3CSK4 had no stimulating effect 
on TxB2 formation in female HWB in general.  
To evaluate if this sex difference was related to a sex dimorphism in the TLR biology, HWB 
was challenged with arachidonic acid (AA; Figure 4.3 A), the Ca2+ ionophore A23187 (Figure 
4.3 B), the bacteria-derived peptide fMLP (Figure 4.3 C) and the protein kinase C activator 
phorbol-12-myristat 13-acetate (PMA; Figure 4.3 D). Similar as for the incubation with TLR 
agonists, AA and A23187 led to a higher prostanoid formation in blood from males compared 
to females, either significantly or with a tendency. Following stimulation with fMLP (10 µM), 
there was a strong increase of PGE2 in male but there was no stimulating effect in female 
HWB. The formation of both TxB2 and PGF2α increased in male and female following fMLP 
stimulation but more efficiently in males. 
   
Figure 4.2: Prostanoid formation after TLR activation is higher in male versus female HWB. (A) 1 ml of HWB 
was either treated with vehicle (w/o; 0.5% PBS) or 10 µg/ml LPS for 24 h at 37 °C. Prostanoids were detected in 
the supernatant via LC-MS/MS. Data is shown as means ± SEM; (B) 1 ml of HWB was either treated with vehicle 
(w/o; 0.2% H2O) or 2 µg/ml Pam3CSK4 for 24 h at 37 °C. Prostanoids were detected via ELISA following 
manufacturer’s instructions. Data is shown as means ± SEM; (A) n = 11-13 (PGE2), n = 10-12 (PGF2α), n = 10-13 
(TxB2); (B) n = 10-14 (PGE2), n = 11-13 (TxB2); data passed normality D'Agostino-Pearson omnibus test; *p < 0.05, 
**p< 0.01, female vs. male, unpaired t-test with Welch’s correction if variances were significantly different. Data of 
HWB is normalized to number of monocytes plus PMNL. 
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Figure 4.3: A tendency for higher prostanoid formation in male HWB samples verus samples from females. 
1 ml of HWB was either treated with (A) vehicle (w/o; 0.25% EtOH) or AA at indicated concentrations, (B) vehicle 
(w/o; 0.5% MeOH) or A23187 at indicated concentrations, (C) vehicle (w/o; 0.1% DMSO) or 10 µM fMLP for 24 h 
at 37 °C. Prostanoids were detected in supernatants via LC-MS/MS. (D) 1 ml of HWB was either treated with vehicle 
(w/o; 0.1% DMSO) or 10 nM PMA for 24 h at 37 °C. Prostanoids were detected by ELISA following manufacturer’s 
protocol. Data is shown as means ± SEM; (A) n = 8-12 (PGE2), n = 11-13 (PGF2α and TxB2); (B)  
n = 6-7 (PGE2), n = 4-6 (PGF2α), n = 9-12 (TxB2); (C) n = 7-11 (PGE2), n = 9-11 (PGF2α), n = 7-12 (TxB2), (D) n = 
11-13 (PGE2), n = 13-14 (TxB2) data passed normality D'Agostino-Pearson omnibus test; *p < 0.05, female vs. 
male, unpaired t-test with Welch’s correction if variances were significantly different. Data of HWB is normalized to 
number of monocytes plus PMNL. 
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Note, the formation of PGF2α and TxB2 significantly differed between male and female already 
in unstimulated blood, which equalized after fMLP treatment. Stimulating the blood with 10 nM 
PMA, PGE2 and TxB2 levels increased after 24 h with no significant sex difference. Incubation 
of human whole blood with various stimuli generated higher levels of prostanoids, mainly 
PGE2, in male samples compared to female. Even after normalization to the same cell number 
of monocytes plus PMNL the sex difference was evident. 
4.1.3 Evaluation of prostanoid formation in male and female PBMC 
isolated from HWB 
Amongst other cell types, monocytes are responsible for the immune response during 
inflammatory conditions [15]. They can be isolated from HWB together with T- and B-cells as 
mixed PBMC fraction. To investigate the sex-related prostanoid formation in PBMC, they were 
isolated from HWB, seeded in 12-well plates in cell culture medium containing human serum 
(sex hormones were removed by charcoal treatment) and stimulated for 24 h with LPS. The 
formed prostanoids were detected in the supernatant using LC-MS/MS (Figure 4.4 A). Due to 
the fact that male and female PBMC fractions contain different numbers of monocytes, data 
were normalized to the number of monocytes. 
  
  
Figure 4.4: Sex differences in prostanoid formation in PBMC following stimulation with LPS are not 
apparent. 1×106 male and female PBMC isolated from HWB were seeded in (A) cell culture medium containing 
0.5% of sex hormone free human serum (0.5% CSS) or (B) non-autologous human plasma, treated with either 
vehicle (w/o; 0.5% PBS) or 10 µg/ml LPS for 24 h at 37 °C. Supernatant was analyzed using LC-MS/MS. Data is 
shown as means ± SEM; (A) n = 14-15 (PGE2), n = 13 (PGF2α), n = 11-15 (TxB2); (B) n = 12-14 (PGE2), n = 12-13 
(PGF2α and TxB2); data passed normality D'Agostino-Pearson omnibus test; female vs. male, unpaired t-test with 
Welch’s correction if variances were significantly different. Data is normalized to number of monocytes. 
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After incubation in cell culture medium and LPS stimulation for 24 h (Figure 4.4 A) no sex 
difference was evident regarding the PGE2, PGF2α and TxB2 levels. Note, the total amount of 
prostanoids detected in stimulated PBMC was clearly below levels quantified in HWB. On one 
hand this could be due to missing factors out of the HWB for example the LPS binding protein 
(LBP), which is necessary for the activation of the TLR4 by LPS [212] or on the other hand due 
to lack of sex hormones [213, 214]. Therefore, female PBMC were seeded in non-autologous 
female plasma and male PBMC in non-autologous male plasma, respectively, to overcome 
this discrepancy (Figure 4.4 B). Interestingly, incubation of PBMC in human plasma could 
increase the overall prostanoid levels but could not restore the sex difference found in HWB, 
i.e. higher levels for male cells. In contrast, PGE2 and PGF2α levels were slightly higher in 
female PBMC, whereas there was no difference in TxB2 formation. 
4.1.4 Cyclooxygenase-2 gene expression and protein biosynthesis in 
isolated cells 
During inflammation, the inducible cyclooxygenase-2 (COX-2) determines prostanoid 
formation [60] after LPS stimulation and is abundantly found in monocytes. To investigate if a 
diverse COX-2 expression was responsible for the sex difference in prostanoid formation in 
HWB, PBMC were isolated and mRNA levels were analyzed. Cells were either stimulated with 
vehicle or with LPS for 5 and 18 h. Total mRNA was extracted using a RNA Kit following 
manufacturer’s instructions, cDNA was generated by reverse transcription and amplified by 
RT-qPCR. Figure 4.5 A shows the amounts of COX-2 mRNA expressed in female PBMC 
relative to male, where male data was set to 1 arbitrary. Independent of LPS stimulation female 
COX-2 mRNA levels were similar to male levels, indicating that in both healthy and 
inflammatory conditions no sex difference was evident in COX-2 mRNA expression. 
Additionally, the relative fold change in mRNA expression of stimulated to corresponding 
unstimulated samples was determined. Upon 5 h stimulation, the fold change in male and 
female PBMC was similar, whereas after 18 h stimulation a stronger increase occurred in male 
COX-2 mRNA expression.  
                
Figure 4.5: Sex differences in COX-2 mRNA expression in PBMC are not apparent. (A) 3×106 male and female 
PBMC were seeded in medium (0.5% CSS) and either incubated with vehicle (0.5% PBS) or 10 µg/ml LPS for 5 or 
18 h at 37 °C. mRNA was extracted and determined using RT-qPCR. mRNA was normalized to β-actin. Data is 
shown as (A) fold of male samples (male mRNA level set to 1 arbitrary) or as fold of unstimulated controls at 5 h 
and 18 h of each sex (B), means ± SEM, (A)/(B) n = 3. 
A B 
RESULTS 
46 
However, mRNA-levels do not necessarily reflect protein biosynthesis. Therefore, the actual 
amount of COX-2 protein was evaluated using immunoblotting analysis. PBMC isolated from 
HWB were stimulated for 24 h with LPS and dexamethasone was used as negative control, 
since it is a well-known inhibitor of COX-2 expression [215]. COX-2 protein levels were 
determined as well as the formation of prostanoids in corresponding supernatants (Figure 4.6 
A and B). In response to LPS the COX-2 protein biosynthesis in PBMC from HWB increased 
as expected, but with no sex difference. In parallel, the prostanoid formation, was evaluated 
upon LPS stimulation but with no difference either. It is important to mention that male and 
female donors show different numbers of monocytes within the mixed PBMC fractions. In this 
case, only for the prostanoid formation in the supernatants normalization could be performed, 
but is not possible for the Western blot data.  
 
Table 4.1: Percentage of monocytes within PBMC fractions of male and female donors on different 
experimental days. LYM, lymphocytes; mono, monocytes; similar amounts of monocytes marked in bold. 
 female male 
 LYM 
109/L 
mono 
109/L 
mono 
% 
LYM 
109/L 
mono 
109/L 
mono 
% 
day 1 2.2 0.6 21.4% 2.7 1.1 28.9% 
day 2 2.9 0.9 23.7% 2.8 0.7 20.0% 
day 3 1.3 0.5 27.8% 1.8 0.7 28.0% 
day 4 2.1 0.7 25.0% 1.0 0.7 41.2% 
day 5 2.2 0.4 15.4% 1.1 0.7 38.9% 
day 6 2.1 0.7 25.0% 1.2 1.1 47.8% 
day 7 2.4 0.5 17.2% 1.3 0.9 40.9% 
day 8 2.2 0.6 21.4% 2.0 0.6 23.1% 
day 9 2.0 0.8 28.6% 1.6 0.8 33.3% 
day 10 1.6 0.6 27.3% 1.1 0.4 26.7% 
day 11 1.6 0.3 15.8% 0.9 0.9 50.0% 
day 12 1.2 0.6 33.3% 2.5 0.9 26.5% 
day 13 2.5 0.6 19.4% 1.9 1.1 36.7% 
        
sex F M F M F M 
LPS - - + + + + 
dexa - - - - + + 
 
Figure 4.6: Sex differences in COX-2 protein expression and prostanoid formation after LPS stimulation in 
PBMC are not apparent. 3×106 PBMC were seeded in medium (0.5% CSS) and preincubated with 1 µM 
dexamethasone (dexa) or vehicle (w/o; 0.5% PBS) for 30 min, followed by stimulation with 10 µg/ml LPS for 24 h at 
37 °C. (A) Cell lysates were obtained using NP-40 lysis buffer. COX-2 protein expression was determined via 
Western blot analysis; β-actin was used as control. Image represents 1 out of 13 independent experiments (dexa: 
n = 5). Data is presented as ratio of densitometry. (B) Prostanoids were determined in supernatant of cells used for 
Western blot analysis by LC-MS/MS. Data is shown as means ± SEM; n = 5-12; data passed normality D'Agostino-
Pearson omnibus test; female vs. male, unpaired t-test. Data is normalized to number of monocytes. 
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Table 4.1 shows the percentage of monocytes in different PBMC fractions of the blood samples 
used for Western blot analysis. Only on few experimental days, the number of monocytes were 
comparable (bold font). Taken together, male PBMC distinctly contained more monocytes what 
in turn did not lead to a higher COX-2 protein synthesis or a higher prostanoids formation. In 
fact, COX-2 protein and prostanoid levels were similar in males and females, indicating a 
higher COX-2 expression in female monocytes. Therefore, COX-2 protein expression was 
investigated additionally in monocytes isolated from leukocyte concentrates (buffy coats). 
Unexpectedly, after 24 h treatment with LPS no sex difference in COX-2 protein expression 
and no difference in prostanoid formation was evident, as seen before (Figure 4.7 A and B).  
However, monocytes isolated following the standard protocol (Methods 3.2.2.1) still show 
impurities of lymphocytes (T-/B-cells). To prevent the influence of these cells, PBMC were 
separated using fluorescence-activated cell sorting (FACS). Therefore, PBMC isolated from 
leukocyte concentrates were incubated with appropriate antibodies (monocytes: CD14, APC-
labelled; T-cells: CD3, PE-labelled; B-cells: CD19, FITC-labelled), separated by FACS analysis 
and stimulated with vehicle (0.5% PBS) or LPS for 24 h (Figure 4.8 A). COX-2 protein 
expression and prostanoid formation in the respective supernatants were analyzed. The 
results clearly show that (I) COX-2 was only expressed in monocytes and (II) when 99% pure 
monocytes were used, higher amounts of COX-2 protein were evident in females compared to 
males. However, prostanoid formation showed no significant sex difference (Figure 4.8 B). 
Taken together, neither the COX-2 mRNA expression nor the COX-2 protein biosynthesis was 
higher in male monocytes after LPS stimulation. Therefore, the COX-2 enzyme does not seem 
to be the cause for the determined difference in prostanoid levels in male HWB versus female. 
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Figure 4.7: Sex differences in COX-2 protein expression and prostanoid formation after LPS stimulation in 
monocytes isolated from leukocyte concentrates are not apparent. 1×106 monocytes from leukocyte 
concentrates were seeded in medium (0.5% CSS) and preincubated with 1 µM dexamethasone (dexa) or vehicle 
(w/o; 0.5% PBS) for 30 min, followed by stimulation with 10 µg/ml LPS for 24 h at 37 °C. (A) Cell lysates were 
obtained using NP-40 lysis buffer. COX-2 protein expression was determined via Western blot analysis; β-actin was 
used as control. Image represents 1 out of 5 independent experiments. Data is presented as ratio of densitometry. 
(B) Prostanoids were determined in supernatant from cells used for Western blot by LC-MS/MS. Data is shown as 
means ± SEM; n = 5; data passed normality D'Agostino-Pearson omnibus test; female vs. male, unpaired t-test. 
Data is normalized to number of monocytes. 
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4.1.5 Influence of TLR4 expression on the monocyte cell surface 
An initial step of the LPS-mediated COX-2 expression is the binding and thus activation of 
TLR4 on the cell surface. Hence, the presence of TLR4 on male and female monocytes was 
evaluated. Monocytes were isolated from leukocyte concentrates and TLR4 expression was 
analyzed by flow cytometry in untreated conditions and after 1 h stimulation with LPS. In 
untreated cells TLR4 expression was elevated on female monocytes compared to male and 
after 1 h incubation the TLR4/LPS complex got internalized to equal proportions, leaving a 
higher amount of TLR4 on the cell membrane of female monocytes.  
 
 
  
 
 
Figure 4.8: Higher COX-2 protein expression in female monocytes but no sex difference in prostanoid 
formation. (A) 50×106 PBMC isolated from leukocyte concentrates were treated with antibodies for 15 min on ice 
(monocytes, CD14, APC; B-cells: CD19, FITC; T-cells: CD3, PE). After cell separation by FACS, 0.6×106 
monocytes, 0.6×106 B-cells and 2.5×106 T-cells were seeded in medium (0.5% CSS) and incubated with vehicle 
(w/o; 0.5% PBS) or 10 µg/ml LPS for 24 h at 37 °C. Cell lysates were obtained using NP-40 lysis buffer. COX-2 
protein expression was determined via Western blot analysis; β-actin was used as control. Image represents 1 out 
of 5 (T-/B-cells) - 8 (monocytes) independent experiments. Data is presented as ratio of densitometry and passed 
normality D'Agostino-Pearson omnibus test; female vs. male, paired t-test. (B) Prostanoids were determined in 
supernatants from cells used for Western blot by LC-MS/MS. Data is shown as means ± SEM; n = 5-7 (PGE2),  
n = 4-6 (PGF2α), n = 4-7 (TxB2); data passed normality D'Agostino-Pearson omnibus test; female vs. male, unpaired 
t-test with Welch’s correction if variances were significantly different. 
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Figure 4.9: Higher TLR4 expression on the cell surface of female 
monocytes. 1×106 monocytes isolated from leukocyte concentrates were 
left untreated (w/o) or stimulated with 10 µg/ml LPS for 1 h at 37 °C. 
Afterwards cells were incubated with fluorescent antibodies for flow 
cytometry (monocytes: CD14, APC; TLR4, PE). Data is shown as 
percentage of monocytes expressing TLR4 (parental monocytes = 100%), 
n = 3; female vs. male paired t-test. 
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4.1.6 Influence of exogenously provided sex hormones in HWB and 
isolated cells 
Sex hormones could play a role in the sex-related difference of prostanoid formation in blood, 
since there are several reports that sex hormones are involved in immune reactions [76, 216]. 
Therefore, HWB was preincubated with different sex hormones, followed by stimulation with 
LPS for 24 h. Unfortunately, in this set of experiments no sex difference in prostanoid formation 
was evident following LPS stimulation for 24 h in HWB (Figure 4.10 A). As a result, it could not 
be answered whether male sex hormones are able to increase prostanoid formation in female 
HWB to levels detected in males, or the other way around, if female sex hormones are able to 
decrease prostanoid formation in male HWB down to levels seen in female HWB. Nonetheless, 
none of the sex hormones appeared to affect prostanoid formation in female blood, whereas 
all hormones independent of sex marginally increased prostanoid formation in male HWB. To 
exclude the influence of other cell types and plasma proteins like albumin, which can bind the 
sex hormones, PBMC were isolated from HWB and seeded in cell culture medium, additionally 
(Figure 4.10 B). Male and female PBMC were preincubated with sex hormones and stimulated 
with LPS for 24 h. As seen before, if PMBC were isolated from the HWB, there was nearly no 
difference in prostanoid formation between males and females.  
 
 
Figure 4.10: Lack of influence of sex hormones on prostanoid formation in HWB and isolated PBMC. (A)  
1 ml of HWB or (B) 3×106 male and female PBMC isolated from HWB, seeded in their distinct plasma, were 
preincubated for 30 min at 37 °C with sex hormones as follows (HWB): test. = 300 nM testosterone, 5α-DHT = 300 
nM 5α-dihydrotestosterone, 17β-ES = 300 nM 17β-estradiol, prog. = 3 µM progesterone; or in PBMC as follows: 
30 nM 5α-DHT or 30 nM 17β-ES. Upon preincubation HWB or PBMC were treated with vehicle (w/o; 0.5% PBS) 
or 10 µg/ml LPS for 24 h at 37 °C. Prostanoid formation was determined in supernatants by LC/MS-MS. Data is 
shown as means ± SEM; (A) n = 7-11 (PGE2), n = 8-11 (PGF2α), n = 9-10 (TxB2); (B) n = 4-6 (PGE2, TxB2), n = 4-
7 (PGF2α); data passed normality D'Agostino-Pearson omnibus test; female vs. male, unpaired t-test with Welch’s 
correction if variances were significantly different. Data of HWB is normalized to number of monocytes plus PMNL, 
data of PBMC is normalized to number of monocytes. 
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In contrast to the findings of HWB pre-treated with sex hormones where the exogenous 
hormones exerted rather stimulating effects, they showed a moderately decreasing effect in 
both male and female PBMC, regarding all three prostanoids. 
4.1.7 Prostanoid formation in HWB and cyclooxygenase-1 in short-term 
incubations 
In long term incubations, e.g. for 24 h, prostanoid formation is mainly mediated by inducible 
COX-2. Additionally, there exists also the constitutively expressed COX-1, which mediates 
prostanoid formation within shorter incubation periods. To determine if the sex difference 
discovered in HWB was mediated rather by COX-1 activity than COX-2, short time stimulations 
were performed (Figure 4.11). Male and female HWB was incubated with AA (40 µM and  
100 µM) for 10 min or with A23187 (30 µM) for 10 and 30 min at 37 °C. 
 
In contrast to incubations for 24 h with AA, in short time incubations there was no significant 
sex difference in prostanoid formation for all three mediators derived from AA (Figure 4.11 A). 
In treatment of HWB with A23187 all three prostanoids appeared to increase stronger in female 
blood over time compared to male (Figure 4.11 B), showing a significant difference in TxB2 
formation after 30 min.  
   
  
Figure 4.11: Sex differences in short term incubations of HWB following stimulation with A23187 but not 
with AA. (A) 1 ml of HWB was treated with (A) vehicle (w/o; 0.5% EtOH) or 40 µM or 100 µM AA for 10 min at  
37 °C, or (B) with vehicle (w/o; 0.5% MeOH) or 30 µM A23187 for 10 and 30 min. Prostanoid formation was analyzed 
by LC-MS/MS in supernatants. Data is shown as means ± SEM; (A) n = 10-15 (PGE2), n = 7-10 (PGF2α), n = 8-14 
(TxB2); (B) n = 7-9 (PGE2, TxB2), n = 8-9 (PGF2α); data passed normality D'Agostino-Pearson omnibus test; female 
vs. male, unpaired t-test with Welch’s correction if variances were significantly different. Data is normalized to 
number of monocytes plus PMNL. 
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Furthermore, the COX-1 protein levels were investigated in PBMC isolated from HWB (Figure 
4.12). Only male and female samples with comparable amounts of monocytes were used 
(Table 4.2). Western blot analysis revealed a tendency to higher COX-1 expression in female 
PBMC from HWB. This finding might explain the results of prostanoid formation obtained in 
incubations with AA and A23187 for 10 or 30 min in male and female HWB but otherwise  
COX-1 does not contribute to the sex difference in prostanoids in HWB after 24 h. 
4.1.8 Evaluation of prostanoid formation in male and female PMNL 
isolated from HWB 
PMNL are responsible for the early immune response but display a shorter lifetime compared 
to monocytes [217]. To investigate whether these cells contribute to the sex difference in 
prostanoid formation in HWB, they were isolated from male and female HWB and incubated 
for 10 min with 5 µM AA (Figure 4.13 A). In general, PMNL produced only little amounts of 
prostanoids and showed no difference in prostanoid formation between males and females. 
Under these conditions, PGF2α formation was below detection limit. Additionally, in PMNL 
isolated from leukocyte concentrates the release of AA was investigated (Figure 4.13 B). 
 
Table 4.2: Percentage of mono-
cytes within PBMC fractions. 
 female male 
 mono 
(%) 
mono 
(%) 
day 1 16.7 22.7 
day 2 26.1 33.3 
day 3 21.1 27.8 
day 4 21.2 25.0 
day 5 31.3 24.1 
 
Figure 4.12: COX-1 protein expression in male 
and female PBMC isolated from HWB. 3×106 
PBMC isolated from male and female HWB were 
used untreated. Cell lysates were obtained using 
lysis buffer. COX-1 protein expression was 
determined via Western blot analysis; β-actin was 
used as control. Image represents 1 out of 5 
independent experiments. Data is presented as 
ratio of densitometry and passed normality 
D'Agostino-Pearson omnibus test. Female vs. 
male, paired t-test. 
          
Figure 4.13: Sex differences in prostanoid formation and AA-release in isolated PMNL are not apparent. (A) 
5×106 PMNL isolated from male and female HWB were treated with vehicle (w/o; 0.5% EtOH) or 5 µM AA for  
10 min at 37 °C in PBS-glucose. Prostanoid formation was determined in supernatants using LC-MS/MS. Data is 
shown as means ± SEM; n = 5-8 (PGE2), n = 7-8 (TxB2); data passed normality D'Agostino-Pearson omnibus test 
female vs. male, unpaired t-test. (B) PMNL isolated from leukocyte concentrates were treated with 0.5 µCi/ml tritium 
labelled AA ([3H]-AA) for 2 h at 37 °C. Afterwards, cells were pre-treated with 2 µM RSC-3388 (RSC) or vehicle 
(0.5% MeOH) for 10 min and stimulated with 0.5 µM A23187. Radioactivity was measured with scintillation counter 
in supernatants at indicated time points. Data is shown as counts per minute (CPM); means ± SEM, n = 2; curve 
fitted with one side exponential association. 
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PMNL were incubated with [3H]-AA for 2 h to incorporate the fatty acid in their cell membranes. 
Upon cell stimulation by 0.5 µM A23187, [3H]-AA was released from the membranes and 
converted into lipid mediators. The well-known cPLA2 inhibitor RSC-3388 was used as control. 
With detection of scintillation not only free [3H] labelled AA but also all mediators derived from 
the labelled AA were determined. After 15 to 30 min, the A23187-induced AA release/AA-
product formation in male and female cells reached a plateau, stable up to 2 h, with no sex 
difference, comparable with the prostanoid formation in PMNL after 10 min. This indicates that 
PMNL do not contribute to the sex specific difference in prostanoid formation in HWB.  
4.1.9 Differences in the time-dependent degradation of prostanoids 
Levels of prostanoids in the blood not only depend upon the rate of synthesis, but also on the 
rate of degradation. Therefore, the prostanoid catabolism is another point to consider, 
regarding the difference in prostanoid levels. The enzyme responsible for PGE2 degradation 
and in parts also for other prostanoids is the 15-hydroxyprostaglandin dehydrogenase  
(15-PGDH) [218] and several studies showed sex-dependent effects in its expression and 
activity [219, 220]. To test whether the catabolism was responsible for the different prostanoid 
formation in HWB, a high-affinity and non-competitive 15-PGDH inhibitor (SW033291) was 
used [221]. HWB was preincubated with the inhibitor followed by stimulation.  
 
         
                    
Figure 4.14: Evaluation of the 15-PGDH inhibitor SW033291 in HWB in short-and long-term incubations.  
(A) 1 ml of HWB was pre-incubated with 10 µM SW033291 for 30 min at 37 °C, followed by stimulation with 40 µM 
AA. Prostanoid formation was analyzed at indicated time points using LC-MS/MS. Data is shown as means ± SEM;  
n = 2 (6 h)-3. Data is normalized to number of monocytes plus PMNL. (B) 1 ml of HWB was pre-incubated with  
10 µM SW033291 or vehicle (w/o; 0.5% PBS) for 30 min at 37 °C, followed by stimulation with 10 µg/ml LPS for  
24 h at 37 °C. Prostanoid formation was analyzed in supernatants by LC-MS/MS. Data passed normality 
D'Agostino-Pearson omnibus test female vs. male, unpaired t-test. Data is shown as means ± SEM; n = 5. Data is 
normalized to number of monocytes plus PMNL. 
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For early time points up to 6 h AA was used as stimulus (Figure 4.14 A), for long term 
incubation (24 h) LPS (Figure 4.14 B). To verify whether initially higher prostanoid formation in 
male individuals in HWB was mediated due to a higher activity or expression of 15-PGDH in 
females, the prostanoid levels should be equalized after pre-treatment with the inhibitor. After 
short-term incubations up to 2 hours with AA, no difference in female blood between samples 
with and without pre-treatment appeared. Only at 6 h AA incubation, the inhibitor increased the 
PGE2 formation in female HWB up to the level obtained in males (M w/o SW: 28.0 ± 9.3 ng/ml; 
F plus SW: 30.1 ± 8.3 mg/ml). The same effect was visible in TxB2 formation, though the higher 
PGE2 level detected in female samples treated with SW033291 could not entirely reach the 
level in males (M w/o SW: 2073.0 ± 1016.2 ng/ml; F plus SW: 1326.3 ± 39.32 ng/ml). In 
contrast, the inhibitor had no effect in male blood on TxB2 formation, PGE2 formation appeared 
to be even lower compared to untreated samples. Amounts of PGF2α were not influenced in 
both sexes by the inhibitor (data not shown). Even though, after 24 h incubations with LPS, the 
inhibitor did not longer influence the prostanoid biosynthesis (Figure 4.14 B), 15-PGDH seems 
to play a role in the sex-biased prostanoid formation in blood. 
4.1.10 Involvement of cell-cell interactions in sex related differences of 
prostanoid formation 
So far, a concrete cause leading to the sex difference in prostanoid formation in HWB could 
not be identified. Interactions between platelets and immune cells forming heterogeneous 
aggregates are known to play an important role in inflammation, e.g. in cardiovascular 
diseases [222-224]. Therefore, the cross talk between PMNL and PBMC was evaluated in 
more detail. One part of HWB was used to obtain plasma, as well as PBMC and PMNL, the 
other part was left untreated. Then, PMNL and PBMC were added in autologous plasma alone 
or together to investigate the effect of a cell-cell interplay. Afterwards, blood, cells and cell 
mixtures of PMNL and PBMC were stimulated with LPS (Figure 4.15) or AA (Figure 4.16) for 
24 h. After LPS stimulation, only in PMNL formation of PGE2 was higher in female cells, 
whereas in PBMC, PBMC plus PMNL and HWB itself, prostanoid formation was higher in 
males. Cell interactions seemed to push the formation in male cells, overcoming the higher 
amount of PGE2 formed by female PMNL. TxB2 formation showed a similar pattern, though the 
higher formation in female PMNL lowered the TxB2 difference in the cell mixture consisting of 
PBMC plus PMNL, compared to PBMC alone. In whole blood, there was the previous 
determined tendency to higher prostanoid levels in males. In contrast, PGF2α formation in 
unstimulated PMNL was substantially higher in female cells and rather equal after LPS 
treatment, which resulted in same PGF2α levels in both sexes. In PBMC alone, there was a 
tendency to a higher PGF2α formation in male cells, but in the cell mixture of PBMC plus PMNL 
to higher levels in female cells. Nevertheless, in HWB the difference in prostanoid formation 
was restored to higher levels in male blood, as seen before. 
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Stimulation with AA for 24 h revealed somewhat different results (Figure 4.16). PMNL showed 
no sex difference in PGE2 formation, whereas a tendency to higher level in PBMC alone, in 
PBMC plus PMNL and in HWB in male was detected. This indicated that cell interactions could 
push the formation to higher level in male samples. TxB2 and PGF2α did not show a different 
formation in isolated PMNL and PBMC alone, but in the combination of both cell types there 
was a tendency to higher prostanoid levels in male cells, also seen in male whole blood. This 
indicated again that cell interactions could play an important role in sex-related differences in 
prostanoid formation, depending on the stimulus and the mediator analyzed. Furthermore, 
these experiments show that the combination of cells led to higher amounts of prostanoids as 
the single cell types formed by itself, stimulating each other. 
  
     
    
    
Figure 4.15: Cell-cell cross talk and sex differences in the prostanoid formation following LPS stimulation. 
PMNL and PBMC were isolated from HWB. 3.5×106 PMNL, 2.5×106 PBMC were seeded in autologous plasma, 
alone or together. Cells or 1 ml of the same HWB were stimulated with 10 µg/ml LPS for 24 h at 37 °C. Prostanoid 
formation was analyzed by LC-MS/MS in supernatants. Data is shown as means ± SEM; (A) n = 4-12 (PGE2, 
PGF2α), n = 7-12 (TxB2); data passed normality D'Agostino-Pearson omnibus test; *p < 0.05, **p < 0.01, female vs. 
male, unpaired t-test with Welch’s correction if variances were significantly different. Data of PBMC is normalized 
to number of monocytes, data of PMNL plus PBMC and of HWB is normalized to number of monocytes plus PMNL. 
 
PMNL 
 
PBMC 
 
PBMC + PMNL 
 
HWB 
RESULTS 
55 
 
  
         
     
         
Figure 4.16 ell-cell cross talk and sex differences in the prostanoid formation following AA stimulation. 
PMNL and PBMC were isolated from HWB. 3.5×106 PMNL, 2.5×106 PBMC were seeded in autologous plasma, 
alone or together. Cells or 1 ml of the same HWB were stimulated with 40 µM AA for 24 h at 37 °C. Prostanoid 
formation was analyzed by LC-MS/MS in supernatants. Data is shown as means ± SEM; (A) n =3-6; data passed 
normality D'Agostino-Pearson omnibus test; *p < 0.05, **p < 0.01, female vs. male, unpaired t-test with Welch’s 
correction if variances were significantly different. Data of PBMC is normalized to number of monocytes, data of 
PMNL plus PBMC and of HWB is normalized to number of monocytes plus PMNL. 
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4.2 Modulation of the inflammatory response by benzoquinones and benzo-
hydroquinones 
4.2.1 Inhibitory potential of 1,2- and 1,4-benzoquinones on 5-LO 
Previous data by our group revealed a potent dual inhibitory effect of the 1,4-benzoquinone 
embelin on 5-LO and mPGES-1, indicating a modulation of the inflammatory response [8]. 
Starting from embelin as parental compound additional benzoquinone derivatives were 
systematically synthesized. First, the n-alkyl chain in 3-position was modified, introducing 
residues varying in the number of carbon atoms. Next, the 1,4-benzoquinone core was altered 
to a 1,2-benzoquinone and the free hydroxy groups were partially methylated. Four different 
series, namely 2,5-methoxy-1,4-benzoquinones (series A), 2-hydroxy-5-methoxy-1,4-
benzoquinones (series B), 4,5-dimethoxy-1,2-benzoquinones (series C) and 2,5-dihydroxy-
1,4-benzoquinones (series D), in total 48 compounds, were synthesized and biologically 
evaluated. The synthesis was performed by collaboration partners (Prof. Rosanna Filosa, 
Univeristy of Naples, Italy) and the compounds were provided to us. 16 of these compounds 
are part of this thesis and published in [225]. To evaluate the pharmacological relevance, the 
inhibition of 5-LO product formation was analyzed. Direct effects on 5-LO were determined in 
a cell-free assay with the partially purified enzyme incubated with exogenous AA. Intact human 
neutrophils (PMNL) and monocytes were used to evaluate the potency of the compounds in a 
cellular environment and on other lipoxygenases, when challenged with the Ca2+ ionophore 
A23187 with or without exogenous AA. The functionality of the assays was monitored with the 
reference control inhibitor N-[1-(1-benzothien-2-yl)ethyl]-N-hydroxyurea (zileuton) [196], which 
is the only 5-LO inhibitor on the market for asthma therapy so far. Furthermore, the ability to 
affect mPGES-1 was evaluated in an established cell-free assay, using microsomes from 
interleukin-1β-stimulated A549 cells with PGH2 as substrate and 3-[3-(tert-butylsulfanyl)-1-[(4-
chlorophenyl)methyl]-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethyl-propanoic acid (MK886) as 
control inhibitor.  
Table 4.3 - 4.6 show the effects of all four series on 5-LO, as well as on 12- and 15-LO and 
mPGES-1. Regarding 5-LO, the results clearly revealed the most potent effects for the  
1,2-benzoquinones (series C, Table 4.5) in cell-free as well as in cell-based settings, except 
for EA-112C. Regardless of the chain length, ortho-quinones were superior over para-
quinones in all three assays. EA-110C was identified as the most promising compound (IC50 
cell-free: 0.08 ± 0.01 µM; cell-based with A23187:0.12 ± 0.01 µM; cell-based with A23187 plus 
AA: 0.05 ± 0.03 µM) revealing a 1,2-benzoquinone core substituted with a C13-n-alkyl residue 
in 3-position as the optimal structure to suppress 5-LO activity. Regarding mPGES-1, the 
potency depended on both, the free hydroxy groups and the length of the alkyl chain in  
3-position. Combination of the two free hydroxy groups with a C8-n-alkyl chain, EA-109D, 
exerted the most pronounced effect with an IC50 of 0.8 ± 0.2 µM. In contrast, compounds from 
other 1,4-benzoquinone series showed highest inhibitory potential when bearing a C13-n-alkyl 
residue. Derivatives of the 1,2-quinone series were not able to interfere with mPGES-1 
catalytic activity at all. Furthermore, none of these 16 compounds affected 12- and 15-LO, 
indicating that especially the 1,2-benzoquinones were highly active and specific for 5-LO. 
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Table 4.3: Effects of 2,5-methoxy-1,4-benzoquinones (series A) on the activity of 5-, 12- and 15-LO and 
mPGES-1. IC50 values are presented as means ± SEM of two to three independent experiments. Values given in 
parentheses: remaining activity in % at 10 µM. Cmpd., compound. 
 
Table 4.4: Effects of 2-hydroxy-5-methoxy-1,4-benzoquinones (series B) on the activity of 5-, 12- and 15-LO 
and mPGES-1. IC50 values are presented as means ± SEM of two to three independent experiments. Values given 
in parentheses: remaining activity in % at 10 µM. Cmpd., compound. 
 
Table 4.5: Effects of 4,5-methoxy-1,2-benzoquinones (series C) on the activity of 5-, 12- and 15-LO and 
mPGES-1. IC50 values are presented as means ± SEM of two to three independent experiments. Values given in 
parentheses: remaining activity in % at 10 µM. Cmpd., = compound. 
 
5-LO 
activity   
12-LO 
activity 
15-LO 
activity 
mPGES-1 
activity 
IC50 (µM) or (remaining activity in %) at 10 µM 
 
  cell-free  cell-based  cell-based  cell-free 
cmpd. residue 
AA 
 
A23187 A23187 + AA 
 
A23187 + AA 
 
PGH2 
EA-109A n = (CH2)7 1.2±0.29   0.32±0.01 0.57±0.17  > 10 (89.6±13.1%) 
>10 
(123.0±26.9%)  
> 10  
(63.0±8.2%) 
EA-110A n = (CH2)12 0.26±0.01  0.23±0.04 0.31±0.05  > 10 (58.8±15.5%) 
> 10 
(84.1±17%)  1.8±0.4 
EA-111A n = (CH2)13 0.21±0.03  0.29±0.09 1.4±0.75  > 10 (84.5±6.7%) 
> 10 
(115.6±8.5%)  4.4±1.3 
EA-112A n = (CH2)14 0.27±0.1  0.39±0.14 0.86±0.27  >10 (87.3±5.7%) 
>10 
(115.4±3.2%)  7.2±1.1 
 
5-LO 
activity   
12-LO 
activity 
15-LO 
activity 
mPGES-1 
activity 
IC50 (µM) or (remaining activity in %) at 10 µM 
 
  cell-free  cell-based  cell-based  cell-free 
cmpd. residue 
AA 
 
A23187 A23187 + AA 
 
A23187 + AA 
 
PGH2 
EA-109B n = (CH2)7 3.01±0.38  > 10 (73.5±8.6%) 
> 10 
(72.9±12%)  
> 10 
(86.8±13.7%) 
> 10 
(104.9±27.1%)  
> 10 
(81.4±11.2%) 
EA-110B n = (CH2)12 0.92±0.47  0.77±0.26 2.3±1.10  > 10 (73.2±15.7%) 
> 10 
(88.1±20.7%)  6.1±1.2 
EA-111B n = (CH2)13 0.42±0.01  0.27±0.04 0.49±0.1  > 10 (113.5±8.3%) 
> 10 
(115.8±8.8%)  
> 10  
(52.1±2.9%) 
EA-112B n = (CH2)14 0.34±0.04  0.76±0.13 1.51±0.46  > 10 (92.8±3.7%) 
> 10 
(103.2±3.2%)  9.3±0.8 
 
5-LO 
activity   
12-LO 
activity 
15-LO 
activity 
mPGES-1 
activity 
IC50 (µM) or (remaining activity in %) at 10 µM 
 
  cell-free  cell-based  cell-based  cell-free 
cmpd. residue 
AA 
 
A23187 A23187 + AA 
 
A23187 + AA 
 
PGH2 
EA-109C n = (CH2)7 0.33±0.05  0.38±0.07 0.82±0.38  > 10 (59.3±15.8%) 
> 10 
(101.7±24%)  
> 10  
(51.1±3.4%) 
EA-110C n = (CH2)12 0.08±0.01  0.12±0.01 0.05±0.03  > 10 (78.5±28.8%) 
> 10 
(137.1±36.9%)  
> 10  
(77.5±4.4%) 
EA-111C n = (CH2)13 0.04±0.02  0.12±0.0 0.13±0.0  > 10 (87.3±11.6%) 
> 10 
(138.9±8.9%)  
> 10  
(84.0±3.6%) 
EA-112C n = (CH2)14 0.6±0.1  > 10 (57.6±3.2%) 
> 10 
(66.8±3.5%)  
> 10 
(88.9±6.8%) 
> 10 
(114.8±9.5%)  
> 10  
(97.3±11%) 
O
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Table 4.6: Effects of 2,5-hydroxy-1,4-benzoquinones (series D) on the activity of 5-, 12- and 15-LO and 
mPGES-1. IC50 values are presented as means ± SEM of two to three independent experiments. Values given in 
parentheses: remaining activity in % at 10 µM. Cmpd., compound. 
 
4.2.2 Variation of the 1,2-benzoquinone to a 1,2-benzohydroquinone 
core improves the inhibitory potency against 5-LO 
Based on the results obtained from the previous series, further structural optimizations were 
made to improve the inhibitory potential of the 1,2-benzoquinones to intervene with 5-LO 
product formation. There are many active hydroquinone compounds known so far by literature 
[226, 227]. Therefore, the quinone moiety was reduced, resulting in a 1,2-benzohydroquinone 
(RED). Out of the overall 48 structures tested, two other promising compounds emerged 
besides EA-110C, namely EA-107C and EA-100C with a C11- and C12-n-alkyl residue, 
respectively (Table 4.7) published in [168]. Additionally, the reduced forms of these two 
derivatives were synthesized as well as different hydroquinone derivatives of EA-110C. 
The new series was analyzed in cell-free 
and cell-based assays (Figure 4.17 A and 
B) and compared with their oxidized 
analogues to evaluate the benefit of the 
reduction to the hydroquinone core, 
regarding the inhibitory capacity on 5-LO 
product formation, also published in [198]. 
Figure 4.17 A shows that only the hydro-
quinone EA-107C RED was about 10-fold 
superior over the parental quinone 
structure in cell-free conditions (EA-107C 
IC50 = 0.94 ± 0.4 µM; EA-107C RED IC50 = 
0.11 ± 0.05). In agreement with the 
literature, this indicated that the hydroquinone moiety is the active form in cellular environments 
[228], where components like GSH create reducing conditions [229]. Two other hydroquinones 
with a different O-methylation pattern were synthesized, one with a tri-hydroxylated core and 
one with a para-hydroxy moiety (Table 4.8). All three EA-110C hydroquinones contained a 
C13-n-alkyl chain in 3-position. In cell-free, as well as in cell-based assays (Figure 4.17 A  
 
5-LO 
activity   
12-LO 
activity 
15-LO 
activity 
mPGES-1 
activity 
IC50 (µM) or (remaining activity in %) at 10 µM 
 
  cell-free  cell-based  cell-based  cell-free 
cmpd. residue 
AA 
 
A23187 A23187 + AA 
 
A23187 + AA 
 
PGH2 
EA-109D n = (CH2)7 0.38±0.04  > 10 (53.6±4.8%) 
> 10 
(80.1±8%)  
> 10 
(75.7±11.3%) 
> 10 
(88.9±18.4%)  0.8±0.2 
EA-110D n = (CH2)12 0.22±0.0  2.52±0.38 4.65±0.24  > 10 (84.3±2.9%) 
> 10 
(123.6±11.7%)  0.9±0.2 
EA-111D n = (CH2)13 0.17±0.01  3.14±0.45 5.12±0.57  > 10 (101.2±11%) 
> 10 
(138.9±12.1%)  1.6±0.3 
EA-112D n = (CH2)14 0.23±0.08  4.3±0.52 > 10 (61.7±2.1%)  
> 10 
(87.7±17.8%) 
> 10 
(103.4±6.8%)  2.1±0.4 
O
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Table 4.7: Effect of the 4,5-dimethoxy-1,2-benzo-
quinone EA-107C and EA-100C on 5-LO activity. IC50 
values are presented as means ± SEM of three to four 
independent experiments. Cmpd., compound [168]. 
 
5-LO activity 
IC50 (µM)   IC50 (µM)  
  cell-free  cell-based 
cmpd. residue AA 
 A23187 + 
AA 
EA-107C n = (CH2)10 0.94±0.40  0.10±0.03 
EA-100C n = (CH2)11 0.26±0.02  0.15±0.03 
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and B), altered O-methylation reduced the ability to intervene with 5-LO product formation. 
Interestingly, the 1,2-quinone/-hydroquinone core combined with a C13-n-alkyl residue (EA-
110C/RED) appeared to be the most effective compound of the entire series in cell-free as well 
as in cell-based experiments (Table 4.8). 
Based on this result, further studies were performed to characterize the mechanism of 5-LO 
inhibition and to analyze the physiological relevance in animal models of the two most 
promising compounds. First, the mode of inhibition was analyzed.  
  
      
Figure 4.17: Inhibition of 5-LO product formation by EA-107C, EA-100C and EA-110C and by their reduced 
analogues. (A) Partially purified recombinant 5-LO was preincubated with compounds or vehicle (0.1% DMSO) at 
the indicated concentrations for 10 min at 4 °C, followed by stimulation with 20 µM AA plus 2 mM Ca2+ for 10 min at 
37 °C. (B) PMNL were preincubated with compounds at the indicated concentrations or vehicle (0.1% DMSO) for 
15 min at 37 °C, followed by stimulation with 2.5 µM A23187 plus 20 µM AA for 10 min at 37 °C. 5-LO product 
formation was detected by RP-HPLC. Data is shown as percentage of control (100%); means ± SEM, n = 3-7. 
A 
B 
Table 4.8: Effect of the different benzohydroquinones on 5-LO activity. IC50 values are presented as means ± 
SEM of three to four independent experiments. Cmpd., compound. See also [198]. 
 
  
5-LO activity 
 
 IC50 (µM) or (remaining activity in 
%) at 10 µM 
     cell-free   cell-based 
cmpd. residue R R2  AA   A23187 + AA 
EA-107C RED n = (CH2)10 -H -CH3  0.11±0.05   0.04±0.04 
EA-100C RED n = (CH2)11 -H -CH3  0.24±0.03   0.09±0.06 
EA-110C RED n = (CH2)12 -H -CH3  0.06±0.02   0.03±0.02 
EA-110C T RED n = (CH2)12 -H -H  0.29±0.05   0.16±0.58 
EA-110C P RED n = (CH2)12 -CH3 -H  0.26±0.07   0.31±0.03 
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n
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Therefore, partially purified 5-LO was preincubated with the compounds and stimulated with 
AA at varying concentrations. Although these compounds showing a fatty acid like structure, 
results (Figure 4.18) revealed a non-competitive mode of EA-110C and EA-110C RED with 
AA. This suggested that the compounds did not compete with AA for the binding site.  
 
To assess the exact binding mode, docking simulations were performed, using Pocket-Finder 
software. Two binding sites were identified, one cavity on the opposite side of the substrate 
channel and one located between the membrane binding C2 domain and the catalytic domain. 
The docking simulation was conducted in collaboration with Dr. Daniela Schuster (University 
of Innsbruck, Austria) and suggested a possible positioning of the substituted benzene moiety 
in a region of the binding pocket also accessible for polar solvents. At this location, hydrogen 
bonds with Tyr-383, Tyr-81, Trp-102 and Glu-622 were most likely. Docking simulations of  
EA-110C and EA-110C RED revealed a similar binding mode at the 5-LO binding site opening. 
The quinone interacted with Tyr-81 and Tyr-383 whereas the hydroquinone formed hydrogen 
bonds with Tyr-81 and Glu-622 (Figure 4.19 A, B). According to the simulation, the 
hydroquinone did not directly interact with the active site iron. 
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Figure 4.18: Effect of variation of the substrate concentration on inhibition of 5-LO activity by EA-110C and 
EA-110C RED. Partially purified recombinant 5-LO was preincubated with compounds at the indicated 
concentration or vehicle (0.1% DMSO) for 10 min at 4 °C, followed by stimulation with 20 µM AA plus 2 mM Ca2+ 
for 10 min at 37 °C. 5-LO products were detected by RP-HPLC. Data are given as percentage of control (100%); 
means ± SEM, n = 3. 
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Figure 4.19: Docking simulations of EA-110C and EA-110C RED at the 5-LO binding site. Both, the quinone 
(A) and hydroquinone ring (B) were located at the binding site opening, allowing the n-alkyl chain to fill the 
hydrophobic ion channel. Binding to 5-LO is mediated through hydrogen bonds with Tyr-81 and Tyr-383 (A) or  
Tyr-81 and Glu-622 (B). Red arrow – hydrogen bond acceptor, green arrow – hydrogen bond donor, yellow spheres 
– hydrophobic interaction. See also [198].  
A B 
EA-110C EA-110C RED 
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Next, the pharmacological relevance in treatment of inflammatory conditions was analyzed in 
two different in vivo models of acute inflammation performed in the lab of Prof. Bruno 
D’Agostino, University of Naples, Italy. Carrageenan-induced paw oedema in mice was 
induced by intraplantar injection of carrageenan in the hind paw. This led to a massive swelling 
and oedema formation. Both EA-110C and EA-110C RED could significantly reduce paw 
swelling during the early (4 h) as well as the late (48 h) time points, in a concentration of  
1 mg/kg given i.p. 30 min prior carrageenan injection (data not shown, published in [198]). 
Peritonitis in mice was generated by intraperitoneal injection of zymosan. Pre-application of 
the two EA-compounds (1 mg/kg i.p.) 30 min prior zymosan injection showed a marked 
repression of cys-LT formation and migration of inflammatory cells into the peritoneal cavity 
for both compounds, equally effective as the control inhibitor zileuton (data not shown, 
published in [198]). 
4.2.3 Lipophilic catechols exhibit inhibitory capacity on 5-LO product 
formation 
Encouraged by the results obtained with the previous 1,2-hydroquinone series, which potently 
modulated the inflammatory response, another set of 15 compounds was synthesized to 
further improve the inhibitory capacity (synthesized by Prof. Rosanna Filosa, University of 
Naples, Italy). The novel structures were substituted with various rather bulky aromatic 
residues in 4-position, in contrast to the linear n-alkyl chains in 3-position used in the previous 
studies. A screening on 5-LO activity revealed highly active compounds (Table 4.9), especially 
in cell-free assays where IC50 values were in a range from 7 to 210 nM.  
Table 4.9.1: Effect on 5-LO activity in cell-free and cell-based assays by 1,2-hydroquinones; part 1. 
  5-LO activity 
  IC50 (µM)  IC50(µM) 
  cell-free  cell-based 
cmpd STRUCTURE AA  A23187 + 
AA 
A23187 
F-I 
 
0.05 ± 0.01  0.93 ± 0.11 0.37 ± 0.11 
F-III 
 
0.02 ± 0.002  0.44 ± 0.0 0.26 ± 0.07 
F-IV 
 
0.02 ± 0.005  0.36 ± 0.11 0.21 ± 0.02 
F-V 
 
0.21 ± 0.0  2.31 ± 0.02 1.33 ± 0.47 
F-XI 
 
0.04 ± 0.01  0.62 ± 0.25 0.24 ± 0.03 
F-XII 
 
0.02 ± 0.01  0.07 ± 0.03 0.07 ± 0.004 
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Inhibition of cellular activity in PMNL stimulated with A23187 displayed IC50 values in a range 
of 0.07 to 2.31 µM, whereas in cells stimulated with A23187 plus exogenous AA, the IC50 
values were between 0.07 and 2.34 µM. To exert intracellular inhibition, it seemed rather linear 
structures with lipophilic residues were favored, e.g. compounds F-III, F-XII or F-XVI. 
Interestingly, linear structures bearing an inflexible or an additional hydrophilic substituted 
aromatic residue led to reduction of activity, e.g. compounds F-XXIII or F-V. 
 
Table 4.9.2: Effect on 5-LO activity in cell-free and cell-based assays by 1,2-hydroquinones; part 2. 
*data published in [225]. 
  5-LO activity 
  IC50 (µM)  IC50(µM) 
  cell-free  cell-based 
cmpd structure AA  A23187 + 
AA 
A23187 
F-XIII 
 
0.01 ± 0.002  0.23 ± 0.05 0.17 ± 0.11 
F-XV 
 
0.03 ± 0.005  0.43 ± 0,04 1.11 ± 0.54 
F-XVI 
 
0.02 ± 0.031  0.11 ±0.03 0.06 ± 0.004 
F-XVII 
 
0.02 ± 0.006  1.14 ±0.08 1.21 ± 0.51 
F-XVIII 
 
0.007 ± 0.001  0.30 ±0.03 0.22 ± 0.05 
F-XIX 
 
0.01± 0.005  0.40 ± 0.01 0.27 ± 0.02 
F-XXII 
 
0.008 ± 0.001  0.19 ± 0.04 0.22 ± 0.04 
F-XXIII 
 
0.01 ± 0.001  0.40 ± 0.14 2.34 ±0.49 
F-XXIV 
 
0.007 ± 0.001  0.25 ± 0.06 0.31 ± 0.11 
Zileuton* 
 
0.59 ± 0.10  2.5 ± 1.2 0.9 ± 0.3 
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4.3 Inhibitory potential of F-XII and F-XVI on 5-LO activity 
4.3.1 Interaction of F-XII and F-XVI with 5-LO in cell based assays 
Encouraged by this positive outcome, pharmacological relevance and the possibility to apply 
such compounds in the therapy of inflammatory disorders were assessed. The mechanism of 
5-LO product formation was characterized in detail using the two most promising compounds 
F-XII, containing a benzothiophene residue in 4-position and F-XVI bearing a diphenyl ether. 
First, the effect on 5-LO activity in human leukocytes was analyzed (Figure 4.20 A).  
 
In PMNL stimulated with A23187 plus AA, F-XII and F-XVI were equally active in suppressing 
5-LO product biosynthesis (F-XII: IC50 = 0.07 ± 0.03 µM; F-XVI: IC50 = 0.11 ± 0.03 µM, see 
also table 4.9). Of note, they were able to outperform the control inhibitor zileuton (PMNL 
stimulated with A23187 IC50 = 2.5 ± 1.2 µM, see also [225]). Up to a concentration of 1 µM 
both hydroquinones had no effect on the related 12- and 15-LO. Remaining activity regarding 
15-LO was 135.4 ± 17.4% for F-XII and 137.0 ± 15.5% for F-XVI, respectively. Inhibitory 
potency on 12-LO activity was more pronounced but was not reduced below 65% (F-XII: 
remaining activity = 67.2 ± 13.2%; F-XVI: remaining activity = 65.5 ± 9.7%).  
Next, PMNL were stimulated either with A23187 alone or by priming with the bacterial product 
LPS, followed by stimulation with fMLP (Figure 4.20 B). The latter is a pathophysiological 
means to induce leukotriene biosynthesis in immune cells. Regardless of the stimulus used, 
F-XII and F-XVI were equally potent in decreasing LTB4 formation (F-XII: A23187 IC50 =  
0.07 ± 0.004 µM, LPS/fMLP IC50 = 0.1 ± 0.01 µM; F-XVI: A23187 IC50 = 0.06 ± 0.004 µM, 
LPS/fMLP IC50 = 0.12 ± 0.01 µM). Stimulation with A23187 alone or LPS/fMLP leads to AA 
release from nuclear membranes by cPLA2 and to leukotriene formation in concert with 5-LO 
and FLAP. Since stimulation in the presence of exogenous AA did not change the potency of 
F-XII and F-XVI, this indicated that cPLA2 is not a primary target of these hydroquinones.  
 
     
      
A 
B 
Figure 4.20: Effect of F-XII and F-XVI on  
5-LO activity in cellular assays. (A) PMNL 
were preincubated with compounds at the 
indicated concentrations or vehicle (0.1% 
DMSO) for 15 min, followed by stimulation 
with 2.5 µM A23187 plus 20 µM AA for  
10 min. (B) PMNL were preincubated with 
compounds at the indicated concentrations 
or vehicle (0.1% DMSO) for 15 min, followed 
by stimulation with 2.5 µM A23187 for  
10 min. Alternatively, PMNL were primed 
with 1 µg/ml LPS for 30 min and 0.3 U/ml for 
20 min, followed by stimulation with 1 µM 
fMLP for 5 min. Compounds were added  
15 min prior fMLP stimulation. 5-LO product 
formation was determined by RP-HPLC. 
Data are given as percentage of control 
(100%), means ± SEM, n= 3-7. 
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The instable epoxide Leukotriene A4 (LTA4) can either be converted to LTB4 via the LTA4-
hydrolase, or to the cys-LTs by the LTC4-synthase. Therefore, the formation of cys-LTs in 
monocytes was explored with parallel detection of LTB4 (Figure 4.21). The hydroquinones 
showed a likewise influence on the formation of both LTB4 and the cys-LTs, suggesting no 
additional inhibition of the LTC4-synthase.  
 
In order to verify that the ability to interfere with 5-LO was due to the hydroquinone moiety,  
O-methylated analogues of F-XII (AF-06) and F-XVI (AF-13) were used as control compounds 
(Figure 4.22 A and B). Apparently, masking the hydroxy groups substantially decreased the 
inhibitory potency of AF-06 (stimulation with A23187: IC50 = 2.7 ± 0.2 µM; stimulation with 
A23187 plus AA: IC50 = 2.9 ± 0.5 µM) and led to a complete loss of activity of AF-13 (stimulation 
with A23187: remaining activity at 10 µM = 63.8 ± 19.4%; stimulation with A23187 plus AA: 
remaining activity at 10 µM = 84.5 ± 3.5%).  
Nevertheless, high efficiency of 5-LO inhibition was not due to cytotoxic effects. Monocytes 
challenged by F-XII or F-XVI for 24 h did not show detrimental effects on cells as shown by 
MTT as well as LDH assays (Figure 4.23). Staurosporine (stsp), a well-known apoptosis 
inducer was used as positive control.  
    
Figure 4.21: Influence of F-XII and F-XVI 
on cys-LT and LTB4 formation in human 
monocytes. Monocytes were preincubated 
with compounds at the indicated 
concentrations or vehicle (0.1% DMSO) for 
15 min, followed by stimulation with 2.5 µM 
A23187 for 10 min. LTB4 formation was 
determined using RP-HPLC analysis, cys-
LTs were analyzed using ELISA. Data are 
presented as percentage of control (100%), 
means ± SEM, n = 4-6. 
                            
Figure 4.22: Chemical structures of AF-06 and AF-13 and their effect on 5-LO activity in PMNL. PMNL were 
preincubated with (A) AF-06 or (B) AF-13 at the indicated concentrations or vehicle (0.1% DMSO) for 15 min, 
followed by stimulation with 2.5 µM A23187 with or without 20 µM AA for 10 min. 5-LO product formation was 
determined using RP-HPLC. Data is given as percentage of control (100%); means ± SEM, n = 3. 
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4.3.2 Effect of F-XII and F-XVI on 5-LO activity in cell-free assays 
Next, the ability to interact with the isolated 5-LO in cell-free conditions was investigated. 
Therefore, partially purified 5-LO was preincubated with the test compounds followed by 
incubation with AA. The capacity of 5-LO inhibition was higher as compared to cellular settings. 
(IC50 values: F-XII = 0.02 ± 0.01 µM, F-XVI = 0.02 ± 0.03 µM; Figure 4.24 A) and again superior 
over zileuton (IC50 = 0.59 ± 0.01 µM). 
   
       
Figure 4.24: Effects of hydroquinones and methylated analogous on 5-LO activity in cell-free assays.  
(A) Partially purified recombinant 5-LO was preincubated with F-XII or F-XVI, (C) AF-06 or AF-13 at the indicated 
concentrations or vehicle (0.1% DMSO) for 10 min at 4 °C followed by stimulation with 20 µM AA and 2 mM Ca2+ 
for 10 min at 37 °C. Triton X-100 was added as indicated. (B) PMNL were homogenized by sonication at 4 °C. 
Homogenates (corresponding to 2×106 cells) were preincubated with F-XII or F-XVI at the indicated concentrations 
or vehicle (0.1% DMSO), followed by stimulation with 20 µM AA and 2 mM Ca2+ for 10 min at 37 °C. 5-LO product 
formation was determined by RP-HPLC. Data are given as percentage of control (100%); means ± SEM, n = 3. 
A 
B C 
       
Figure 4.23: Effect of F-XII and F-XVI on cell viability. (A) Monocytes were preincubated with compounds at the 
indicated concentrations, 3 µM staurosporine (stsp), or vehicle (0.3% DMSO) for 24 h. Afterwards cell viability was 
monitored by addition of MTT and photometric measurement at 570 nm. Data are presented as percentage of 
untreated control (100%). (B) Monocytes were preincubated with compounds at indicated concentrations, 3 µM 
staurosporine, 0.2% triton X-100 or vehicle (0.5% DMSO) for 24 h. Afterwards, cell viability was monitored by LDH 
activity at 340 nm. Data are given as percentage of triton X-100 control (100%); means ± SEM, n = 3-6.  
**p < 0.01***p < 0.001 vs. untreated sample, repeated measures ANOVA followed by Bonferroni (MTT) or Tukey 
(LDH) post hoc test applied to absolute values. 
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One possibility of 5-LO inhibition could be the formation of compound aggregates. Compounds 
executing this mechanism are called nuisance inhibitors [230]. They form colloid like 
aggregates with the enzyme protein without target specificity. These aggregates can be 
prevented by non-ionic detergents like triton X-100. After pre-treatment of the partially purified 
5-LO with triton X-100 at a concentration of 0.1% the potency of F-XII and F-XVI was not 
decreased, excluding nuisance inhibition (F-XII with triton: IC50 = 0.01 ±0.001 µM, F-XVI with 
triton: IC50 = 0.01 ± 0.001 µM) (Figure 4.24 A). In PMNL homogenates F-XII and F-XVI were 
less effective compared to purified 5-LO preparations (Figure 4.24 B). The IC50 value of F-XII 
shifted only slightly to 0.04 ± 0.01 µM, whereas the value of F-XVI shifted to 0.13 ± 0.02 µM, 
similar to the value seen in intact cells. As well as in PMNL, AF-06 and AF-13 were used in 
cell-free conditions to confirm that he inhibitory activity relies on the hydroquinone structure 
(Figure 4.24 C). Both molecules lost their ability to interfere with 5-LO (F-XII: remaining activity 
at 10 µM = 84.6 ± 5.3%, F-XVI: remaining activity at 10 µM 92.2 ± 9.8%).  
4.3.3 Detailed investigations of the binding mode of F-XII and F-XVI to  
5-LO 
Next we studied the binding mode of the compounds to the 5-LO enzyme. First, reversibility of 
inhibition was evaluated. Partially purified 5-LO preparation was preincubated with F-XII or 
 F-XVI at a concentration of 30 nM. One aliquot was diluted 10-fold with assay buffer, the other 
was not altered. Following incubation of both aliquots with AA neither F-XII nor F-XVI showed 
an irreversible inhibition (Figure 4.25 A). Second, competition of the compounds with AA was 
analyzed by incubation of 5-LO with varying AA concentrations (Figure 4.25 B). The results 
indicated no competitive inhibition for both F-XII and F-XVI.  
 
 
    
Figure 4.25: Investigation of the reversibility and substrate competitive mode of inhibition of 5-LO by F-XII 
and F-XVI. (A) Partially purified recombinant 5-LO was preincubated with F-XII or F-XVI at 3 and 30 nM for 10 min 
at 4 °C. An aliquot of the 30 nM sample was diluted 1:10 with assay buffer to give 3 nM. After another 10 min 
samples were stimulated with 20 µM AA and 2 mM Ca2+ for 10 min at 37 °C. (B) Partially purified recombinant  
5-LO was preincubated with compounds at the indicated concentrations or vehicle (0.1% DMSO), followed by 
stimulation with varying concentrations of AA plus 2 mM Ca2+ as described in (A). Data are given as percentage of 
control (100%), means ± SEM, n = 3-4. *p < 0.05, ***p < 0.001 vs. not diluted sample (30 nM), paired t-test applied 
to absolute values. 
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For some benzoquinones e.g. AA-861 containing a Michael acceptor function an interaction 
with some of the cysteines Cys-159, Cys-300, Cys-416 and Cys-418 located on the surface of 
the catalytic C-terminal domain, in close proximity to the substrate entrance, could be shown 
[167]. To evaluate the possible interference of F-XII and F-XVI with these specific amino acids, 
HEK293 cells stably expressing the mutant 5-LO_4C, where Cys-159, Cys-300, Cys-416 and 
Cys-418 are replaced by serines (kindly provided by Dr. Steinhilber, University of Frankfurt) 
were used (Figure 4.26). Interestingly, both hydroquinones were equally active on wild type 
and mutant 5-LO, with even lower IC50 values for the mutated 5-LO (F-XII: 5-LO_wt IC50 = 0.11 
± 0.01 µM vs. 5-LO_4D IC50 = 0.08 ± 0.03 µM; F-XVI: 5-LO_wt IC50 = 0.14 ± 0.05 µM vs. 5-
LO_4D IC50 = 0.12 ± 0.01 µM). Thus, the four critical cysteines that are targeted by 5-LO 
inhibitors with Michael acceptor functions are not required for 5-LO inhibition by F-XII and  
F-XVI. 
 
To get a more detailed insight into the binding mode, docking simulations with the 5-LO 
(“Stable-5-LO”) were performed in collaboration with Dr. Daniela Schuster (University of 
Innsbruck, Austria). Docking simulation revealed a similar binding mode for both compounds. 
The ortho-hydroquinone ring was coordinated by three amino acids (F-XII; Arg-138, Tyr-142, 
Asp-166) or two amino acids (F-XVI; Tyr-142, Asp-166) on the C-terminal catalytic domain 
(Figure 4.27 A). Interestingly, Asp-166 on the catalytic domain is considered to interact 
intramolecular with Arg-101 on the regulatory N-terminal C2 like domain. It is also part of a 
short α2 helix, which is proposed to control access to the active site [101]. In the compounds 
AF-06 and AF-13, the hydroxy groups were replaced with methoxy groups, hence making it 
difficult to form stabilizing hydrogen bonds due to a displacement of the molecules within the 
binding pocket. Although methoxy groups are capable to form hydrogen bonds, they are 
considered very weak. Figure 4.27 B clearly shows the different docking positions in the 
binding site compared to the hydroquinones, displacing the oxygens of forming the ideal 
interactions. 
 
Figure 4.26: Impact of F-XII and F-XVI on HEK293 cells 
stably expressing FLAP and 5-LO_wt or 5-LO_4C, 
respectively. Cells were preincubated with F-XII or F-XVI at the 
indicated concentrations or vehicle (0.1% DMSO) for 15 min, 
followed by stimulation with 2.5 µM A23187 and 3 µM AA for  
10 min. LT formation was detected by RP-HPLC. Data are given 
as percentage of control (100%); means ± SEM, n = 4. 
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4.3.4 Interference with 5-LO translocation and activation  
Inhibitors of LT formation can not only interfere with 5-LO itself, they may also intervene with 
the cellular 5-LO redistribution as well. Hyperforin [231] for example is known to hamper the 
intracellular translocation of 5-LO to the nuclear membrane, where interaction with FLAP and 
LT formation takes place. In order to evaluate the possible inhibition of subcellular 
redistribution of 5-LO by hydroquinones, PMNL were preincubated with F-XII or F-XVI, 
followed by stimulation with A23187. Subsequent incubation with fluorescent antibodies 
enabled to visualize the translocation of 5-LO by immunofluorescence microscopy (Figure 4.28 
A). Independent of cell stimulation, the helper protein FLAP was permanently located at the 
nuclear envelope (green fluorescence signal), presented in Figure 4.29 A in the top row. In 
unstimulated conditions 5-LO was located within the nucleus, appearing as diffuse red 
fluorescence signals (Figure 4.28 A, left column). Upon cell stimulation with A23187 5-LO 
translocated to the nuclear membrane, visible as yellow signals in the overlay with FLAP, 
(Figure 4.28 A third row). F-XII failed to affect 5-LO translocation but F-XVI seemed to impair 
the redistribution of 5-LO to some extent. In contrast, pre-incubation with hyperforin led to a 
complete inhibition of the 5-LO translocation. 
 
 
Figure 4.27: Molecular docking simulations with F-XII, F-XVI and the methylated analogous into the  
“Stable-5-LO”. Exemplary docking poses are shown. (A) Molecular docking poses of F-XII (left) and F-XVI (right). 
The location of the hydroquinone ring is stabilized through hydrogen bonds formed by the amino acids Arg-138, 
Tyr-142 and Asp-166. (B) comparison between docking poses of F-XII (green) and AF-06 (purple) on the left and 
F-XVI (brown) and AF-13 (dark blue) on the right. Interactions are displayed colored. Red arrow – hydrogen bond 
acceptor, green arrow – hydrogen bond donor, yellow spheres – hydrophobic interaction. 
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Ca2+ mediates the binding of 5-LO to membrane phospholipids (PC) via distinct tryptophan 
residues. HEK293 cells stably expressing FLAP and 5-LO_3W, respectively, were used to 
study if the hydroquinones may act via the PC-binding site of 5-LO (Figure 4.29 B). In the  
5-LO_3W mutant the three tryptophans W13, W75 and W102 were replaced by alanine (kindly 
provided by Dr. Steinhilber, University of Frankfurt), resulting in a disability to bind PCs.  
 
Figure 4.28: Interference of F-XII and F-XVI with subcellular translocation of 5-LO, effects on 5-LO_3W. (A) 
PMNL were seeded on poly-D-lysine coated glass cover slips, preincubated with 1 µM F-XII, 1 µM F-XVI or 10 µM 
hyperforin for 15 min, followed by stimulation with 2.5 µM A23187 for 5 min. Cells were fixed with 4% 
paraformaldehyde solution, permeabilized with 100% acetone and incubated with antibodies against 5-LO (Alexa 
Fluor 555, red) and FLAP (Alexa Fluor 488, green). Nuclei were stained with DAPI (blue). Images were taken by 
immunofluorescence microscopy. Images are representative out of 3 independent experiments; scale bar: 5 µM. 
(B) Impact of F-XII and F-XVI on HEK293 cells stably expressing FLAP and 5-LO_wt or 5-LO_3W mutant lacking 
the Ca2+ binding site, respectively. Cells were preincubated with F-XII or F-XVI at the indicated concentrations or 
vehicle (0.1% DMSO) for 15 min, followed by stimulation with 2.5 µM A23187 and 3 µM AA for 10 min. 5-LO product 
formation was detected by RP-HPLC. Data are given as percentage of control (100%); means ± SEM, n = 4. 
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Figure 4.29: Influence of F-XII and F-XVI on intracellular Ca2+ levels in PMNL. PMNL were pre-stained with  
1 mM Fura-2/AM for 45 min and incubated with compounds at the indicated concentrations or vehicle (1% DMSO) 
for 10 min. Upon addition of 1 mM Ca2+ intracellular Ca2+ increase was induced by 1 µM fMLP. (A) Data are given 
as means of ratio 380/340 nm; n = 3. (B) Data are given as percentage of fMLP stimulated control (ratio  
380/340 nM at tmax minus tmin), means ± SEM, n = 3, **p < 0.01 vs. fMLP stimulated sample. Repeated measures 
ANOVA followed by Bonferroni post hoc test applied to absolute values. 
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Interestingly, F-XII and F-XVI showed nearly the same activity (F-XII: 5-LO_wt IC50 =  
0.3 ± 0.03 µM, 5-LO_3W IC50 = 0.4 ± 0.06 µM; F-XVI: 5-LO_wt: IC50 = 0.4 ± 0.04 µM, 5-LO_3W 
IC50 = 1.0 ± 0.2 µM), suggesting that W13, W75 and W102 residues as PC-binding sites play 
no major role in 5-LO inhibition by the hydroquinones. Since the intracellular increase of Ca2+ 
leads to 5-LO activation, the possible interference of F-XII and F-XVI with Ca2+ mobilization 
was assessed (Figure 4.29). PMNL were pre-stained with a Ca2+ sensitive dye Fura-2 followed 
by pre-incubation with F-XII and F-XVI. Subsequent fMLP stimulation led to an intracellular 
Ca2+ increase (Figure 4.29 A). Interestingly, F-XII displayed a decrease of the Ca2+ level to 
about 50% at a concentration of 1 µM (Figure 4.29 B), whereas F-XVI showed no effect. 
Activation of 5-LO can not only be achieved by cellular Ca2+ increase but also by different 
kinases via phosphorylation [110, 111]. Therefore, effects of F-XII and F-XVI on the activation 
of ERK1/2 and p38 MAPK were analyzed. PMNL were preincubated with both hydroquinones 
and stimulated with fMLP. The selective ERK pathway inhibitor U0126 was used as control. 
Western blots showed no effect of F-XII and F-XVI on the phosphorylation and thus activation 
of these protein kinases (Figure 4.30). 
 
4.3.5 Effects of F-XII and F-XVI on other enzymes involved in the 
biosynthesis of lipid mediators 
Besides 5-LO, other enzymes are involved in the formation of inflammatory lipid mediators.  
F-XII did not impair the activity of mPGES-1, COX-2, LTC4S or sEH but had a moderate effect 
on COX-1 activity, with an IC50 of 3.8 ± 0.3 µM (Table 4.10). Effects of F-XVI were comparable, 
but also marginally affected mPGES-1 with an IC50 of 8.1 ± 1 µM and also sEH to some degree. 
        
Figure 4.30: F-XII and F-XVI fail to affect activation of MAPKs relevant for 5-LO. PMNL were preincubated with 
F-XII or F-XVI at the indicated concentrations, 3 µM U0126 or vehicle (0.1% DMSO) for 15 min, followed by 
stimulation with 1 µM fMLP for 90 s. Cell lysates were obtained by sonication. Phosphorylation of ERK1/2 and p38 
was detected via Western blot analysis. Protein amounts are given as percentage of control (fMLP stimulated 
samples are set to 100%), means ± SEM. Representative Western blots out of 3-5 independent experiments.  
*p < 0.05, **p < 0.01 vs. fMLP stimulated sample. Repeated measures ANOVA followed by Bonferroni post hoc test 
applied to absolute values. 
RESULTS 
71 
Table 4.11 shows the interactions of the two hydroquinones on further pro-inflammatory 
enzymes, analyzed in cell-based settings. Here, inhibition of COX-1 activity was similar to the 
cell-free assay, however, F-XII and F-XVI were more potent on COX-2 (F-XII IC50 = 1.1 ±  
0.3 µM; F-XVI IC50 = 0.4 ± 0.2 µM). Regarding IL-1β, -6 and -8 and TNFα formation, F-XII and 
F-XVI showed no suppressive effects. 
 
To strengthen the data, a complete screening of lipid mediators formed by monocytes following 
90 min stimulation with A23187 was performed. Interestingly, a preferential inhibition of all lipid 
mediators was detectable, where 5-LO was involved in the biosynthesis (Figure 4.31), for 
example LTB4 and its isomers or 5-HETE/5-HEPE (IC50 around 0.03 µM, white squares). 
Similar to evaluations in PMNL, 12- and 15-LO, as well as COX enzymes were only affected 
at much higher concentrations of F-XII and F-XVI (IC50 between 1 to 3 µM, white squares). 
Table 4.10: Effects of F-XII and F-XVI on various enzymes involved in lipid mediator biosynthesis in cell-
free assays. F-XII, F-XVI or inhibitors were added to respective enzymes 15 min (mPGES-1, COX-1/2, sEH) or  
10 min (LTC4-S) prior induction of the enzyme reaction. Data are given as IC50-values (µM) or as percentage of 
control (100%) means ± SEM, n = 3-4. Indo, indomethacin. Assay performed by aKatrin Fischer, bStefanie Liening, 
cErik Romp. 
 F-XII (10 µM) F-XVI (10 µM) control inhibitor 
enzyme 
(cell-free) 
remaining activity (%) or 
IC50 (µM)  
remaining activity (%) 
mPGES-1a 59.6 ± 6.7% 8.1 ± 1 µM 23.04 ± 1.4% MK886 10 µM 
COX-1 3.8 ± 0.3 µM 4.0 ± 0.2 µM 24.4 ± 2.8% indo 10 µM 
COX-2 153.2 ± 19.9% 103.5 ± 19.1% 48.2 ± 17.1% indo 10 µM 
LTC4Sb 110.2 ± 7.3% 105.2 ± 9.7% 3.48 ± 0.7% MK886 10 µM 
sEHc 94.5 ± 11.7% 46.3 ± 15.3% 11.1 ± 0.5% AUDA 1 µM 
 
Table 4.11: Effects of F-XII and F-XVI on COX enzymes and cytokine formation in cell-based assays. F-XII, 
F-XVI or inhibitors were added 15 min (COX-1/2, 12-/15-LO) or 30 min (ILs, TNFα) prior stimulation of cell system. 
Data are given as IC50-values or as percentage of control (100%) means ± SEM, n = 3-4. Indo, indomethacin; cele, 
celecoxib; dexa, dexamethasone. aAssays performed by Stefanie König. 
  F-XII (10 µM) F-XVI (10 µM) control inhibitor 
enzyme/ 
mediator cell type 
remaining activity (%) or remaining activity (%) 
IC50 (µM) 
COX-1 platelets + AA 3.8 ± 0.1 µM 3.2 ± 0.2 µM 6.8 ± 3% indo 10 µM 
COX-2 monocytes + LPS/AA 1.1 ± 0.3 µM 0.4 ± 0.2 µM 31.9 ± 7.7% cele 1 µM 
IL-1βa monocytes + LPS 121.2 ± 6.6% 85.1 ± 12.2% 35.6 ± 7% dexa 1 µM 
IL-6a monocytes + LPS 100.7 ± 11.1% 73 ± 11.6% 51.6 ± 3.4% dexa 1 µM 
IL-8a monocytes + LPS 94.4 ± 3.4% 73.5 ± 3.4% 57.3 ± 3.5% dexa 1 µM 
TNFαa monocytes + LPS 105.9 ± 8.9% 63.1 ± 10.4% 24 ± 1% dexa 1 µM 
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4.3.6 Radical scavenger and antioxidant properties of F-XII and F-XVI 
Since antioxidant activity is an underlying mechanism of 5-LO inhibition, the ability of F-XII and 
F-XVI to scavenge the stable free radical DPPH was determined (Figure 4.32 A). Ascorbic acid 
as typical antioxidant agent was used as control. Up to 1 µM F-XII and F-XVI were inactive, 
but scavenged DPPH nearly completely at a concentration of 10 µM. This indicated effective 
antioxidant activities at concentrations that are about 150-fold higher than needed for 5-LO 
inhibition. 
Additionally, both F-XII and F-XVI showed antioxidant properties in a cellular setting, based on 
inhibition of ROS formation in PMNL. In fMLP stimulated PMNL they decreased ROS formation 
to the basal level at a concentration of 1 µM, upon PMA stimulation at a concentration of  
10 µM Figure 4.32 B).  
 
 
            
Figure 4.31: Influence of F-XII and F-XVI on the lipid mediator profile of monocytes. Monocytes were 
preincubated with F-XII or F-XVI at the indicated concentrations or vehicle (0.1% DMSO) for 15 min followed by 
stimulation with 0.5 µM A23187 for 90 min. Data are given as percentage of control in a heat map (from 100% blue 
to 0% red), means ± SEM, n = 3-4. 
 
Figure 4.32: Radical scavenger and antioxidant properties of F-XII and F-XVI. (A) Effect on the stable free 
radical DPPH. F-XII, F-XVI or ascorbic acid were diluted in ethanol to indicated concentrations and 50 µM DPPH 
was added for 30 min. Radical scavenging was photometrically detected at 520 nm. Data are shown as percentage 
of DPPH sample (100%), means ± SEM, n = 3-5. (B) Influence on cellular ROS formation. PMNL were preincubated 
with F-XII and F-XVI at the indicated concentrations, 10 µM DPI or vehicle (1% DMSO) for 15 min. 1 µg/ml DCFH-
DA and 1 mM CaCl2 were added 2 min prior stimulation with either 1 µM fMLP for 8 min or 0.1 µg/ml PMA for  
6.5 min. Fluorescence of oxidized DCFH-DA was monitored (excitation wavelength: 485 nm, emission wavelength: 
535 nm). Data are shown as fold increase of vehicle control, means ± SEM, n = 5. **p < 0.01, ***p < 0.001 vs. fMLP 
or PMA stimulated sample, repeated measures ANOVA followed by Tukey post hoc test applied to absolute values. 
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4.3.7 Effects of F-XII and F-XVI in human blood and efficacy in vivo 
Finally, the pharmacological relevance was investigated in human blood and in an in vivo 
model of acute inflammation in mice. Heparinized blood was preincubated with the compounds 
and either stimulated with A23187 alone, A23187 with AA or by priming the blood with LPS 
and subsequent stimulation with fMLP. Compared to F-XVI, compound F-XII was about 4-fold 
more active in HWB challenged with A23187 alone (IC50 = 0.7 ± 0.3 µM vs. 2.3 ± 0.5 µM) , 
3-fold in HWB challenged with A23187 plus AA (IC50 = 0.6 ± 0.2 µM vs. 1.9 ± 0.5 µM), and  
2-fold in HWB challenged with LPS/fMLP (IC50 = 1.1 ±0.5 µM vs. 2.4 ± 0.6 µM) (Figure 4.33 
A). The zymosan induced peritonitis in mice was performed in the lab of Prof. Lidia Sautebin 
(University of Naples, Italy) (Figure 4.33 B). The compounds were given intraperitoneally  
30 min prior zymosan induced inflammation and were able to suppress the migration of 
inflammatory cells into the peritoneal cavity (vehicle: 3.1 ± 0.7 ×106/ml cells; F-XII:  
1.22 ± 0.2 ×106/ml cells; F-XVI: 0.8 ± 0.1 ×106/ml cells; zileuton: 0.4 ± 0.1 ×106/ml cells). F-XII 
prevented migration about 60%, whereas F-XVI subdued the migration about 75%. Zileuton 
was used as control (reduction of migrating cells about 87%). These results prove their 
potential in vivo and their possible use in pharmacotherapy in the future. 
 
 
      
Figure 4.33: Suppression of 5-LO product formation by F-XII and F-XVI in human whole blood and efficacy 
in vivo. (A) 1 ml of HWB was preincubated with compounds at the indicated concentrations or vehicle (0.1% DMSO) 
for 15 min followed by stimulation with 30 µM A23187 with or without 100 µM AA for 10 min. Alternatively, HWB 
was primed with 1 µg/ml LPS for 30 min and 0.3 U/ml ADA for 20 min, followed by stimulation with 1 µM fMLP for 
15 min. Compounds were added 15 min prior fMLP stimulation. 5-LO product formation was detected by LC-MS/MS. 
Data are given as percentage of control (100%), means ± SEM, n = 3-5. (B) Effect of catechols on cell migration in 
zymosan-induced peritonitis in mice. 10 mg/kg F-XII or F-XVI, 10 mg/kg zileuton or vehicle (0.9% saline solution 
containing 2% DMSO) were given intraperitoneally 30 min before zymosan injection (2 mg/ml in 0.9% w/v saline). 
Mice were sacrificed after 4 h and peritoneal exudates were collected. Cells were counted using a light microscope 
in a Burker’s chamber after vital trypan blue staining. Data are expressed as percentage of control (100%), means 
± SEM, n = 6 animals for each group. 
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5 DISCUSSION 
COX products and 5-LO products are involved in inflammation and reactions of the innate 
immune response. Dysregulation of the 5-LO/COX pathways can lead to the inability to initiate 
resolution of inflammation and can escalate into chronic inflammatory diseases like rheumatoid 
arthritis, multiple sclerosis, atherosclerosis, inflammatory bowel diseases as well as cancer [1, 
22]. Moreover, 5-LO-derived leukotrienes play a pivotal role in the development of chronic 
allergic diseases like asthma and rhinitis [6]. Some of these diseases like systemic lupus 
erythematosus, rheumatoid arthritis or asthma have been shown to be sex-biased with higher 
prevalence and severity in females [77]. One possible reason might be sex differences in the 
production of arachidonic acid-derived lipid mediators like leukotrienes, for which a different 
regulation of the formation could be detected in mice [194] as well as in human innate immune 
cells showing higher LT levels in female individuals compared to males. This regulatory effect 
could be shown to be influenced by the male sex hormone testosterone [4, 88]. Furthermore, 
the levels of pro-inflammatory interleukins in human whole blood and monocytes was shown 
to be sex-biased [216, 232]. However, the underlying intracellular mechanisms of the sex-
related modulation of immune reactions in inflammation are largely unknown and the question 
arose, whether the regulation of prostanoid formation in human whole blood is sex-biased as 
well. First, the prostanoid formation in male and female whole blood and in isolated immune 
cells will be discussed. Second, the focus will be on the identification of potent 5-LO inhibitors 
and their mode of action to modulate the leukotriene formation. 
5.1 The impact of sex on the prostanoid formation and degradation 
The initial investigations addressing the sex-specific prostanoid formation were conducted in 
human whole blood, where the cells are in a physiological environment, simulating the in vivo 
situation best. Cell counts of the whole blood samples revealed differences in prostanoid-
producing cells, with monocyte numbers found to be significantly higher in males, whereas 
neutrophil numbers were higher in females, consistent with other studies [209, 210]. Since 
monocytes are the main source of prostanoids in human blood, the enhanced monocyte 
numbers in males already suggested a sex-regulated prostanoid formation, due to the 
enhanced capacity to generate prostanoids. On this rationale, the obtained results were 
normalized on the cell number of monocytes together with neutrophils. The most pronounced 
effect was detected with significantly enhanced prostanoid levels in HWB, especially of PGE2, 
in male samples compared to females after LPS stimulation for 24 h but also with Ca2+ 
ionophore and fMLP, even after normalization. Stimulation with Pam3CSK4, AA and PMA and 
short-term incubations of whole blood with AA or the Ca2+ ionophore displayed no sex 
difference. Very few studies have been conducted addressing sex-related prostanoid formation 
in human whole blood of healthy volunteers. However, similar effects were observed in cell 
based settings, e.g. a study using human platelets, revealing a higher formation of TxB2 in 
males [233], as well as higher formation of PGE2 and TxB2 in kidney medulla cells of rats [234]. 
Another study detected higher PGE2 levels in plasma of male mice suffering haemorrhage and 
sepsis [235]. On the other hand, several studies reported the opposite findings. Macrophages 
of rats and mice susceptible to arthritis or after trauma showed higher prostanoid formation in 
female cells [236-238]. Trying to clarify these inconsistent results obtained in cellular settings, 
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PBMC were isolated from HWB and challenged with LPS. Incubation in cell culture medium, 
containing 0.5% of sex hormones-depleted human serum did not result in different prostanoid 
levels in males compared to females. The lack of a sex difference in isolated cells could be 
explained by intracellular changes occurring during the isolation and purification process. 
Kelley et al. reported activation of monocytes due to attachment to plastic surfaces [239] and 
several other studies revealed changes in the monocyte response upon stimulation [240-242]. 
This could lead to the loss of contributing mechanisms to the differential prostanoid formation. 
In contrast, whole blood preparations partially prevent monocyte attachment [243]. Incubation 
of the isolated PBMC in autologous plasma could not restore the sex difference but increased 
the PGE2 level about 8-fold and TxB2 levels about 2-fold. Pre-incubation of human whole blood 
with sex hormones had no effect on prostanoid formation in female blood, whereas in blood 
from males, pre-incubation resulted in a modest increase of prostanoids with all four applied 
sex hormones. In contrast, in isolated PBMC pre-incubation rather decreased TxB2 and PGF2α 
levels in both sexes, whereas PGE2 remained unaffected. To address transcriptional regulation 
of the prostanoid production by the steroids, preincubation with sex hormones for 5 h was 
evaluated as well, but the prolonged pre-incubation time had no effects (data not shown). In 
contrast, several studies showed regulatory mechanisms of sex hormones regarding the 
inflammatory response. For example, Miyagi et al. showed suppressing effects of testosterone 
and estradiol in low concentrations on the PGE2 production, whereas progesterone appeared 
to enhance the PGE2 formation in LPS stimulated human monocytes [244]. Unfortunately, they 
did not indicate the length of the pre-incubation periods with sex hormones or the LPS 
stimulation time. Sullivan and colleagues detected higher urinary excretion of PGE2 
metabolites from female spontaneous hypertensive rats concluding higher plasma levels and 
could furthermore show that gonadectomy of male rats increased PGE2 levels [214]. This 
suggests that PGE2 formation is sensitive to testosterone. On the other hand, Vegeto et al. 
showed suppressive effects of estradiol on the LPS-activated expression of pro-inflammatory 
genes like the proteolytic matrix metallo-protease-9 gene in murine RAW267.4 cells [245].  
Besides the prostanoid biosynthesis, the catabolism of prostanoids in human whole blood was 
evaluated as variable affecting overall prostanoid levels. The prostanoid-degrading enzyme is 
the 15-PGDH, producing 15-keto-prostaglandins with impaired biologic activity [218].  
15-PGDH is known to be counter-regulated to COX-2 [246, 247], and the expression is 
increased by classical COX-2 inhibitors [220, 248]. At early time points up to six hours after 
LPS stimulation, the activity of 15-PGDH appeared to be enhanced in female samples 
compared to males. Treatment with the specific 15-PGDH inhibitor SW033291 [221] elevated 
PGE2 levels in female whole blood compared to male blood. Interestingly, after stimulation with 
LPS for 24 h the inhibitor lost its efficiency, and no differences in the activity could be seen. 
Further studies are needed to monitor the PGE2 metabolites during LPS stimulation in order to 
verify the sex differences in the prostanoid catabolism. Consistent with this result are findings 
by others showing that progesterone is able to increase 15-PGDH activity in human 
erythroleukemia cells [220]. However, contrary results in the literature reported an elevated 
inactivation of prostaglandins in male rat medulla cells [234] and the ability of male sex 
hormones to induce 15-PGDH expression in hormones-responsive prostate cancer cells [219]. 
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5.2 The effect of sex on intracellular signaling 
Since the most pronounced sex difference in prostanoid formation in whole blood was evident 
following LPS stimulation, the TLR signaling cascade was evaluated in more detail. The 
expression of TLR4 on the cell surface of isolated monocytes was found to be enhanced in 
female cells compared to male monocytes, although not significantly. This finding could 
provide evidence for a negative prerequisite involved in the development of autoimmune 
diseases, which occur with higher prevalence in females. Several studies could demonstrate 
that upregulation of TLR4 on immune cells is involved in the pathogenesis of systemic lupus 
erythematosus [249] and rheumatoid arthritis [250]. However, other findings described in the 
literature suggested no sex difference regarding the expression of TLR4 on PBMC of gastric 
cancer patients [85] and the CD14/TLR4 expression on murine macrophages after trauma-
haemorrhage [251]. In contrast to the results obtained in this thesis, Mariott et al. reported 
opposite findings: Higher expression levels of CD14 and TLR4 on male macrophages, and 
elevated PGE2 formation in females [87]. Stimulation with LPS requires the formation of a 
receptor complex consisting of LPS, LBP, CD14, MD-2 and TLR4, which initiates intracellular 
signaling resulting in the activation of NF-κB and expression of COX-2, taking several hours 
[44]. However, Mariott at el. examined PGE2 formation 4 h after LPS stimulation. Investigations 
in this thesis could barely determine COX-2 expression in human monocytes until 5 h after 
LPS stimulation and hence nearly no PGE2 production (data not shown). To evaluate the role 
of COX-2, mRNA and protein expression was explored. In isolated PBMC, no differences in 
COX-2 mRNA levels as well as in COX-2 protein expression was observed between males 
and females. Interestingly, in monocytes sorted by FACS, the COX-2 expression appeared to 
be higher in female cells, compared to males. This finding was unexpected, thus elevated 
TLR4 and COX-2 expression in females would suggest enhanced prostanoid levels in female 
but not in male blood. Literature about sex-dependent COX-2 expression is as controversial 
as every other aspect of the sexual dimorphism in prostanoid formation. Higher COX-2 protein 
expression was observed in female rat medulla cells [214] and Martorell and colleagues could 
demonstrate an increase of COX-2 protein expression in aortic segments from 
orchidectomized rats [213]. In contrast, Diodato et al. report decreased COX-2 protein levels 
in liver of female mice exposed to haemorrhage and sepsis, compared to males [235].  
Regarding the possibility that mechanisms contributing to the sex difference in prostanoid 
formation are relevant immediately upon cell stimulation, the constitutively expressed COX-1 
protein was evaluated. In PBMC, isolated from HWB, a moderate, but not significant, sex 
difference in the expression levels could be detected, with higher COX-1 levels in females. 
Along these lines, stimulating effects of estradiol on COX-1 expression in human umbilical vein 
endothelial cells were reported in literature [252]. In contrast, higher COX-1 expression was 
evident in male PMNL, compared to female [5], whereas prostanoid formation was found to be 
equal in both sexes in PMNL isolated from whole blood. The sex difference was independent 
of A23187-induced AA release in PMNL within the first two hours, although, AA release should 
be further elucidated in isolated PBMC or monocytes using LPS as stimulus, regarding the 
pronounced effect after LPS application in whole blood. Furthermore, this thesis did not 
address effects of sex on the intracellular Ca2+ mobilization required for AA release. 
Nevertheless, studies of different groups suggest a sex-dependent regulation in different cell 
types. In ventricular myocytes from mice [253], in vascular smooth muscle cells from rats [254] 
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and in rat platelets [255] investigations report an increased Ca2+ mobilization by male cells 
suggesting the involvement of sex hormones. 
5.3 Sex differences in the cell-cell cross talk 
Regarding the fact that immune cells react in an orchestrated manner [256-258], sex-
dependent differences in the cell-cell cross talk in human whole blood after stimulation needed 
to be considered. Therefore, PBMC and PMNL were isolated from human whole blood and 
stimulated alone or in co-incubations in autologous plasma, concurrent with HWB incubations. 
Following LPS stimulation only PGE2 formation appeared to increase in male blood 
preparations by cell interactions between PBMC and PMNL, whereas all three prostanoids 
showed the observed sex difference in the whole blood incubations. Stimulation with AA 
increased prostanoid formation in male samples due to cell interactions between PBMC and 
PMNL of all three prostanoids. So far, no findings about a sex-specific difference in intercellular 
cross talk in inflammatory processes could be found in literature. Nevertheless, few studies 
identified sex-related disparity in the formation of TxA4 and aspirin-triggered lipoxins [259, 260], 
indicating differences in cell-cell interactions. 
To summarize, regarding the controversial results on sex differences in prostanoid formation 
obtained in this thesis and the plethora of inconsistent reports in literature, no distinct 
mechanism could be identified leading to the data obtained for human whole blood. One major 
drawback is the missing knowledge about the blood donor’s personal information. Due to data 
privacy no specifications about age, hormonal contraception, and the phase of the menstrual 
cycle of the female donors could be obtained. Furthermore, it became obvious that results 
strongly depend on cell type, stimulating agent, regarded lipid mediator of interest and the 
species used for investigations. Nonetheless, elucidation of the sexual dimorphism in 
prostanoid formation should be pursued to provide optimal pharmacological therapy for both 
men and women. 
 
5.4 Inhibition of 5-LO by 1,4- and 1,2-benzoquinones 
In this study, 16 different 1,4- and 1,2-benzoquinones were investigated regarding their 
inhibitory potential on 5-LO. These 16 compounds were part of a series, containing 48 
structures in total, systematically modified trying to increase the inhibitory efficiency of the lead 
compound embelin [225]. Literature suggests that quinones are redox-type inhibitors, Michael 
acceptors reacting with cysteines on 5-LO, or act by defined binding to 5-LO in the active site 
[150, 167, 169]. Furthermore, the intracellular reducing milieu can transform the quinones to 
hydroquinones, which are reducing agents and may interfere with the catalytic cycle of 5-LO 
through their radical scavenging abilities [228, 261]. Nevertheless, recent studies showed that 
the binding mode is rather a non-redox-type. The inhibitory potential of several 1,4-benzo-
quinones did not correlate with the antioxidant properties [262] and exhibited high activity in 
cell-free systems as well, where reducing agents are missing [168]. In addition, the potential 
of the 1,4-benzoquinone embelin was independent of the redox form of the quinone moiety 
and indicated no interaction with the related enzymes 12- and 15-LO. Both LOs possess a 
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non-heme catalytic iron and exert the same catalytic redox cycle as 5-LO [8]. Variation of 
another 1,4-benzoquinone series revealed that the inhibitory potential is rather determined by 
the adjacent residues than the antioxidant capacity [169]. 
The 16 compounds evaluated in this thesis were varied in the hydroxylation and methylation 
pattern of the benzoquinone core and in the length of the n-alkyl chain in 3-position, since 
previous studies showed the importance of the linked substituent for the inhibitory efficiency 
[225]. In cell-free assays, the compounds of all four series showed potent inhibition of 5-LO, 
with series C (4,5-methoxy-1,2-benzo-quinones) as most potent structures. They exhibited IC50 
values in a range of 0.04 to 0.6 µM, followed by series D (2,5-hydroxy-1,4-benzoquinones), 
series B (2-hydroxy-5-methoxy-1,4-benzoquinone) and series A (2,5-methoxy1,4-benzo-
quinones), as shown in Figure 5.1. The lowest efficacy in every group was determined for the 
structures substituted with a short C8-n-alkyl chain (EA-109 A-D) displaying IC50 values 
between 0.3 and 3 µM, whereas an C14-n-alkyl residue was examined as most suitable (Figure 
5.1). In cell-based assays it became apparent that methylation of the hydroxyl groups 
increased the inhibitory potential. An explanation could be that the polarity of the bi-
hydroxylated compounds and the two incorporated vinyloge acids reduced the permeation into 
the cells. Compounds of series B containing one hydroxyl group were less efficient with IC50 
values in a range of 0.3 to 2.3 µM or above 10 µM and compounds of series D with two hydroxy 
groups nearly lost their activity with IC50 values between 2.5 and 5.1 µM or above 10 µM. 
Series C again showed most potent effects on 5-LO (Figure 5.1) with IC50 values in a range of 
0.05 to 0.8 µM. However, the compound EA-112C substituted with a C15-n-alkyl residue was 
an exception in this series and showed no activity on 5-LO. In general, efficacy of the 
 
 
 
Figure 5.1: Structure-activity relationships of the benzoquinones with 5-LO or with mPGES-1 respectively, 
in cell-free and cell-based assays. From left highly active to right less active. 
residues: n = (CH2)13 (CH2)12 (CH2)14 (CH2)7
O
O
O
O n
O
OH
O
O n
O
O
O
O n
O
OH
O
nHO
5-LO
cell-free:
ABDC
residues: n = (CH2)12 (CH2)13 (CH2)14 (CH2)7
5-LO
cell-based:
O
O
O
O n
O
O
O
O n
O
OH
O
O n
O
OH
O
nHO
C A B D
residues: n = (CH2)7 (CH2)12 (CH2)13 (CH2)14
mPGES-1
cell-free:
O
O
O
O n
O
O
O
O n
O
OH
O
O n
O
OH
O
nHO
CA BD
DISCUSSION 
79 
benzoquinones on 5-LO in cellular settings was enhanced along with the number of methylated 
hydroxyl groups on the benzoquinone moiety, the change from the 1,4-benzoquinone to the 
1,2-benzoquinone core, and a n-alkyl residue containing 13 to 14 carbon atoms in 3-position 
(Figure 5.1), revealing compound EA-110C as most potent compound. The activity in intact 
cells challenged with A23187 together with AA was slightly lower compared to stimulation with 
A23187 alone, indicating a possible competition with AA for the binding site, which seemed 
reasonable considering the fatty acid-like structure of the inhibitors. Besides 5-LO, several of 
the 1,4-benzoquinones showed inhibition of mPGES-1 (Figure 5.1). The most pronounced 
effects were exerted by the di-hydroxylated compounds of series D, with IC50 values between 
0.8 and 2.1 µM. EA-109D was the most potent compound of the complete series substituted 
with a C8-n-alkyl chain, whereas in series A, the highest efficacy was obtained by a structure 
bearing a C13-n-alkyl residue. In contrast, series C containing the 1,2-benzoquinone backbone 
completely lost inhibitory potency on mPGES-1. These results denoted that inhibition of 
mPGES-1 depends on both, the hydroxyl groups and the length of the substituted residue. In 
addition, none of the 16 compounds interfered with the related 12- and 15-LO, indicating a 
rather non-redox-type inhibition, since both enzymes feature activity via a redox cycle based 
on a non-heme iron. In summary, evaluation of the 16 benzoquinone compounds revealed 
highly active compounds with EA-110C as most potent and additionally, as selective inhibitor 
for 5-LO comparable to the activity of the 1,2-benzoquinone RF-22c [170] and superior over 
the plant-derived 1,2-benzoquinone aethiopinone [263]. 
5.5 Inhibition of 5-LO by 1,2-benzohydroquinones with linear residues 
Encouraged by the identification of EA-110C as highly potent and selective 5-LO inhibitor, 
further structural modifications were made to yield even more effective compounds. In the 
literature, natural 1,2-hydroquinones (= catechols) are described as 5-LO inhibitors [149, 227] 
such as flavonoids and polyphenols. It could be shown that the position of the hydroxyl groups 
determined the activity. Ortho-benzohydroquinones were found to be effective 5-LO inhibitors 
and substitution in 3-position potentiated the inhibitory effect. In contrast, methylation of one 
of the hydroxyl groups decreased the activity and meta-hydroquinones were poor inhibitors or 
even inactive [261]. The mechanism by which they inhibit leukotriene formation is supposed to 
depend on interference with the redox cycle of the catalytically active iron of 5-LO, interference 
with required lipid peroxides or by complexing the active site iron. Dupon et al. showed that 
polyhydroxylated naphthalenic derivatives could inhibit 5-LO in cellular settings and 
additionally exerted radical scavenging properties. Furthermore, these compounds were able 
to rapidly reduce Fe3+ to Fe2+ in a cell-free assay at low pH of 1-2 but very slowly at a pH 
around 8 [264]. Hence, they concluded the radical scavenging and the reduction of the active 
site iron as responsible mechanism for the inhibitory action. Similarly, Prasad et al. determined 
the potential inhibition on 5-LO product formation of phenolic compounds and flavonoids in 
spices. They determined rather high IC50 values regarding the interference with 5-LO, for 
example of quercetin and eugenol (both around 25 µM) [265]. Quercetin was shown to reduce 
the active site iron to Fe2+ and to chelate Fe2+ preventing participation in the catalytic redox 
cycle [266]. Based on these findings, the 1,2-benzoquinone backbone of EA-110C was 
reduced to a 1,2-hydroquinone backbone (EA-110C RED). Moreover, two more 1,2-hydro-
quinones of EA-110C with different O-methylation patterns were synthesized (EA-110C T 
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RED, EA-110C P RED), as well as the hydroquinone forms of two other compounds (EA-107C 
RED and EA-100C RED) [198]. This new series was first analyzed in cell-free and cellular 
assays to determine the benefit of the quinone core reduction. In comparison with the related 
1,2-benzoquinone the hydroquinone EA-107C was superior over its parental compound 
confirming that the hydroquinone form is the active form in the cellular environment where 
reducing conditions are present [228, 229]. All five hydroquinones were highly active with IC50 
values in cell-free assay between 0.06 and 0.29 µM as well as in cellular settings with IC50 
values in a range of 0.03 to 0.31 µM, whereas trihydroxylation or para-dihydroxylation 
decreased the activity compared with the 1,2-hydroxylation pattern, similar to results of Alanko 
et al. [261]. The 1,2-hydroquinones displayed a more effective inhibition in cell-based assays 
indicating either additional targets, intracellular enrichment or activation within the cell. 
However, the evaluation of these mechanisms were not addressed in this thesis but the binding 
mode of the hydroquinones to 5-LO and physiological relevance were analyzed more in detail. 
Incubations of EA-110C and EA-110C RED with various concentrations of AA revealed a non-
competitive inhibition. The activity of the hydroquinone was the same, regardless of the 
different AA concentrations, whereas the benzoquinone EA-110C was less effective with lower 
AA concentrations (2 and 5 µM). Greiner et al. suggested a second putative binding site of AA 
positively modulating 5-LO activity, which is blocked by several inhibitors in a AA-
uncompetitive manner (e.g. HZ52). Alternatively, higher AA concentrations are needed to form 
micelles incorporating the inhibitor molecules leading to a more efficient access towards 5-LO 
[267]. Docking simulations revealed binding of both, the quinone and the hydroquinone moiety 
in the binding pocket forming hydrogen bonds with Tyr-81, Tyr-383 and Glu-622. In contrast to 
the quinone core, EA-110C RED was able to form bidirectional hydrogen bonds via the two 
hydroxyl groups. Furthermore, docking simulations did not suggest direct interaction of the 
quinone and the hydroquinone with the active site iron.  
The anti-inflammatory potential of both the quinone and the hydroquinone could be verified in 
vivo. In carrageenan-induced paw oedema both compounds reduced hind paw swelling in 
early and late time points along with effective repression of cys-LT formation and migration of 
inflammatory cells [231]. These results confirm the high efficacy of quinones and hydro-
quinones to reduce inflammation by potent suppression of 5-LO. This study revealed a  
1,2-benzoquinone/-benzohydroquinone backbone with a C13-n-alkyl chain in 3 position as 
optimal structure to interfere selectively with 5-LO. No detailed analysis of the radical 
scavenging and iron chelating properties were conducted to clarify the mechanism of inhibition, 
however docking simulation suggested binding to the binding site without direct interaction with 
the active site iron. This indicated that the inhibitory mechanism is not mainly based on 
interference with the catalytic redox cycle. 
5.6 Inhibition of 5-LO by 1,2-benzohydroquinones with bulky residues 
To explore the interference of 1,2-benzohydroquinones with 5-LO and respective SARs, a 
second set of compounds, substituted with bulky aromatic residues in 4-position was 
synthesized. A screening on 5-LO activity revealed highly active compounds, with IC50 values 
in cell-free assays in a range of 7 to 210 nM and of 0.07 to 2.1 µM in cell-based settings. 
Nelson et al showed that the ability of chelating compounds to reduce the ferric state of 5-LO 
is partly dependent on the electron-withdrawing or electron–donating properties of the 
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substituent [268]. Nevertheless, it seemed that rather linear structures with lipophilic residues 
were favored over inflexible hydroxylated substituents in 4-position to yield effective inhibition 
of 5-LO product formation. Out of this series the two compounds F-XII and F-XVI were 
outstanding in their ability to suppress LT formation. Thus, they were chosen for detailed 
investigations of the 5-LO inhibitory mechanisms. In isolated PMNL, they effectively inhibited 
5-LO product formation with IC50 values in a low nanomolar range (between 60 and 120 nM), 
irrespective of the used stimulus (A23187, A23187 plus AA, LPS/fMLP). Of note, both 
compounds were able to outperform zileuton, the only available 5-LO inhibitor on the market 
(PMNL stimulated with A23187: IC50 = 2.5 ± 1.2 µM). Given that the inhibitory potential did not 
change using A23187 or LPS/fMLP compared to additional exogenous AA indicated that F-XII 
and F-XVI did not interfere with the cPLA2 enzyme and thus with the AA supply. In contrast, 
inhibition of AA release could be shown for other 1,2-hydroquinones, like caffeic acid phenyl 
ester [269]. Strengthening the potent inhibition of LT synthesis in cellular settings, both 
compounds were equally active on the suppression of LTB4 and cys-LT formation in isolated 
human monocytes, indicating that the LTC4S or LTA4H are no additional targets. To verify that 
the inhibitory potential is mediated by the 1,2-hydroquinone moiety the O-methylated 
analogues of F-XII (AF-06) and F-XVI (AF-13) were used as control compounds. Both AF-06 
and AF-13 had poor effects on 5-LO product formation in PMNL stimulated with A23187 with 
or without exogenous AA (AF-06: IC50 ≈ 3 µM; AF-13: remaining activity at 10 µM = 64 - 85%). 
Furthermore, monitoring the viability of monocytes treated with the hydroquinones confirmed 
that the potent inhibition is not mediated due to cell toxic effects. In cell-free assays with the 
isolated 5-LO enzyme, the inhibitory potential of F-XII and F-XVI was even enhanced (IC50 = 
20 nM) suggesting that the hydrophilic 1,2-benzohydroquinone structure could hamper the 
permeability into the cells and furthermore, ruling out FLAP as cellular target enzyme. 
Moreover, the inhibition of the isolated enzyme was independent of the presence of detergents 
like Triton X-100, excluding acting as nuisance inhibitors. Involvement of the 1,2-hydroquinone 
core in cell-free assays was again confirmed using the O-methylated analogues as control 
compounds. In PMNL homogenates, efficiency of F-XII was similar but was decreased for  
F-XVI with a shift of the IC50 value to 1.3 µM. This loss of potency could be due to augmented 
binding to cellular debris or possible interaction with the C2-like domain, which is counteracted 
by phospholipids as shown for hyperforin and the pyridinylimidazol EP-6 [231, 270]. Detailed 
study of the binding mode revealed completely reversible inhibition of 5-LO, analyzed by wash 
out experiments. Interestingly, both compounds displayed a non-competitive mode of 
inhibition, suggesting that they do not compete with AA for the substrate binding site. The 
inhibitory potential of F-XII and F-XVI was furthermore independent of interaction with for 
distinct cysteinyl residues (Cys-159, Cys-300, Cys-416, Cys-418) on the surface of the 
catalytic C-terminal domain close to the substrate entrance, as shown for several other 
benzoquinones containing a Michael acceptor function [167]. Using HEK293 cells stably 
expressing a 5-LO mutant in which the cysteinyl residues were replaced by serines revealed 
no reduced activity compared to the 5-LO wild type. In accordance with this findings, docking 
simulation suggested binding to Asp-166, which interacts with Arg-101 connecting the catalytic 
C-terminal domain with the N-terminal C2-like domain. Additionally, Asp166 is part of a short 
α2 helix together with Phe-177 and Tyr-181, also called “FY cork” [102]. Interestingly, 
replacement of the Arg-101 by Asp increased enzyme activity in purified preparations [101], 
whereas replacement of Asp-166 by Asn decreased 5-LO activity [203]. Further investigations 
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are needed, to clarify the implication of the hydroquinone - Asp-166 interaction on the inhibitory 
potential. Probably, binding of the compounds to the α2 helix hampered the ability of the “FY 
cork” to warrant access of AA to the active site. Since, mutations in the “FY cork” were shown 
to impair association with the nuclear membrane and FLAP [271], the intracellular distribution 
of 5-LO in presence of the two hydroquinones was evaluated. The subcellular translocation 
was not affected by F-XII, whereas F-XVI seemed to interfere partly. Alterations in the 
intracellular translocation could be mediated by interaction of the hydroquinones with amino 
acids in the binding site for the membrane phospholipids [106]. In HEK293 cells, stably 
expressing FLAP and a 5-LO mutant where the respective tryptophans (Trp-13, Trp-75, Trp-
102) were replaced by Ala, F-XVI was slightly less active, compared to the 5-LO wild type (5-
LO_wt IC50 = 0.4 µM; 5-LO_3W IC50 = 1 µM). This outcome and the suggested interaction with 
Asp-166 could contribute to the inhibitory potential on 5-LO. In contrast, only F-XII appeared 
to influence the intracellular Ca2+ mobilization required for 5-LO activation at concentrations 
from 1 µM upwards. Besides the cellular Ca2+ increase, the MAPKs ERK1/2 and p38 activate 
5-LO by phosphorylation [110, 111], which however was not influenced by both hydroquinones.  
During the inflammatory process several enzymes form a plethora of inflammatory mediators. 
At concentrations up to 10 µM, F-XII and F-XVI had a nominal effect on mPGES-1 (F-XII: 
remaining activity at 10 µM = 60%; F-XVI: IC50 = 8 µM) and on COX-1 (IC50 ≈ 4 µM) in cell-free 
assays and on COX-2 in monocytes stimulated with LPS plus AA (IC50 between 0.4 – 1 µM). 
Enzymes like LTA4H, sEH and COX-2 and the formation of interleukins and TNFα remained 
unaffected. Furthermore, both benzoquinones did not affect the related enzymes 12- and  
15-LO at concentrations up to 1 µM in PMNL and in monocytes. These results suggested that 
both benzohydroquinones were highly selective for 5-LO at low concentrations. Finally, radical 
scavenging and antioxidant properties were evaluated. F-XII and F-XVI were able to scavenge 
the stable free radical DPPH in a cell-free assay, though at concentrations at least 150-fold 
higher than required for 5-LO inhibition. Similar results were obtained investigating the 
antioxidant properties. Thus, ROS formation in PMNL was decreased to basal levels with 
concentrations 10 to 100-fold higher than needed for the suppression of LT formation. These 
results are consistent with studies from the groups of Dupont [264] and Boudreau [269], where 
the antioxidant and free radical scavenging potency of hydroquinones was not necessarily 
related to their ability to inhibit 5-LO. In addition to the striking efficacy of both 
benzohydroquinones in cellular and cell-free test systems, they both showed promising 
potential in human whole blood (F-XII: IC50 = 0.6 – 1.1 µM; F-XVI: IC50 = 1.9 - 2.4 µM) and 
possessed anti-inflammatory potential in vivo. In a zymosan induced peritonitis model in mice, 
both compounds effectively suppress the migration of inflammatory cells.  
To summarize, 1,2-benzhydroquinones represent a group of potent 5-LO inhibitors dependent 
on their substituted residue in 4-position. The evaluated compounds F-XII and F-XVI were 
shown to be highly effective in cell-free and in different cell-based settings (PMNL, monocytes, 
HEK293 cell lines) with negligible impact on other enzymes involved in the inflammatory 
process. Their inhibitory mode seemed to be rather a non-redox-type or novel type, since 
concentrations required for antioxidant and radical scavenging properties are noticeably higher 
than for inhibition of 5-LO product formation and they both did not interfere with the related 
redox-cycle of 12- and 15-LO. Moreover, F-XVI may interact with the C2-like domain. 
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Conducting a chrome azurol S (CAS) assay (data not shown) suggested the ability of the 
compounds to form a Fe(III) complex. However, these complexes were not stable enough to 
be detectable with mass spectrometry analysis, indicating that chelating the active site iron is 
not the inhibitory mechanism, what was supported by docking simulations as well. Binding to 
amino acids, which are part of the salt bridge connecting the two 5-LO domains and/ or the 
membrane binding site seemed more likely. Additionally, the high efficacy in human whole 
blood and in inflammatory in vivo models identified these 1,2-benzohydroquinones as 
promising candidates demanding further pharmacological investigations for drug development. 
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